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Abstract 
 
Congenital cardiovascular malformations (CCVM) are the most common type of 
birth defect in humans and can be life threatening for the newborn. 22q11 
deletion syndrome (22q11DS) is one of the most common CCVM in humans, 
with patients presenting a wide variety of abnormalities including craniofacial 
dysmorphology, immune deficiency, mental retardation and cardiovascular 
defects, including ventricular septal defects, abnormal right subclavian artery 
and interrupted aortic arch type B. TBX1 is considered the main gene 
underlying the cardiovascular phenotype in 22q11DS patients, however, the 
great phenotypic variability among 22q11DS patients suggests genetic 
modifiers define the presentation of the phenotype. The transcription factor 
Pax9, was found significantly down-regulated in Tbx1-null embryos (a mouse 
model of 22q11DS). 
 
The aim of this project was to determine whether Pax9 is involved in 
cardiovascular development and to study a potential genetic interaction 
between Pax9 and Tbx1 during cardiovascular development. The results show 
that Pax9 is required for cardiovascular development as all Pax9-null embryos 
have severe cardiovascular abnormalities including IAA, VSD, BAV, DORV, and 
abnormal or completely absent common carotids. Furthermore, a strong genetic 
interaction between Pax9 and Tbx1 was found, since double heterozygosity 
leads to lack of formation of the 4th pharyngeal arch arteries consequently 
leading to a significant increase in the incidence of IAA. The molecular 
mechanism of this interaction between Pax9 and Tbx1 was investigated. The 
results show that Tbx1 does not bind to any region within the Pax9 locus in vitro 
and in vivo. A physical interaction between Pax9 and Tbx1 proteins was also 
ruled out by co-immunoprecipitation. qPCR analysis revealed a significant 
downregulation of Gbx2 in double heterozygous embryos, and luciferase 
experiments revealed Pax9 is able to promote luciferase expression of a 
conserved regulatory region within the Gbx2 locus, whereas Tbx1 repressed 
luciferase expression of this Gbx2 cloned regions. The results in this 
dissertation suggest Pax9 and Tbx1 regulate cardiovascular development, at 
least in part, through regulating Gbx2. 
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Chapter 1. Introduction 
 
1.1. Heart Development 
 
The heart is the first organ to form and function during embryonic development 
as it is essential to maintain a sufficient blood supply to support the growing 
embryo, while a vascular network is necessary to efficiently circulate the blood 
throughout the body.  
 
The development of the heart occurs in a similar pattern in all vertebrates 
(Figure 1.1)  (Reviewed in Anderson et al, 2003; Buckingham et al, 2005), 
starting around embryonic day 15 in humans equivalent to embryonic day (E) 
6.5 in the mouse with the specification of the cardiogenic fields (Figure 1.1a) 
(Reviewed in Brade et al, 2013). 
 
In embryonic development the three germ layers (endoderm, mesoderm and 
ectoderm) are specified during gastrulation. The mesoderm, lying between the 
endoderm and ectoderm layers migrates laterally forming the paraxial, 
intermediate and lateral plate mesoderm. The latter is further divided into 
somatic and splanchnic mesoderm. From this bilateral splanchnic mesoderm 
the first cardiogenic precursors are derived, namely the primary heart fields 
(Rawles, 1943; Rosenquist, 1970; Garcia-Martinez and Schoenwolf, 1993; Tam 
et al, 1997). 
 
The primary heart fields migrate from the lateral plates and fuse together in the 
midline of the embryo at E7.5 (about 18 days in human) forming a crescent-
shaped epithelium known as the cardiac crescent (Figure 1.1b; Rosenquist, 
1970; Garcia-Martinez and Schoenwolf, 1993). The cardiac crescent then forms 
a linear tube (Christoffels et al, 2000; Meilhac et al, 2004; Figure 1.1c) 
composed of an inner lining of endocardial cells attached to an intermediate 
thick layer of extracellular matrix known as the cardiac jelly and surrounded by a 
single layer of myocardial cells.  
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At this point, the myocardial cells have the ability to depolarize spontaneously 
which allows peristaltic contractions to appear along the tube, while differences 
between the cardiac chambers become apparent with the presumptive atrial 
and ventricular regions beating at different rates.  
 
The tube further elongates by proliferation of the primary heart field-derived 
cells and by addition of cells from a second population of heart progenitors 
derived from the pharyngeal mesoderm known as the secondary heart field 
(Mjaatvedt et al, 2001; Waldo et al, 2001; Kelly et al, 2001), of which cells 
incorporate to the anterior and posterior poles of the tube and will later 
contribute to the outflow and inflow tracts, the right ventricle, and both atrial 
chambers (Zaffran et al, 2004; Meilhac et al, 2004).  
 
The anterior (arterial) pole of the tube, the truncus arteriosus, is the primitive 
outflow tract that will later septate into the aorta and pulmonary trunk. The 
posterior (venous) pole namely sinus venosus connects the tube with the 
vitelline veins from which blood is drained from the yolk sac and will later form 
the sinus node and part of the right atrium.  
 
As the tube elongates it loops rightward (Figure 1.1d), moving the venous pole 
(presumptive atrial) anteriorly and dorsal to the arterial pole (Christoffels et al, 
2000). As the tube is looping, the presumptive ventricular regions begin to 
balloon outwards to shape the future ventricles, and switching from 
incorporation of extracardiac cells to intramyocardial proliferation (Moorman and 
Christoffels, 2003).  
 
Within the looped tube the four chambers of the heart are then specified by 
initially forming the atrioventricular (AV) canal, which creates a boundary 
between the atrial and ventricular regions (Habets et al, 2002; Harrelson et al, 
2004). Soon after, following signals from the myocardium some endocardial 
cells undergo epithelial-to-mesenchymal transition to migrate through the 
cardiac jelly and form the endocardial cushions (outflow tract and AV cushions) 
which will then define the four chambers (Figure 1.1e) and later become the 
four major valves of the heart (Eisenberg and Markwald, 1995; Timmerman et al, 
2004).  
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The outflow tract cushions will form the aortic and pulmonary valves while the 
AV cushions will form the tricuspid and mitral valves. By E10.5 (about 32 days 
in human) the four chambers of the heart are completely defined (Figure 1.1e) 
and connected to the aorta and pulmonary trunk. 
 
The myocardium then differentiates into two layers: an outer compact region 
and an inner trabeculated sheet protruding within the lumen of both ventricles 
(Wang et al, 1998; Grego-Bessa et al, 2007). Trabeculation starts around E10.5 
(about 32 days in human) with cells of the inner myocardium proliferating and 
migrating into the lumen of the ventricle, forming inward-protruding sheets of 
organised cardiomyocytes to increase the surface area of the heart for 
oxygenation in the absence of coronary circulation (Sedmera et al, 2000; 
Wagner and Siddiui, 2007). 
 
A subpopulation of cells derived from the pharyngeal endoderm, known as 
epicardial cells, migrate and form a monolayer surrounding the heart covering 
the ventricles and atria forming the epicardium (Komiyama et al, 1987). 
Furthermore, a subset of epicardial cells undergo epithelial-to-mesenchymal 
transformation, delaminate from the epicardium and populate the myocardium, 
where they differentiate into smooth muscle and endothelial cells to contribute 
to the formation of the coronary vessels, as well as differentiating into interstitial 
and adventitial fibroblast (Mikawa and Gourdie, 1996; Perez-Pomares et al, 
2002). 
 
By this stage, the cardiac outflow tract (OFT) is septated into the ascending 
aorta and pulmonary trunk, which arise from the left and right ventricles, 
respectively (Sedmera et al, 2000; Nemer et al, 2007).  
 
The remodelling of the outflow tract is a complex process that is disrupted in a 
significant number of CCVM accounting for about 30% of all cardiovascular 
malformations.  
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Figure 1.1. Overview of heart development in human and mouse. 
The development of the mammalian heart starts with the specification of the cardiogenic fields 
(a) around embryonic day (E) 6.5 in mouse (day 15 in humans). The primary heart fields fuse in 
the midline of the embryo forming the cardiac crescent (b). Cells from the cardiac crescent 
proliferate forming a linear tube along the embryo (c); the tube elongates by proliferation of 
primary heart field cells (red) and by incorporation of cells from the secondary heart field (blue). 
As the tube grows it loops rightwards (d), moving the venous pole (presumptive atrial) anteriorly 
and dorsal to the arterial pole. The four chambers of the heart are then specified and completely 
septated (e) by E10.5 (32 days in humans). By E11.5 the outflow tract (OFT) is completely 
septated into the aorta and pulmonary trunk, and from E11.5 the symmetrical pharyngeal arch 
arteries undergo a complex remodelling process to form the assymetrical great arteries. The 
remodelling of the PAAs and the formation of the heart is finished (f) by E15.5 (50 days in 
humans). 
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1.1.1. Extracardiac Contributions 
 
1.1.1.1. Secondary Heart Field 
 
The secondary heart field is a population of progenitor cells derived from the 
pharyngeal mesoderm located posterior to the dorsal surface of the developing 
heart tube (Figure 1.1a) (Mjaatvedt et al, 2001; Waldo et al, 2001; Kelly et al, 
2001). Secondary heart field cells start to migrate and incorporate to the arterial 
pole of the heart tube around E8.0 in the mouse embryo (about 21 days in 
humans) contributing to the elongation and then the looping of the heart tube. 
Later on, the secondary heart field cells form the outflow tract, the right ventricle 
and both atria (Zaffran et al, 2004; Meilhac et al, 2004). 
 
1.1.1.2. Cardiac Neural Crest Cells 
 
Neural crest cells are a multipotent population of highly migratory cells 
originating from the dorsal neural tube at the early gastrula stage of vertebrate 
embryo development. Neural crest cells migrate and colonize the embryo to 
finally settle in different locations and generate a wide array of cell types and 
tissues (Le Douarin and Kalcheim, 1999). 
 
A subpopulation of neural crest cells, namely cardiac neural crest cells, 
originate from the level of the otic placode and the third somite, and migrate 
through the pharyngeal arches (described in section 1.2.1) to the outflow tract of 
the heart (Figure 1.1c) around E9.0 in the mouse embryo (around 21 days in 
humans) to help with the septation of the outflow tract (Phillips et al, 1987; Jiang 
et al, 2000). The role of neural crest cells in the pharyngeal arches and for the 
formation of the great arteries will be discussed in more detail in section 1.2.1. 
 
1.1.2. Outflow Tract Septation 
 
The septation of the outflow tract involves three main elements (reviewed in 
Webb et al, 2003): the formation of the aorticopulmonary septum, distinct 
histological identity of the truncus arteriosus and the outflow tract, and 
hemodynamics.  
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After looping of the heart tube four ridges are formed along the OFT and the 
truncus arteriosus by proliferation of pharyngeal mesenchymal cells. One 
opposing pair of ridges are formed over the endocardial cushions (which will 
later form the semilunar valves) at the near end of the truncus arteriosus, while 
another pair of opposing ridges are formed at the end of the outflow tract 
between the 4th and 6th pharyngeal arch arteries (discussed in detail in section 
1.2.2).  
 
As neural crest cells migrate through the outflow tract they colonize these ridges 
inducing their condensation and proliferation (Kramer, 1942; Pexieder, 1978; 
van Mierop, 1979).  
 
The four ridges grow towards each other in a 180o angle with the OFT ridges 
joining the conotruncal ridges of their opposite side and fusing all in the middle 
of the outflow tract forming a spiral septum. 
 
The outflow tract is histologically different from the truncus arteriosus and the 
junction between them is not symmetrical, with the outflow tract region being 
longer anteriorly than posteriorly and longer towards the left side.  
 
After the formation of the aorticopulmonary septum blood flows in a spiral 
clockwise way through the outflow tract which pushes the OFT towards the left 
side as it lengthens (Kramer, 1942; Pexieder, 1978; van Mierop, 1979). 
 
Finally, the force of blood flowing in a spiral pattern and the myocardialization 
(where mesenchymal cells are replaced with cardiomyocytes) of the 
aorticopulmonary septum causes the complete septation into the aorta and the 
pulmonary trunk (van den Hoff et al, 1999). The asymmetrical spiral flow of 
blood also contributes to the asymmetrical remodelling of the pharyngeal arch 
arteries during the formation of the great vessels as described below. 
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1.2. Development Of The Great Arteries And Pharyngeal Arch-Derived 
Tissues 
 
1.2.1. The Pharyngeal Arches 
 
The pharyngeal arches (Figure 1.2) in mammals appear as a transient series of 
bulges formed on the lateral surface of the developing embryo below the 
forming head around E9.0 in the mouse and about 21 days in humans (Graham 
and Smith, 2001). In mammals, the 5th pharyngeal arch is not formed, with the 
most caudal arch consequently being the sixth (Bamforth et al, 2013). 
 
The pharyngeal arches develop sequentially in a cranio-caudal direction formed 
by a mesenchymal core derived from cardiac neural crest cells and pharyngeal 
mesoderm, surrounded by an outer layer of pharyngeal ectoderm and an inner 
lining of pharyngeal endodermal cells (Figure 1.2b) (Noden, 1988).  
 
 
 
 
Figure 1.2. Anatomy of the pharyngeal arches. 
(a) Wild-type E10.5 embryo injected with India ink to visualise the pharyngeal arch arteries; the 
dotted yellow line underlies each pharyngeal arch. (b) Drawing illustrating the cellular 
components within the pharyngeal arches from a coronal view (red dotted line in Figure a). Five 
pairs (1-4 and 6) of arches are sequentially formed below the developing head and surrounding 
the developing pharynx. (b) Each arch is formed by an external layer of pharyngeal ectoderm 
(blue), an internal lining of pharyngeal endoderm (green), and a mesenchymal core composed 
of pharyngeal mesoderm (pink) and neural crest cells (purple); within each arch, a pharyngeal 
arch artery (red) is formed, (a) connecting the cardiac outflow tract (OFT) with the paired dorsal 
aortas (dAo). PA, pharyngeal arch; OFT, outflow tract; as, aortic sac; dAo, dorsal aorta.  
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As development continues, the endodermal and ectodermal walls invaginate 
towards each other to be in direct contact forming a closing membrane in 
between the arches. The grooves formed externally by the ectoderm are known 
as the pharyngeal clefts while the internal invaginations of the endoderm form 
the pharyngeal pouches. 
 
The physical arrangement of the pharyngeal arches contributes to the 
segmentation of the pharynx but also all different regions and components of 
the arches give rise to distinct tissues around the pharynx (reviewed in 
Grevellec and Tucker, 2010), including the great arteries. 
 
1.2.1.1. Derivatives of the First and Second Pharyngeal Arches 
 
The first pharyngeal arches expand ventrally to form the upper and lower jaw 
while the second arches form the hyoid apparatus, a group of bones that hold 
the larynx and support the pharynx and tongue. The first and second arches are 
separated by the first cleft and pouch, which in turn contributes greatly to the 
external and middle ear (Mallo, 2001). In this context, the first pouch elongates 
and distally forms the epithelium of the tympanic cavity and proximally the 
Eustachian tube, whereas the first cleft forms the external auditory canal, which 
later elongates and joins the tympanic cavity where the joining forms the 
tympanic membrane and connects with the Eustachian tube (Mallo, 2001; 
Lazaridis and Saunders, 2008). Although the second cleft appears to not have 
derivatives, the second pouch forms the tonsil epithelium (Rogers, 1929; Wilson 
et al, 2005) a lymphoid organ that provides antigenic response to foreign 
microbes entering orally.   
 
1.2.1.2. The Caudal Pharyngeal Arches and the Pharyngeal Glands 
 
The third and fourth pouches form the thymus, parathyroid glands and 
ultimobranchial bodies (Cordier and Haumont, 1980). The cranial region of the 
third pouch forms the inferior parathyroid and the caudal part forms the thymus 
epithelium while the anterior part of the fourth pouch forms a second pair of 
parathyroid glands known as the superior parathyroids (Cordier and Haumont, 
1980; Hilfer and Brown, 1984; Gordon et al, 2001).  
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The caudal ventral fourth pouch forms the ultimobranchial bodies, a transient 
tissue which forms calcitonin-producing cells known as C-cells after its fusion 
with the thyroid gland (Hilfer and Brown, 1984). 
 
After specification and differentiation of the different pouch derivatives, the 
thymus, parathyroids and ultimobrachial bodies move along the midline of the 
embryo to reach their final position (Manley and Capecchi, 1998; Kameda et al, 
2004). 
 
The thymus and parathyroid primordium detach from the pharynx and move 
together caudal-ventrally towards the anterior thoracic cavity. As they move, 
they reach the thyroid gland to which the parathyroid connects consequently 
separating it from the thymus. The parathyroids then stay connected to the 
thyroid lobe whereas the thymus descends further caudally along the midline to 
finally settle above the heart behind the sternum (Manley and Capecchi, 1998; 
Kameda et al, 2004). 
 
The ultimobranchial bodies detach from the pharynx as well, moving caudally 
and ventrally along the midline to reach the anterior thyroid lobe. Cells of the 
ultimobranchial bodies then spread around the lobe and fuse with the thyroid 
follicular tissue to finally differentiate into C-cells (Rogers, 1927). 
 
1.2.1.3. Cellular Components of Pharyngeal Arch-Derived Tissues 
 
Within the pharyngeal arches the different cellular components (endoderm, 
mesoderm, ectoderm and neural crest cells) contribute to different parts of the 
tissues described above (pharynx, thymus, parathyroids, ultimobranchial 
bodies). 
 
The epidermis and sensory neurons of the epibranchial ganglia and pharynx are 
derived from the ectoderm (Couly and Le Douarin, 1990; D'Amico-Martel and 
Noden, 1983), while the endoderm generates the epithelial cells covering the 
pharynx and the thyroid, parathyroid and thymus glands (Le Douarin and 
Jotereau, 1975; Cordier and Haumont, 1980).  
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Mesoderm cells differentiate into endothelium and musculature of the 
pharyngeal arch arteries (Couly et al, 1992; Trainor et al, 1994) and neural crest 
cells form connective and skeletal tissue of pharyngeal arch-derived glands 
(Noden, 1983; Couly et al, 1992) and form the latter musculature surrounding 
the aortic arch. Although neural crest cells are not necessary for the formation 
of the pharyngeal arch arteries, they are required after the remodelling into the 
great arteries where they form the vascular smooth muscle cells covering the 
aortic arch and the proximal region of the descending aorta before the left 
subclavian artery (Waldo et al, 1996). 
 
The endoderm in particular plays a key role in both patterning of the pharyngeal 
arches as well as for the specification of the different pharyngeal arch-derived 
tissues. Such specification is driven by differential expression of signalling 
molecules within the pharyngeal endoderm. 
 
1.2.1.4. Signalling Within The Pharyngeal Arches 
 
Although the specific signalling pathways by which the pharyngeal arches are 
initially formed are still not completely clear, numerous evidence has originated 
from knockout mice displaying abnormal formation of the pharyngeal arches. 
For instance, retinoic acid signalling is required for correct formation of the 
pharyngeal arches and subsequent derived tissues as shown by deletion of 
Raldh2, the enzyme that catalyses the synthesis of retinoic acid. Homozygous 
deletion of Raldh2 in mice leads to failure in the formation of the caudal 
pharyngeal arches, with only the first arch forming (Niederreither et al, 1999; 
Begemann et al, 2001); further pharmacological perturbation of retinoic acid 
signalling by blocking the three retinoic acid receptors (RAR α, β, γ) with the 
BMS493 antagonist confirmed retinoic acid signalling requirement for the 
formation of the pharyngeal arches (Wendling et al, 2000). 
 
Deletion of other genes such as Tbx1 has shown their requirement for the initial 
formation of the pharyngeal arches, as homozygous deletion of Tbx1 in mice 
shows complete failure in the formation of the caudal arches with only the first 
pharyngeal arch forming (Jerome and Papaioannou, 2001; Lindsay et al., 2001).  
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Tbx1 haploinsufficiency in mice does not affect the formation of the pharyngeal 
arches or patterning of the pouches, however, TBX1 haploinsuficiency in 
humans is considered to be responsible for underlying the phenotype in 22q11 
deletion syndrome, where patients present a variety of abnormalities mainly 
affecting pharyngeal arch-derived tissues including the jaw, ears, thymus and 
the great arteries. The role of Tbx1 in the development of the great arteries and 
in 22q11 deletion syndrome will be discussed in detail in section 1.4. 
 
Within the pharyngeal endoderm, differential expression of homeobox genes 
(Hox), particularly Hoxa2 and Hoxa3 specify regions of the second and third 
pharyngeal pouches and their derivatives (Hunt et al, 1991; Rijli et al, 1993; 
Pasqualetti et al, 2000; Grammatopoulos et al, 2000).  
 
Moreover, Pax1, Pax9, Six1, Eya1 are all required within the pharyngeal pouch 
endoderm, where they act within the same genetic network to promote Fgf8 
signalling and subsequently inducing Gcm2 and Foxn1 expression to induce 
thymus and parathyroids organogenesis (Manley and Capecchi, 1995; Wallin et 
al, 1996; Su et al, 2001; Abu-Issa et al, 2002; Xu et al, 2002).  
 
Gcm2 is essential for parathyroid proliferation and survival (Gunther et al, 2000; 
Liu et al, 2007), while Foxn1 is then required for differentiation and proliferation 
of thymus epithelial cells. (Manley and Capecchi, 1995; Hetzer-Egger et al, 
2002; Wallin et al, 1996; Xu et al, 2002). Disruption of retinoic acid signalling 
(Mulder et al, 1998; Quinlan et al, 2002; Wendling et al, 2000) or deletion of 
Tbx1 (Ivins et al, 2005; Vitelli et al., 2002; Guo et al., 2011) affects Pax1, Pax9, 
Six1 and Eya1 expression, consequently disrupting thymus development.  
 
Defects of some pharyngeal arch-derived tissues are often found in patients 
with congenital cardiovascular malformations (CCVM). For instance, patients 
with 22q11 deletion syndrome (discussed in detail in section 1.4.2.1.1), present 
thymus hypoplasia, jaw and ears malformations along with cardiovascular 
abnormalities mainly affecting the great arteries; such defects in the great 
arteries are derived from abnormal development of the pharyngeal arch arteries 
as described below. 
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1.2.2 Formation and Remodelling of the Pharyngeal Arch Arteries 
 
The pharyngeal arch arteries (PAAs) are formed sequentially within the core of 
each of the pharyngeal arches (Figure 1.2b) and connect the heart (through the 
aortic sac) with the systemic circulation (paired dorsal aorta; Figure 1.2a).  
 
Although it was initially suggested the pharyngeal arch arteries are formed by 
angiogenesis (Noden, 1989), where new vessels are formed from pre-existing 
ones, mounting evidence suggests they are formed by vasculogenesis 
(DeRuiter et al, 1993; Hiruma and Hirakow, 1995; Waldo et al, 1996), where 
vessels are formed de novo by differentiation of mesoderm cells into 
endothelium. Recent evidence shows mesodermal cells differentiate into 
endothelium forming threads that join the dorsal aorta and the aortic sac, which 
then grow towards each other to form a single vessel (Anderson et al, 2008; Li 
et al, 2012). 
 
Initially, the pharyngeal arch arteries are formed symmetrically on both sides of 
the embryo but then undergo a remodelling process (Hiruma et al, 2002; 
Bamforth et al, 2013) to form the final asymmetrical structure of the great 
arteries as described below (Figure 1.3) 
 
The 1st PAAs become evident as early as E8.5 in the mouse embryo, with the 
2nd PAAs appearing by E9.5; however these PAAs persist only for a short 
period before regressing almost completely, with their remnants contributing to 
parts of the maxillary and stapedial arteries.  
 
Around E9.5 (28-32 days in humans) the 3rd PAAs are visible connecting the 
aortic sac with the dorsal aorta, while the 4th PAAs appear as thin vessels and 
the 6th PAAs are just forming. By E10.5 (31-35 days) the 4th and 6th PAAs are 
completely formed and can be seen connecting the aortic sac with the dorsal 
aorta with the 3 pairs showing a similar diameter (Figure 1.3a). At this stage the 
pulmonary arteries start to sprout from the proximal region of the 6th PAAs 
where they incorporate endothelial cells derived from the pharyngeal mesoderm 
to grow caudally and parallel to the dorsal aorta.  
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By E11.5 (37-42 days in humans) the outflow tract is fully septated into the 
aortic and pulmonary outflows, with the 3rd and 4th PAAs connecting to the 
aortic end and the 6th PAAs connecting to the pulmonary outflow (Figure 1.3b). 
 
As described above, the clockwise spiral flow of blood pushes the aortic and 
pulmonary outflows towards the left side. This rotation causes the right 6th PAA 
to lengthen reducing its diameter and restricting the flow of blood from this side 
(Hiruma et al, 2002; Anderson et al, 2008). This reduction in blood flow on the 
right side causes the right dorsal aorta to also start regressing. By E12.5 (42-44 
days in humans) the right 6th PAA has completely regressed along with the 
portion of the right dorsal aorta below the 4th PAA (Figure 1.3c).  
 
The left 6th PAA forms the ductus arteriosus (Figure 1.3f, da), a connection 
between the pulmonary trunk and the descending aorta that persists during 
foetal life to allow blood to bypass the non-functional lungs and then closes after 
birth. 
 
The portion of the paired dorsal aortas between the 3rd and 4th PAAs is called 
the carotid duct and this also regresses completely by E12.5 (Figure 1.3c). The 
complete regression of the right dorsal aorta by E13.5 forces the flow of blood 
towards the left side, causing the left dorsal aorta to further enlarge. The left 4th 
PAA that is connecting the aortic sac with the left dorsal aorta now forms the 
central part of the aortic arch. As the flow of blood increases, the aortic sac 
enlarges forming a “Y” shape, with the left end connecting to the aortic arch and 
the right end forming the trunk of the brachiocephalic artery.  
 
The brachiocephalic artery further branches, connecting on the right side with 
the right 4th PAA and cranially with the right 3rd PAA. The right 4th PAA persists 
as the central part of the right subclavian artery (RSA), and with the regression 
of the right dorsal aorta, the right 7th intersegmental artery (ISA) is now 
connected with the right 4th PAA forming the right subclavian artery (Figure 
1.3e). As the dorsal aorta enlarges, the left 7th ISA moves cranially closer to the 
aortic arch where it forms the left subclavian artery (Figure 1.3d).  
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At the same time as the embryo grows the 3rd right and left PAAs are pulled up 
cranially, lengthening them and forming the right and left common carotid 
arteries (Figure 1.3d); both common carotids further branch cranially into the 
internal and external carotids (Figure 1.3e). 
 
Thus, the 3rd PAAs form the common carotids; the right 4th PAA forms the 
proximal part of the right subclavian artery while the left 4th forms the aortic arch. 
The left 6th forms the ductus arteriosus, and the 7th ISAs form the subclavian 
arteries. 
 
Evidence suggests that the 5th pair of PAAs exist only briefly, although their 
contribution to the final structure of the great arteries is still unclear (Bamforth et 
al., 2013). 
 
The formation of the PAAs is evolutionarily conserved among vertebrates  
(Reviewed in Kardong, 2008), although some differences are observed among 
different species. For example, in the zebrafish, only two of the initial six PAAs 
are remodelled and the other four persist. Another example is the remodelling of 
the PAAs in chick embryos where the right 4th PAA forms the aortic arch 
instead of the left as in humans and mice. However, the formation of a set of 
bilaterally symmetrical arteries connecting the primitive heart with the paired 
dorsal aorta, which are then remodelled into the great vessels to correctly bring 
blood in and out of the heart, occurs overall in the same fashion in all mammals. 
Imaging studies have revealed that the formation and patterning of the PAAs in 
mouse (Bamforth et al., 2013; Hiruma et al., 2002) closely resembles the 
process that occurs in humans (Bamforth et al., 2013; Congdon, 1922) as both 
present with 5 pairs of pharyngeal arches in the developing embryo and form a 
similar structure of the great arteries in adults. Although the timing slightly 
differs due to the short pregnancy in mice, the remodelling process occurs in 
the same way. Additionally, the genetics underlying this process in mice also 
appears to be similar to humans, making the mouse a good model for the study 
of PAA development in congenital heart disease. 
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Figure 1.3. Remodelling of the pharyngeal arch arteries. 
The pharyngeal arch arteries start as symmetrical pairs on both sides of the developing embryo. 
(a) at E10.5, the 3
rd
, 4
th
 and 6
th
 pairs of arteries are patent connecting the heart through the 
aortic sac (as) with the paired dorsal aortas (dAo). (b) by E11.5, the aortic sac is fully septated 
into the aorta and pulmonary trunk, whereas the carotid duct (cd) and the right dorsal aorta start 
to regress, whilst the left dorsal aorta begins to enlarge; the right 6
th
 PAA degenerate due to 
regression of the right dorsal aorta. (c) by E12.5 the carotid duct, the right dorsal aorta and the 
right 6
th
 PAAs have almost completely disappeared, and the 7
th
 intersegmental arteries (7
th
 ISA) 
move up opposite to the 4
th
 PAAs. (d) by E13.5, the remodelling is almost completed. (f) the 3
rd
 
PAAs (yellow) form the common carotids (RCC, LCC), while the right 4
th
 PAA forms the central 
part of the right subclavian artery, and the left 4
th
 PAA forms the central region of the aortic arch. 
The right 6
th
 PAA regresses completely, whereas the left 6
th
 PAA forms the ductus arteriosus 
(da). The 7
th
 intersegmental arteries (ISA) form the distal part of the subclavian arteries. Ao, 
aorta; dAo, dorsal aorta; RSA, right subclavian artery; RCC, right common carotid artery; LSA, 
left subclavian artery; LCC, left common carotid artery; da, ductus arteriosus; pAs, pulmonary 
arteries; PT, pulmonary trunk; as, aortic sac. 
 
 
 
 
 
 
16 
 
  
1.3. The Mouse As A Model To Study Cardiovascular Development 
 
Mice are commonly used in research to study different aspects of physiology or 
disease as they share with humans many important genetic and physiological 
features. Although mice also have physiological differences, more than 99% of 
human genes are conserved in mice (Pennacchio, 2003), and their low 
maintenance cost and ease to breed make them a good tool for research.  
 
In particular, the development of the heart (Reviewed in Anderson et al, 2003; 
Buckingham et al, 2005) and the great arteries (Reviewed in Kardong, 2008; 
Bamforth et al, 2013) is highly conserved including the genetics underlying their 
development. 
 
Although the chicken and zebrafish have proved invaluable models in 
cardiovascular development research, key differences in the formation of the 
great arteries as mentioned before, with the chicken having a right-sided aortic 
arch and the zebrafish PAAs remaining symmetrical, the mouse is a superior 
model for the study of PAAs development.  
 
Furthermore, the ability to modify the mouse genome by genetic engineering 
allows researchers to generate models to study a specific gene or disease.  
 
There are two ways to generate a genetically modified mouse: by pronuclei 
microinjection (transgenesis; Gordon et al, 1980), and by gene targeting (knock-
out; Thomas and Capecchi, 1987). 
 
In the first approach (transgenesis), an exogenous gene or piece of artificial 
DNA (transgene) is injected into the egg directly after fertilization (Gordon et al, 
1980), where the transgene will incorporate randomly into the genome. 
Transgenes are typically used to over-express a gene, interfere with its function 
as dominant-negative isoforms, or simply as reporters.  
 
Although this approach is easier as it does not require to know the specific 
genomic sequence of the target gene, this means the integration of the 
transgene into the genome cannot be controlled, and the integration site may 
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interfere with other gene’s function. Additionally, multiple copies of the 
transgene may integrate into the genome, making it difficult to control for copy 
numbers and levels of expression of the transgene.  
 
In the second approach (knock-out), the artificial DNA is designed containing 
identical or homologous sequence to the target gene both up- and down-stream 
of the gene location in the chromosome; the homologous DNA sequence is then 
inserted into embryonic stem (ES) cells, where during DNA replication for cell 
division the cell’s machinery will recognize the exogenous DNA as its own, and 
will interchange it with the endogenous sequence by homologous 
recombination, therefore knocking out the endogenous gene typically by 
replacing it with a reporter gene cassette (i.e. neomycin).  
 
Although this approach allows for a controlled modification as it is specifically 
targeted, it requires knowing the specific sequence of the target gene and a 
more complex genomic integration, thus making it more technically difficult. 
 
Newer genetic engineering techniques allow the conditional inactivation of a 
gene spatially and/or temporally using site-directed recombination, such as the 
Cre/LoxP recombination system, in which a target gene is flanked by LoxP 
sites, which are recognized by the Cre complex and recombined. 
 
The LoxP (locus of X-over P1) is a 34bp site on the bacteriophage P1 DNA that 
includes a core asymmetric 8bp sequence in between two sets of 13bp 
palindromic inverted repeats (ATAACTTCGTATA-NNNTANNN-
TATACGAAGTTAT); the central senquence, where the recombination takes 
place is variable (-NNNTANNN-) and specifies the direction of recombination.  
 
Upon Cre induction, the Cre complex binds to the 13bp flanking repeats of a 
LoxP site forming a dimer, which in turn binds to another dimer of a second 
LoxP site to form a tetramer. The adjacent double stranded DNA is cut at both 
LoxP sites at the central 8bp sequence by the Cre protein, and the strands are 
then re-joined by the DNA ligase. The result of recombination depends on the 
orientation of the central sequence, where parallel sequences will cause a 
deletion, whereas inverted sequences will cause an inversion. 
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Cre can be driven by a specific promoter, thus when the promoter of the gene of 
interest is expressed, Cre is expressed targeting a specific cell type at a specific 
time. The system can be used in the opposite way to activate a gene, where 
LoxP sites flank a “stop” codon or a “stop” sequence that prevents gene 
transcription, therefore upon Cre activation, the “stop” sequence is excised 
allowing gene transcription.  
 
Cre can also be pharmacologically induced, to selectively promote 
recombination at a specific time. To achieve this, a Cre chimeric protein fused 
to a mutated estrogen receptor-binding domains (ER) is used, where 
ubiquitously expressed but inactive chimeric Cre is localised within the 
cytoplasm, and upon ER agonist administration (i.e. Tamoxifen), Cre is 
translocated into the nucleous to be able to mediate DNA recombination 
(Danielian et al, 1998). 
 
The ability to specifically target a gene has helped to expand knowledge in 
genetics; regarding cardiovascular development, the use of mouse models has 
revealed more than 500 genes potentially related to cardiovascular 
development (reviewed in Andersen et al, 2013), some of which have already 
been directly associated with human congenital cardiovascular malformations. 
 
1.4 Congenital Cardiovascular Malformations 
 
Abnormalities in the formation of the heart or the main vessels that bring blood 
in and out of it (great arteries) can lead to defects in the newborn that can be life 
threatening. Such defects commonly denominated congenital cardiovascular 
malformations (CCVM) are the most common type of birth defect occurring 
about 10-12 in every 1000 live births (Hoffman, 2013).  
 
The main defects found in patients with CCVM involve abnormal blood flow 
between the cardiac chambers (ventricles and atria) or between the chambers 
and cardiac outflows (aortic and pulmonary arteries) (Figure 1.4).  
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Figure 1.4. Congenital cardiovascular malformations. 
Diagram illustrating the structures affecting in CCVM with their estimated incidence  per 1000 
live births indicated in parentheses AC, aortic coarctation; AS, aortic stenosis; ASD, atrial septal 
defect; AVSD, atrioventricular septal defect; BAV, bicuspid aortic valve; DORV, double outlet 
right ventricle; Ebstein’s, Ebstein’s anomaly of the tricuspid valve; HLHS, hypoplastic left heart 
syndrome; HRHS, hypoplastic right heart; IAA, interrupted aortic arch; MA, mitral atresia; MS, 
mitral stenosis; PDA, patent ductus arteriosus; PS, pulmonary artery stenosis; PTA, persistent 
truncus arteriosus; TA, tricuspid atresia; TAPVR, total anomalous pulmonary venous return; 
TGA, transposition of the great arteries; TOF, tetralogy of Fallot; VSD, ventricular septal defect. 
(from Bruneau, 2008). 
 
 
For instance, ventricular septal defects (VSD) are one of the most common 
defects (4 in every 1000 live births; Hoffman et al, 2004) that cause abnormal 
flow of blood between the ventricles, since the interventricular septum fails to 
fully close allowing blood to flow between the right and left ventricles mixing 
oxygenated and deoxygenated blood. VSD can be asymptomatic (which means 
the incidence could be higher) and patients can survive with no complications 
without the need for treatment, with more than 70% of VSD closing in the first 
year after birth (Hoffman et al, 2004). 
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Cardiovascular abnormalities that affect the flow of blood between the cardiac 
chambers and the cardiac outflows are usually the result of abnormal formation 
of the valves, which control a unidirectional flow in or out of the cardiac 
chambers. For instance, bicuspid aortic valve (BAV) is the most common CCVM 
occurring in about 14 per 1000 live births (Bruneau, 2008). BAV is caused when 
two leaflets of the aortic valve fuse during embryonic development resulting in a 
valve with only two leaflets instead of three which later causes regurgitation of 
blood back from the aorta into the left ventricle. Although patients may be 
asymptomatic, BAV has been associated with a tendency to develop ascending 
aorta aneurisms in adulthood due to the stress caused by the regurgitation of 
blood (Tadros et al, 2009). 
 
Double outlet right ventricle (DORV) affects 1-3% of patients with CCVM (Obler 
et al, 2008), and occurs when both the aorta and pulmonary trunk arise from the 
right ventricle; DORV is typically accompanied by a VSD to allow oxygenated 
blood from the left ventricle to reach the aorta. Patients with DORV require 
surgery, and the severity of the symptoms varies depending on the presentation 
of the DORV and other cardiovascular malformations. 
 
A more rare but severe malformation affecting the flood of blood in and out of 
the heart is a persistent truncus arteriosus (PTA, also known as common 
arterial trunk, CAT), in which the primitive outflow tract (truncus arteriosus) fails 
to properly septate into the aorta and pulmonary trunk, resulting in a single 
arterial tube arising from the heart, providing mixed blood to the pulmonary and 
systemic circulation.  
 
Other abnormalities affecting the flow of blood in or out of the cardiac chambers 
are directly caused by malformation of the great arteries (aortic and pulmonary 
arteries), which are the result of abnormal development of the pharyngeal arch 
arteries.  
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1.4.1 Pharyngeal Arch Artery Defects 
 
Anomalies specifically affecting the formation of the great arteries account 
together for about 30% of all CCVM (Thom et al, 2006) and are derived from 
failure during the formation or remodelling of the pharyngeal arch arteries in the 
developing embryo. 
 
One of the most common pharyngeal arch artery-derived defect is the 
anomalous right subclavian artery (ARSA) which is the most common aortic 
branching abnormality occurring in about 1% of the population and 3% of 
patients with CCVM (Zapata et al, 1993). ARSA occurs when the right 4th PAA 
abnormally regresses or is not formed (Figure 1.5a), causing the right dorsal 
aorta to persist as a connection with the right 7th intersegmental artery (future 
right subclavian artery). The abnormal right dorsal aorta travels cranially along 
the thoracic aorta reaching the aortic arch proximal to the left subclavian artery, 
where it travels behind the oesophagus towards the right side (Figure 1.5c) 
(Bergwerff et al, 1999). 
 
Although ARSA is not lethal per se, it can cause complications when the artery 
presses against the oesophagous causing difficulty swallowing, and the 
continuous compression of the artery against the oesophagous frequently 
causes aneurisms or complete rupture of the artery with a 50% mortality rate 
(Leong et al, 2012). 
 
If the right 4th PAA is absent and the right carotid duct fails to regress, the 7th 
ISA joins the carotid duct forming a right subclavian artery that originates from 
the right common carotid at a higher cervical position known as cervical right 
subclavian artery (coRSA; Figure 1.5d) (Kellenberger, 2010). 
 
When the left 4th PAA is affected either by abnormal regression or a complete 
lack of its formation (Figure 1.5b), the result is a cervical aortic arch (coAA) or 
an interrupted aortic arch (IAA). A cervical aortic arch is formed when the left 4th 
PAA is absent and the left carotid duct persists forming an arch that connects 
the thoracic aorta to the left common carotid (Figure 1.5e) (Kellenberger, 2010). 
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If the left 4th PAA is absent and the carotid duct normally regresses, the result is 
an interrupted aortic arch (IAA, Figure 1.5f), which is a complete disruption in 
the connection between the ascending and descending aorta that disrupts the 
flow of oxygenated blood.  
 
 
Figure 1.5. Pharyngeal arch artery defects. 
(a) When the right 4
th
 PAA abnormally regresses or is not formed, the right dorsal aorta may 
persist as a connection with the right 7
th
 intersegmental artery, thus the right dorsal aorta travels 
cranially along the thoracic aorta proximal to the left subclavian artery, where it travels behind 
the oesophagus towards the right side forming an anomalous retro-esophageal right subclavian 
artery (ARSA) (c). If the right 4
th
 PAA is absent and the right carotid duct fails to regress, the 7
th
 
ISA joins the carotid duct forming a right subclavian artery that originates from the right common 
carotid with a cervical origin (coRSA) (d). (b) When the left 4
th
 PAA abnormally regresses or is 
not formed, a cervical aortic arch (coAoA) may be formed if the left carotid duct persists (e), 
whereas if the carotid duct regresses normally, the result is an interrupted aortic arch (IAA) (f). 
Ao, aorta; dAo, dorsal aorta; RSA, right subclavian artery; RCC, right common carotid artery; 
LSA, left subclavian artery; LCC, left common carotid artery; da, ductus arteriosus; PT, 
pulmonary trunk. 
 
There are 3 types of IAA: type A (IAA-A) occurs when the interruption is just 
beyond the left subclavian artery (distal); in type B (IAA-B) the interruption 
occurs between the left common carotid and the left subclavian artery (Figure 
1.5f), whereas in type C the interruption is between the brachiocephalic artery 
and the left common carotid (proximal). IAA type C is the least common case 
accounting for less than 5% of cases, whereas type B is the most common 
occurring in more than 55% of patients with IAA.  
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In utero the embryo is not affected by this disruption since oxygenated blood 
flows to the descending aorta through the ductus arteriosus. However, the 
ductus arteriosus closes after birth cutting down the flow of oxygenated blood to 
the rest of the body. Patients born with IAA need to be treated immediately by 
administering prostaglandins to maintain the ductus arteriosus open to preserve 
the flow of blood, followed by open heart surgery to graft an arterial connection 
between the ascending and descending aorta to prevent lethality, which occurs 
within 4 days in 90% of patients with IAA if left untreated. 
 
Although IAA is not common as an isolated defect (2 per million live births), it is 
usually found in association with other CCVM. Interestingly, about 50% of 
patients with IAA-B have 22q11 deletion syndrome.  
 
1.4.2 Genetics of Congenital Cardiovascular Malformations 
 
The aetiology of congenital cardiovascular malformations is complex typically 
involving environmental and genetic causes. In the context of genetics, more 
than 55 genes have been associated with human CCVM (reviewed in Andersen 
et al, 2013), either in isolated CCVM or as part of the phenotype in genomic 
syndromes (syndromic CCVM). 
 
1.4.2.1 Chromosomal aberrations associated with CCVM 
 
About 8-18% of CCVM are due to chromosomal aberrations (Meberg et al, 2007; 
Schellberg et al, 2004), including aneuploidy, micro-deletions and micro-
duplications. 
 
Within typical aneuploidy syndromes presenting cardiovascular malformations 
are Down syndrome (trisomy 21; Freeman et al, 2008), Turner syndrome 
(monosomy X; Mazzanti and Cacciari, 1998) and Edward syndrome (trisomy 18; 
Embleton et al, 1996). 
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About 40% of patients with Down’s syndrome present cardiovascular 
abnormalities including atrial/ventricular septal defects, valve defects, persistent 
ductus arteriosus and tetralogy of Fallot (Freeman et al, 2008). Cardiovascular 
defects are the main cause of mortality in patients with monosomy X (Turner 
syndrome; Price et al, 1986), typically presenting coarctation of the aorta and 
biscupid aortic valves (Mazzanti and Cacciari, 1998). Edward syndrome 
patients typically present atrial/ventricular septal defects and persistent ductus 
arteriosus. Cardiovascular defects in patients with trisomy 18 are the second 
main cause of mortality (Embleton et al, 1996).  
 
Among micro-deletion syndromes presenting cardiovascular malformations are 
Williams-Beuren syndrome, Wolf-Hirschhorn syndrome and 22q11 deletion 
syndrome. 
 
Williams-Beuren syndrome is caused by a 1.5-1.8 Mb deletion in 7q11.23 
encompassing about 28 genes (Ewart et al, 1993; Perez Jurado et al, 1996); 
About 75% of patients present cardiovascular malformations mainly aortic and 
pulmonary arterial stenosis (del Pasqua et al, 2009).  Wolf-Hirschhorn 
syndrome is caused by a micro-deletion in 4p16.3, and patients may present 
atrial (ASD) and ventricular septal defects (VSD) (Maas et al, 2008). 
 
1.4.2.1.1 22q11 Deletion Syndrome 
 
22q11 deletion syndrome (22q11DS) is the common term for patients carrying a 
micro-deletion on the long arm of chromosome 22 that includes DiGeorge 
Syndrome, velo-cardio-facial syndrome and conotruncal anomaly face 
syndrome patients.  
 
22q11DS is the most common micro-deletion syndrome occurring in humans, 
affecting 1 in every 4000 live births (Wilson et al, 1994; Devriendt et al, 1998) 
where affected individuals present with a wide variety of abnormalities 
(reviewed in Shprintzen, 2008) including craniofacial dysmorphology, cleft 
palate, immune deficiency, mental retardation and cardiovascular defects. 
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Although the craniofacial dysmorphology along with immunodeficiency and 
hypothyroidism are the classical features of 22q11DS, the main cause of 
morbidity and mortality are cardiovascular defects (Ryan et al, 1997). About 80% 
of patients with 22q11DS have cardiovascular abnormalities including 
ventricular septum defects (VSD), persistent truncus arteriosis (PTA), tetralogy 
of Fallot, anomalous right subclavian artery (ARSA) and interrupted aortic arch 
type B (IAA-B).  
 
The cardiovascular abnormalities seen in patients with 22q11 deletion seem to 
particularly affect the outflow tract and the great arteries. Along with craniofacial 
abnormalities and immune deficiency due to thymus hypoplasia, 22q11DS 
seem to predominantly affect the development of the pharyngeal arch-derived 
tissues.  
 
About 90% of 22q11DS patients harbour a 3Mb deletion known as the typical 
deleted region (TDR) while most of the remaining patients have a smaller 1.5Mb 
deletion (known as the critical region) on band 11.2 on the long arm (q) of 
chromosome 22 (Figure 1.6).  
 
 
Figure 1.6. 22q11 deletion. 
Schematic of human 22q11 chromosomal region, illustrating the typical and critical deletions. 
22q11 deletions are caused by recombination between four low copy repeats (LCR-A-D, red 
boxes); LCR-A and D producing the typical 3Mb deletion, and LCR-A and B generating the 
critical 1.5Mb deletion. More than 85% of 22q11DS patients harbour the 3Mb typical deletion, 
while less than 10% of patients have a smaller 1.5Mb deletion. Within the typical region several 
genes are deleted, including TBX1 (green box) and CRKL. (Adapted from Lindsay, 2001 and 
Dykes et al, 2014). 
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The 22q11 chromosomal region presents a high frequency of de novo 
rearrangements, attributed to the presence of 8 highly homologous low copy 
repeats (LCRs) (Shaikh et al, 2000); these LCR present a high sequence 
identity (<98%) and are known to typically mediate interchromosomal 
exchanges during meiosis (Saitta et al, 2004). 
 
Recombination of the four most proximal LCRs (LCR-A through -D), mediate 
the typical and critical 22q11 deletions (Figure 1.6), with LCR-A and D 
producing the typical 3Mb deletion and LCR-A and B generating the critical 
1.5Mb deletion (Shaikh et al, 2000; Shaikh et al, 2001; Spiteri et al, 2003). Due 
to the high conservation of the LCRs among eukaryotic genomes these 22q11 
deletions are highly homogeneous.  
 
In this context, the 22q11-deleted region is highly conserved in mouse within 
chromosome 16 (Galili et al, 1997; Botta et al, 1997; Puech et al, 1997; 
Sutherland et al, 1998), which has allowed the generation of different mouse 
models to dissect the genetic aetiology of 22q11DS.  
 
Heterozygous deletion of the mouse homologue of the 22q11 region (Df1) can 
recapitulate most of the cardiovascular defects seen in human patients (Lindsay 
et al, 1999); however, 22q11 deletions result in heterozygosity for more than 30 
genes deleted within the typical region, suggesting the 22q11DS phenotype 
may result from complex genetic interactions. 
 
Targeted specific deletions of genes within the 22q11 typical region revealed 
Tbx1 as the main determinant gene underlying the 22q11DS phenotype (Yagi et 
al, 2010), as Tbx1 haploinsufficiency in mice resembled the typical 
cardiovascular phenotypes seen in 22q11DS patients, including 4th PAA-derived 
defects such as IAA-B (Jerome and Papaioannou, 2001; Lindsay et al., 2001; 
Merscher et al., 2001). 
  
Another deleted gene within the typical 22q11 regions is CRKL, which encodes 
an adaptor protein required for normal FGF8 signalling. Although Crkl-null mice 
present cardiovascular defects including VSD, the incidence of 4th PAA-derived 
defects (a hallmark of 22q11DS) is low in Crkl-null mice (Guris et al, 2001), and 
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such penetrance only increases with Fgf8 heterozygosity (Moon et al, 2006); 
Crlk haploinsufficiency does not affect cardiovascular development, rather it 
seems to modify the Tbx1 heterozygous phenotype by affecting FGF and 
retinoic acid signalling (Guris et al, 2006). 
 
Moreover, sole transgenic expression of TBX1 can rescue the 22q11DS-like 
defects seen in haploinsufficient mice (Merscher et al, 2001). Additionally, point 
mutations in TBX1 have been reported in patients without 22q11 deletion but 
presenting cardiovascular phenotypes similar to those of 22q11DS patients 
(Zweier et al, 2007), further identifying TBX1 as the gene underlying the 
22q11DS phenotype. 
 
1.5 TBX1 In Cardiovascular Development 
 
TBX1 belongs to a family of T-box genes, which encode transcription factors 
that play key roles during embryonic development for the formation of many 
tissues (Bollag et al, 1994).  
 
There are 17 T-box genes grouped in 5 sub-families based on amino acid 
homology, although the T-box binding domain is highly conserved (Muller et al, 
1997). The T-box binding domain (also known as T-box binding element, TBE) 
consists of about 180 residues (17-26 kDa) which recognize a characteristic 
palindromic DNA sequence known as the T-half site (5’-AGGTGTGAAATT-3’) 
however, T-box proteins bind to this sequence in different orientations and 
spacing which could determine gene specificity for each particular T-box gene 
(Bollag et al, 1994; Sinha et al, 2000; Conlon et al, 2001). In this context, it was 
recently reported that Tbx1 binds preferentially to tandem repeats of the T-half 
site on a 5’-3’ orientation unlike other T-box family members that typically 
recognize palindromic sequences of the T-half site (Castellanos et al, 2014). 
 
Tbx1 is initially expressed exclusively in the embryonic mesoderm at E7.5 and 
its expression remains restricted to the pharyngeal region and the otic vesicle 
by E9.5 (Chapman et al, 1996). Within the pharyngeal arches Tbx1 is 
expressed in the ectoderm, mesoderm and endoderm but not in neural crest 
cells (Chapman et al., 1996; Zhang et al., 2005). 
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Tbx1 expression is induced and sustained by Sonic hedgehog (Shh) expression 
in the pharyngeal endoderm (Garg et al., 2001), which in turn promotes 
mesodermal expression of the Forkhead transcription factors Foxa2, Foxc1 and 
Foxc2, which directly promote Tbx1 expression (Hu et al., 2004; Yamagishi et 
al., 2003). Foxa2 is also a direct target of Tbx1, which in turn generates a 
positive feedback loop (Hu et al., 2004; Yamagishi et al., 2003). 
 
The significant role of Tbx1 during embryonic development has been 
extensively described using transgenic mice, in which deletion of Tbx1 leads to 
severe cardiovascular defects (Jerome and Papaioannou, 2001; Lindsay et al., 
2001; Merscher et al., 2001). Tbx1 knockout mice die soon after birth due to 
severe cardiovascular anomalies and present various craniofacial abnormalities 
such as shorter neck, abnormally folded or absent external ears and they all 
lack the thymus glands (Jerome and Papaioannou, 2001). The majority of Tbx1-
null pups or late-stage embryos present a persistent truncus arteriosus (also 
known as common arterial trunk) where the truncus arteriosus fails to septate 
into the aorta and pulmonary trunk, delivering mixed oxygenated and 
deoxygenated blood into the systemic circulation. 
 
The origin of the persistent truncus arteriosus in Tbx1 knockout mice is due to 
abnormal development of the pharyngeal arches at earlier stages of embryonic 
development. By E9.5 the 1st, 2nd and 3rd arches should be completely formed 
however, in Tbx1-null embryos only the 1st pair of arches is developed while the 
caudal pharyngeal arches are not formed, consequently causing the pharyngeal 
arch arteries to be absent with a single artery connecting the aortic sac with the 
dorsal aorta that gives rise to a common arterial trunk in the later embryo.  
 
The majority of Tbx1 heterozygous (Tbx1+/-) mice are viable with only about 5% 
of perinatal lethality due to interrupted aortic arch (Vitelli et al, 2002; Guris et al, 
2006; Zhang et al, 2008; Calmont et al, 2009; Randall et al, 2009; Ryckebusch 
et al, 2010). These defects are caused by abnormal development of the 
pharyngeal arch arteries by E10.5 in mouse embryos, where a proportion of 
Tbx1+/- display abnormal 4th PAAs, which can be hypoplastic or completely 
absent either unilaterally or bilaterally  (Lindsay and Baldini, 2001; Calmont et al, 
2009; Randall et al, 2009; Ryckebusch et al, 2010). 
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Complete absence of the left 4th PAA by E10.5 is the cause of an interrupted 
aortic arch seen later in development, while absence of the right 4th may cause 
an aberrant right subclavian artery (ARSA). 
 
The frequency of abnormal 4th PAAs (hypoplastic and/or aplastic PAA) seen 
around mid-embryogenesis (E10.5) in Tbx1+/- embryos is much higher 
compared to the incidence of 4th PAA-derived defects (IAA, ARSA) seen in 
older embryos (Vitelli et al, 2002; Guris et al, 2006; Zhang et al, 2008; Calmont 
et al, 2009; Randall et al, 2009; Ryckebusch et al, 2010), indicating that some 
form of recovery occurs during the remodelling of the PAAs in Tbx1 
haploinsufficient embryos (Lindsay and Baldini, 2001; Calmont et al, 2009; 
Papangeli and Scambler, 2012). 
 
Tbx1 mRNA levels are critical for correct PAAs development as shown using 
hypomorphic alleles of Tbx1 (Zhang and Baldini, 2007). Reduced levels of Tbx1 
mRNA mainly affects the development of the 4th PAAs and the septation of the 
outflow tract, and the severity of the cardiovascular defects observed increases 
with further reductions in the levels of Tbx1 expression. Whereas over-
expression of Tbx1 in mice with extra copies of the gene, leads to 
cardiovascular abnormalities similar to those seen in Tbx1 heterozygous mice 
(Liao et al., 2004).  
 
Furthermore, timed conditional inactivation of Tbx1 revealed its requirement at a 
precise time frame between E7.5 and E8.5 for correct PAAs development, 
whereas septation of the outflow tract requires Tbx1 expression between E8.5 
and E9.5 (Xu et al., 2005). Later deletion of Tbx1 at E11.5 or E12.5 affects only 
the formation of other tissues such as the thymus and secondary palate but not 
the outflow tract or the pharyngeal arch arteries. 
 
Tbx1 is known to be required for correct development of the pharyngeal arches 
and their derived tissues, including the jaw, ears, thymus and the pharyngeal 
arch arteries (Arnold et al, 2006; Reviewed in Scambler, 2010, and Gao et al, 
2013).  
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The required expression of Tbx1 within the different compartments of the 
pharyngeal arches has been shown using conditional-knockout models to 
delete Tbx1 specifically from the mesoderm (Zhang et al., 2006), endoderm 
(Arnold et al., 2006) and ectoderm (Calmont et al., 2009; Randall et al., 2009).  
 
In this context, conditional deletion of Tbx1 from the mesoderm using MesP1cre 
(Zhang et al, 2006), or the endoderm using Foxg1cre (Zhang et al, 2006) results 
in abnormal patterning of the pharyngeal arches resembling the Tbx1-null 
phenotype, where the caudal pharyngeal arches are not developed and only the 
first arch is formed, consequently the PAAs are not formed and embryos 
present with persistent truncus arteriosus (Arnold et al., 2006; Zhang et al., 
2006). 
 
Conditional deletion of Tbx1 from the pharyngeal surface ectoderm does not 
affect the patterning of the pharyngeal arches but affects the formation of the 4th 
PAAs, presenting defects similar to the heterozygous (Tbx1+/-) embryos 
(Calmont et al., 2009; Randall et al., 2009). Additionally, Tbx1 expression in the 
pharyngeal ectoderm was shown to be required to control cardiac neural crest 
cell migration (Zhang Z et al, 2006; Calmont et al., 2009). In this context, Tbx1 
regulates ectodermal Gbx2 expression, which in turn controls neural crest cell 
migration through Slit/Robo signalling (Calmont et al, 2009). 
 
The requirement of Tbx1 for correct pharyngeal arch development and their 
related arteries is highly conserved as shown by using zebrafish. Mutation of 
tbx1 (vgo) in zebrafish results in abnormal patterning of the caudal pharyngeal 
arches and a reduction in the number of pharyngeal arch arteries (Piotrowski 
and Nusslein-Voldhard, 2000; Piotrowski et al, 2003), similar to the phenotypes 
seen in mice. Additionally, tbx1 mutation in zebrafish also affects neural crest 
cells (Piotrowski and Nusslein-Voldhard, 2000) similar to that seen in mouse 
models (Zhang Z et al, 2006; Calmont et al., 2009). 
 
The cardiovascular defects seen in Tbx1-null mice are largely due to a 
significant reduction in proliferation of secondary heart field cells. Such 
reduction in proliferation is caused mainly by down-regulation of Fgf8, a direct 
target of Tbx1 (Vitelli et al., 2002).  
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Further studies have found that Tbx1 interacts with Six1-Eya1 transcription 
factors which in turn regulate Fgf8 expression, and loss of either Six1, Eya1 or 
both lead to cardiovascular defects similar to those in Tbx1 mutant mice and 
22q11DS patients (Guo et al., 2011). Moreover, proliferation of secondary heart 
field cells is also affected by down-regulation of Wnt5a in Tbx1-null embryos, as 
Tbx1 is required to interact with Baf60a/Smarcd1 chromatin remodelling factors 
to promote Wnt5a expression (Chen et al., 2012).   
 
It has also been suggested that Tbx1 may promote proliferation of secondary 
heart field cells by directly interacting with Smad1, which inhibits Bmp4 
signalling (Fulcoli et al., 2009). 
 
It was recently reported that proliferation of secondary heart field cells are 
negatively regulated by p53 through repressing Gbx2 expression (Caprio and 
Baldini, 2014). In this context, Tbx1 regulates expression of Gbx2 by binding to 
a conserved T-box binding element within the Gbx2 locus, however, p53 is able 
to bind a close genomic element within the same region and recruit the 
polycomb repressive complex to methylate and silence Gbx2 expression 
(Caprio and Baldini, 2014).  
 
Gbx2 is a downstream target of Tbx1 required for correct NCC migration and 4th 
PAA development; in this context, Gbx2-null embryos present with 4th PAA-
derived cardiovascular defects including IAA-B and ARSA (Byrd and Meyers, 
2005), due to defective migration of NCC towards the PAs as a consequence of 
Slit/Robo signalling lose in NCC (Calmont et al, 2009). Consequently, 
heterozygous deletion of p53 ameliorates the Tbx1 heterozygous phenotype by 
rescuing Gbx2 expression and promoting SHF cells proliferation (Caprio and 
Baldini, 2014). 
 
However, Tbx1 does not only regulate heart and PAA development by 
promoting proliferation of progenitor cells, but also by regulating their 
differentiation. Tbx1 has been found to regulate Smad7 expression by binding 
directly to T-box elements within the Smad7 gene and further regulating Tgfβ 
signalling to control vascular smooth muscle differentiation, which is essential 
for PAAs remodelling (Papangeli and Scambler, 2012). 
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Although Tbx1 haploinsufficiency resembles most of the 22q11DS 
cardiovascular defects, 22q11DS patients present with a high phenotypic 
variability in terms of penetrance and severity, suggesting the presence of 
genetic modifiers that influence the presentation of the phenotype. 
 
The possibility of stochastic events causing the great phenotypic variability in 
22q11DS has been shown less likely, with evidence sustaining the existence of 
genetic modifiers influencing the 22q11 phenotype; the evidence shows that 
genetic background strongly affects the presentation of cardiovascular and 
thymic defects in a mouse model of 22q11DS (Df1) (Taddei et al, 2001); 
similarly, genetic background strongly influences the incidence of 4th PAA 
defects in Tbx1 heterozygous embryos (Zhang et al, 2005).  
 
Moreover, analysis of genes within the 22q11 deletion region showed no 
variations among these genes related to changes in the genetic background, 
suggesting genes elsewhere in the genome are capable of influencing the 
phenotype supporting the existence of genetic modifiers, which may potentially 
be in epistasis (the interaction between two or more genes to define a 
phenotype) with TBX1 to define the phenotype. 
 
In this context, various genes have been shown to genetically interact with Tbx1 
(reviewed in Aggarwal and Morrow, 2008) including Vegf (Stalmans et al, 2003), 
Crkl (Guris et al, 2006), Pitx2 (Nowotschin et al, 2006), Gbx2 (Calmont et al, 
2009), and Aldh1a2 (Ryckebusch et al, 2010), typically by increasing the 
incidence of 4th PAA-derived defects and modifying the Tbx1 heterozygous 
phenotype penetrance. 
 
However, more than 200 genes are affected by homozygous loss of Tbx1 in 
mouse embryos (Ivins et al, 2005; Liao et al, 2008) that could potentially be in 
epistasis with TBX1 and be genetic modifiers of the 22q11 deletion syndrome.  
 
Among those genes, the transcription factor Pax9 was found significantly down-
regulated by microarray of Tbx1-null embryos and further validated by 
quantitative PCR and in situ hybridisation (Figure 1.7) (Ivins et al, 2005). 
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Figure 1.7. Pax9 mRNA is down-regulated in Tbx1-null embryos. 
Whole-mount in situ hybridisation using a riboprobe for Pax9 showing Pax9 down-regulation in 
Tbx1-null embryos at E8.5 and E9.5, further validating results from a microarray analysis and 
qPCR. (modified from Ivins et al, 2005). 
 
 
1.6 Paired Box 9, PAX9 
 
PAX9 belongs to a family of 9 transcription factors characterized by a common 
motif, the DNA-binding paired domain (Chi and Epstein, 2002), all of which play 
essential functions during mammalian embryogenesis.  
 
The paired domain is a highly conserved 128 amino acid motif found in the N- 
terminal that binds to specific sequences within the DNA (Goulding et al, 1991; 
Chalepakis et al, 1991; Czerny et al, 1993; Epstein et al, 1994). Pax genes are 
classified into four subfamilies according to their genomic organization and 
expression patterns (Chalepakis and Gruss, 1995). 
 
The chromosomal location of PAX9 in humans is 14q13.3, and mutations in 
PAX9 and deletions within this chromosomal region are commonly associated 
with syndromic and non-syndromic oligo-/hypodontia (Reviewed in Cudney and 
Vieira, 2012; and De Coster et al, 2009) and holoprosencephaly (HPE) (Chen et 
al, 1997; Kamnasaran et al, 2005).  
 
 
 
34 
 
  
The critical role of Pax9 for tooth development has been described by deletion 
of Pax9 in mouse models (Kist et al, 2005), which has also revealed the 
requirement of Pax9 for correct development of some pharyngeal arch- derived 
tissues including the thymus, parathyroids and ultimobrachial bodies (Peters et 
al, 1998). 
 
During mouse embryogenesis Pax9 expression starts around E8.5, and 
becomes more evident within the pharyngeal arches by E9.5 (Figure 1.8a) 
(Neubüser et al, 1995; Peters et al, 1998), and its expression is restricted to the 
pharyngeal endoderm. Later on, Pax9 is also expressed in the axial skeleton 
and in neural crest-derived mesenchyme involved in craniofacial, tooth and limb 
development (Figure 1.8b; Peters et al, 1998). 
 
 
 
Figure 1.8. Pax9 expression and skeletal defects in Pax9-null embryos 
Pax9 expression starts around E8.5 exclusively within the pharyngeal arches (a); by E10.5 
Pax9 expression extends along the body axis and facial mesenchyme (b). Pax9-null mice 
present with preaxial duplication of the 1
st
 digit of the fore- (e) and hindlimbs (f).  
(adapted from Peters et al, 1998) 
 
 
Pax9 knockout embryos lack most derivatives of the caudal pharyngeal arches 
such as the thymus, parathyroid glands and ultimobranchial bodies. Additionally, 
they present craniofacial and skeletal defects including a supernumerary digit 
on the limbs (Figure 1.8e, g), absent teeth and cleft palate (Peters et al, 1998). 
Although most pharyngeal arch-derivatives are absent in Pax9-null mice, the 
pharyngeal arches are actually formed, however development of the 3rd and 4th 
arches stops at E11.5 (Peters et al, 1998). Pax9-null mice die shortly after birth 
because of respiratory insufficiency due to the cleft palate (Peters et al, 1998).  
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Pax9 expression is induced and sustained by ectodermal Fgf8, whereas Bmp2 
and 4 signalling repress Pax9 expression (Neubüser et al, 1995). Moreover, 
expression of Pax9 is affected by loss of Tbx1, as shown by microarray analysis, 
quantitative PCR and in situ hybridisation of Tbx1 knockout embryos. Pax9 
expression is down-regulated in Tbx1-null embryos prior to the formation of the 
caudal pharyngeal arches (around E8.5), therefore before any anatomical 
abnormalities appear (Figure 1.7; Ivins et al, 2005). Additionally, expression of 
Pax9 and Tbx1 co-localizes within the pharyngeal endoderm at E9.5 and 10.5 
mouse embryos (Okubo et al, 2011). 
 
Although there is no published evidence to date indicating Pax9 involvement in 
cardiovascular development, there is some evidence in humans that potentially 
links PAX9 with cardiovascular development. 
 
In a study screening for deletions within chromosome 14q13 (the chromosomal 
location of PAX9), a patient was identified that had been born with several 
cardiovascular malformations including interrupted aortic arch type B (IAA-B), 
bicuspid aortic valve, ventricular septal defect and hypoplastic aorta. This 
patient was carrying a 14q13 deletion including PAX9, however no other 
cardiovascular-related mutations were found such as 22q11 deletion (Santen et 
al, 2012). Two other cases of 14q chromosomal deletions that include PAX9 in 
patients with cardiovascular abnormalities have been reported: a male patient 
with persistent ductus arteriosus and pulmonary stenosis (Schuffenhauer et al, 
1999), and a female patient with persistent ductus arteriosus (Kamnasaran et al, 
2001). 
 
There is therefore some evidence potentially linking PAX9 to cardiovascular 
development: The requirement of both Tbx1 and Pax9 for the development of 
the pharyngeal arches and their derived tissues as well as the overlap between 
some defects found in both Tbx1 and Pax9 knockout embryos including the cleft 
palate, abnormal teeth, craniofacial abnormalities and abnormal development of 
the pharyngeal arch-derived tissues; and together with Pax9 down-regulation in 
Tbx1-null embryos and their co-localization within the pharyngeal endoderm, 
the role of Pax9 during cardiovascular development as well as a potential 
genetic interaction with Tbx1 were investigated in this project. 
 
36 
 
  
 
1.7 Aims  
 
1. To determine whether Pax9 is involved in cardiovascular development 
2. To study a potential genetic interaction between Pax9 and Tbx1 
3. To determine the molecular mechanism of Pax9 and Tbx1 interaction  
 
1.7.1. To determine whether Pax9 is involved in cardiovascular 
development 
 
Previous reports have shown Pax9 expression is down-regulated in Tbx1-null 
embryos, suggesting Pax9 could potentially be a downstream target of Tbx1. 
Additionally, preliminary results from our group shows Pax9-null embryos 
present some cardiovascular defects at E14.5 
 
Therefore, the first aim of this project was to determine whether homozygous 
deletion of Pax9 affects cardiovascular development. 
 
1.7.2. To study a potential genetic interaction between Pax9 and Tbx1 
 
Given that homozygous deletion of Pax9 leads to severe cardiovascular 
defects, most of them phenocopying the Tbx1 heterozygous phenotype, the 
second aim of this project was to study a potential genetic interaction between 
Tbx1 and Pax9, determining whether double haploinsufficiency affects 
cardiovascular development.  
 
1.7.3. To determine the molecular mechanism of Pax9 and Tbx1 
interaction  
 
With the results showing a strong genetic interaction between Tbx1 and Pax9 
during cardiovascular development, the third aim of this project was to 
determine the molecular mechanism of this interaction. 
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Chapter 2. Materials and Methods 
 
2.1. Mouse Lines And Crosses 
 
All animals used in this project were maintained and euthanized according to 
the requirements of the Animals (Scientific Procedures) Act 1986 of the UK 
government. All mice were kept in individual ventilated cages with food and 
water ad libitum under a 12-hour light/dark cycle. 
 
Pax9LacZ/+ mice (Peters et al, 1998), referred as Pax9+/- throughout the thesis, 
were obtained from Dr. Heiko Peters (Newcastle University, UK), and Tbx1+/- 
mice (Jerome and Papaioannou, 2001) were obtained from Dr. Robert Kelly 
(Aix Marseille University, France). Both Pax9+/- and Tbx1+/- mouse lines were 
maintained on a C57Bl/6J genetic background. 
 
Pax9-null embryos were generated by intercrossing Pax9 heterozygous mice, 
and double heterozygous (Tbx1+/-;Pax9+/-) embryos were generated by crossing 
Pax9+/- mice with Tbx1+/- mice.  
 
Embryos were collected at the specified stages for each experiment considering 
embryonic day (E) 0.5 the day of detection of a vaginal plug in the female. 
Pregnant females were euthanized by dislocation of the neck and the uterus 
was dissected and collected in phosphate-buffered solution (PBS, pH 7.0) or 
pre-warmed balanced Hank’s solution with EDTA for MRI.  
 
Embryos for MRI and histology were then fixed in 4% (w/v) paraformaldehyde 
(PFA, in PBS) for at least 2 days, whereas embryos for whole-mount in situ 
hybridisation (WISH) were fixed in DEPC-treated 4% PFA overnight, followed 
by dehydration in methanol as described below (section 2.6.2).    
 
For E9.5 and E10.5 embryos the somites were counted to properly stage match 
the embryos. For E15.5 embryos the stage was confirmed by the presence of 
hair follicles in the trunk but its absence in the head region and closed eyelids 
according to the Theiler staging criteria (The House Mouse: Atlas of Mouse 
Development; 1989). 
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Newborn pups were collected to analyze the survival of double heterozygotes. 
Pups were euthanized by intraperitoneal injection of anaesthetic and dissected 
under a stereomicroscope (Leica, Stemi 2000) to visualize the heart and the 
great vessels.  
 
2.2. Genotyping 
 
2.2.1 DNA Extraction 
 
DNA for genoyping was extracted from tissue samples using 600μg/mL of 
proteinase K in lysis buffer (50 mM KCl, 1.5 mM MgCl2, 10 mM Tris, 0.45% 
NP40, 0.45% Tween-20) incubating the samples for 2 hours at 56oC followed by 
a final 10 minutes incubation at 95oC to inactivate proteinase K.  
 
Ear notches (150μl of lysis buffer) were used to genotype and identify adult 
mice. For E9.5 (50μl) and E10.5 (100μl) embryos the yolk sacs were collected, 
whereas a limb or a piece of tail (400μl) was used for genotyping older embryos 
and newborn pups. 2μl of the lysate was used for PCR. The primers used in 
PCR reactions for each gene are described in Table 2.1. 
 
Table 2.1. List of primers used for genotyping 
Gene Primer Sequence TM Product size 
Tbx1 
Tbx1.1 TGCATGCCAAATGTTTCCCTG 
58°C 
WT 196 bp 
Tbx1.2 GATAGTCTAGGCTCCAGTCCA 
Mutant 450 bp 
Tbx1.3 AGGGCCAGCTCATTCCTCCCAC 
Pax9 
P9-gen2-F1 ACTCACCGGCCTGCACCAATTAC 
58°C 
WT 268 bp 
P9-gen2-R1 TTGTTCTCACTGAGCCGGCCTGT Mutant 350 bp  + 
480 bp P9-gen2-R2 GGATGTGCTGCAAGGCGATTAAG 
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2.2.2. Polymerase Chain Reaction And Electrophoresis 
 
PCR reactions were performed using 1 unit of GoTaq polymerase (Promega) in 
1x GoTaq reaction buffer containing 1.5 mM MgCl2, 0.25mM of each 
deoxyribonucleotide triphosphate (dATP, dCTP, dGTP and dTTP), 0.5 μM of 
each primer and 2μl of DNA sample as mentioned above in a final volume of 
20μl. 
 
Samples were then incubated in a thermocycler with an initial denaturation step 
of 94oC for 2 minutes, followed by 35 cycles of denaturation at 98oC for 30 
seconds, followed by 30 seconds at the specific annealing temperature (Table 
2.1) and extension at 72oC for 30 seconds, followed by a single final elongation 
incubation at 72oC for 10 minutes. 
 
PCR samples were then analysed by electrophoresis in a 1.5% (w/v) agarose 
gel in 1x TAE buffer (40mM tris, 20mM acetic acid, 1mM EDTA) containing 
0.5μg/ml ethidium bromide (EtBr). Gels were run at 100 volts for 30-45 minutes 
and photographed under a UV light transilluminator. DNA ladders (100bp or 
1Kb, Promega) were run along with samples in gels to analyse the band size of 
the PCR products.  
 
2.3 Magnetic Resonance Imaging 
 
Magnetic resonance imaging (MRI) was performed as described (Bamforth et 
al, 2011).  Pregnant female mice were euthanized by cervical dislocation and 
the uterus was dissected and collected in pre-warmed (37°C) Hank’s balanced 
salt solution with 5mM EDTA. Embryos were dissected out of the uterus and 
carefully from the yolk sacs to expose the umbilical vessels, which were 
subsequently cut firmly with Vannas scissors and the embryos were allowed to 
bleed out for no more than 20 minutes removing blood clots.  
 
Bleeding is critical in order to remove as much blood as possible, since blood 
can give a high contrast signal and interfere with the MRI, therefore embryos 
are dissected in pre-warmed Hank’s solution plus EDTA on a heating mat to 
maintain the hearts beating to help the bleeding.  
 
40 
 
  
 
Embryos were subsequently washed twice in PBS and photographed to record 
any external phenotype. The left forelimb was cut and used for genotyping. 
Embryos were then fixed in 4% paraformaldehyde (PFA) and kept at 4°C until 
used. Slits were cut on each side of the trunk of the embryos to help penetration 
of the fixative.  
 
Four days before sending the embryos for MRI, Gd-DTPA (Magnevist), was 
added (6μl/mL) as contrast agent. Fixed embryos were then embedded in 1% 
agarose plus Gd-DTPA in a 28mm diameter glass tube, stacking the embryos in 
8 layers of 4 embryos each. To identify embryos in each layer, a different limb 
or the tail was removed, and this was recorded on a data sheet with the ID of 
each embryo for subsequent analysis. The loaded tube was sent to the British 
Heart Foundation MRI unit in Oxford (University of Oxford, UK) for imaging. The 
embryos and MRI datasets were later returned and embryos were subsequently 
processed for histology as described below, and the data sets were used to 
analyse the phenotype and reconstruct 3D models using Amira software 
(Visage Imaging).  
 
2.4. Histology 
 
2.4.1. Embedding And Sectioning 
 
Fixed embryos (4% PFA) were dehydrated through a series of ethanol dilutions 
(Table 2.2) and then cleared with Histoclear (National Diagnostics) to 
completely remove ethanol. Embryos were then incubated in wax to allow the 
paraffin to penetrate the tissue, and embryos were finally embedded in paraffin 
blocks. The incubation times depending on the age are shown in Table 2.2. 
 
Embedded embryos were sectioned transversally using a microtome (Leica, RM 
2235) to obtain 8μm slices. Sections were placed on glass microscope slides 
(VWR) pre-coated with warm water (37oC) to allow the sections to stretch. 
Excess water was then removed and slides were allowed to dry overnight in an 
oven at 37oC to completely dry the slides. 
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Table 2.2. Dehydration of embryos for histology 
  E9.5 E10.5 E15.5 
Room 
temperature 
50% Ethanol 30 minutes 30 minutes 3 hours 
70% Ethanol 
30 minutes 30 minutes 3 hours 
30 minutes 30 minutes 3 hours 
95% Ethanol 30 minutes 30 minutes 3 hours 
100% Ethanol 
30 minutes 30 minutes 3 hours 
30 minutes 1 hour Overnight 
Histoclear 
10 minutes 15 minutes 30 minutes 
10 minutes 15 minutes 30 minutes 
60°C 
Histoclear/wax 15 minutes 20 minutes 1 hour 
Wax 
20 minutes 
20 minutes 
20 minutes 
30 minutes 
30 minutes 
30 minutes 
1 hour 
1 hour 
1 hour 
1 hour 
 
 
2.4.2. Hematoxylin And Eosin Staining 
 
To analyse the morphology in detail, sections were stained with haematoxylin, 
which stains cell nuclei in purple, and eosin to counterstain the cytoplasm in 
pink.   
 
Slides were dewaxed by incubating them in Histoclear for 10 minutes twice; 
Sections were then washed for 3 minutes twice in 100% ethanol and rehydrated 
through ethanol dilutions (90%, 70% and 50%) immersing the slides on each 
solution for 2 minutes each with a final wash in distilled water for 2 minutes. 
Sections were then stained in Harris’ hematoxylin solution for 10 minutes and 
then washed under running tap water for 5 minutes. Slides were then dipped 
twice in an acid ethanol solution (1% v/v hydrochloric acid (HCl) in 70% ethanol) 
for differentiation to remove background staining of hematoxylin. Slides were 
washed again under running tap water for 5 minutes and then immersed in 
Eosin for 5 minutes followed by a final wash under running tap water until water 
was clear. Slides were rehydrated through 50%, 70% and 90% ethanol 
solutions dipping them twice on each solution.  
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Slides were then incubated 3 minutes twice in 100% ethanol and finally cleared 
for 10 minutes twice in Histoclear to remove all ethanol. Stained slides were 
mounted in Histomount (National Diagnostics) with a coverslip and left to dry 
overnight. 
 
Mounted sections were photographed under bright-field using a transmitted light 
microscope (Zeiss, Axioplan) with its corresponding AxioVision software (Zeiss). 
 
2.5. Ink Injections 
 
India ink was used to visualize the patterning of the pharyngeal arch arteries at 
mid embryogenesis. Embryos were collected at E10.5 in 1x PBS at room 
temperature and the yolk sacs were kept for genotyping. Diluted India ink (1:1 in 
water v/v) was injected into the left ventricle of the beating heart using a pulled 
glass pipette and a mouthpiece to slowly inject the ink into the heart. The 
pipette was removed to allow the heart to pump ink through the arteries and 
embryos were immediately photographed from both sides under a 
stereomicroscope (Leica, Stemi 2000).     
 
2.6. Whole-Mount In Situ Hybridisation 
 
For whole-mount in situ hybridisation all solutions (water, PBS and stock 
solutions) were pre-treated with 0.1% Diethylpyrocarbonate (DEPC), and all 
material and tools (dissection tools, flask, sieves) were washed with RNAse 
Away (Fisher) to remove any traces of RNAses prior to commencing the 
procedure.    
 
2.6.1 Probe Dig-Labelling 
 
The Pax9 plasmid probe was donated by Dr. Ralf Kist (Newcastle University, 
UK), and Gbx2 plasmid probe was donated by Dr. Alexandra Joyner (Sloan 
Kettering Institute, USA). To generate each probe, plasmids were linearized 
with the respective restriction enzyme (Table 2.3). Linearized plasmids were 
purified using a PCR purification kit (Qiagen) according to manufacturer’s 
protocol and quantified using a Nanodrop spectrophotometer (Thermofisher).  
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Table 2.3. Restriction enzymes and RNA polymerases used for probe preparation. 
Probe 
Restriction 
enzyme 
RNA 
polymerase 
Pax9 
Antisense Eco RI T7 
Sense Hind III T3 
Gbx2 
Antisense Hind III T7 
Sense Kpn I T3 
 
Probes were then generated from each linearized plasmid using the respective 
RNA polymerase (Table 2.3) and labelled with Digoxygenin (DIG) using a DIG 
labelling kit (Roche) according to manufacturer’s protocol, in a mix containing 
1μg of linearized plasmid, 40 units of the respective RNA polymerase (Table 
2.3) 1x NTP labelling mixture, 1x transcription buffer and 20 units of RNAse 
inhibitor; each sample mix was incubated at 37oC for 2 hours, and subsequently 
treated with DNAse I to remove template DNA.  
 
DIG-labelled RNA probes were purified by precipitation with ethanol, adding two 
volumes of tris-EDTA buffer (TE pH 8.0), 5 volumes of ice-cold ethanol (100%) 
with 0.1M lithium chloride (LiCl), and left overnight at -20oC. The following day, 
samples were centrifuged at 13,000g for 30 minutes at 4oC, the supernatants 
were discarded and pellets were air-dried for 5 minutes before re-dissolving in 
100μl of TE buffer containing 80 units of RNAse inhibitor.  
 
Probes were quantified using the Nanodrop spectrophotometer, and tested by 
electrophoresis in a 1% agarose gel ran quickly for 10 minutes at 200V to 
minimise RNA degradation. 
 
Probes were aliquoted in single use aliquots (final concentration of 1μg/mL) to 
avoid multiple thawing/freezing, and stored at -80oC, and prior to hybridisation, 
probes were denatured at 100oC for 5 minutes in hybridisation solution. 
 
2.6.2. Hybridisation 
 
Embryos were collected and dissected in cold 1x PBS. The yolk sacs were kept 
for genotyping and embryos were fixed overnight at 4oC in 4% PFA (in PBS).  
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Embryos were then washed for 5 minutes twice with PBS and then dehydrated 
through a series of methanol dilutions (25, 50, 75%) in PBS for 10 minutes each 
at room temperature, followed by two 10 minutes washes in 100% methanol. 
Embryos were then stored in 100% methanol at -20oC until used.  
 
Embryos of the same genotype were pooled and processed in 12-well plates 
using 15mm Netwell inserts (Corning) pre-washed with RNAse-away. 
 
Embryos were re-hydrated through methanol dilutions (75, 50, 25%) in PBT 
(0.1% Tween-20 in PBS) for 5 minutes each at room temperature, and then 
washed twice for 5 minutes in PBT. Embryos were then bleached in 6% 
hydrogen peroxide (in PBT) for 1 hour at room temperature, followed by three 5 
minutes washes in PBT. Embryos were then permeabilized with 10μg/mL 
Proteinase K (in PBT) for 15 minutes at room temperature. Proteinase K activity 
was quenched by incubating embryos in 2mg/mL glycine (in PBT) for 5 minutes 
at room temperature, followed by two 5 minutes washes with PBT. Embryos 
were then re-fixed in 0.2% glutaraldehyde/4% PFA (in PBS) for 20 minutes at 
room temperature, followed by two 5 minutes washes with PBT. 
 
Embryos were then transferred to cryovials and incubated in pre-hybridisation 
solution (50% Formamide, 5x saline-sodium citrate buffer (SSC) pH 4.5, 0.1% 
Tween-20, 50μg/mL heparin in DEPC-treated ddH2O) for 1 hour at 70
oC in a 
hybridisation oven with gentle rocking. 
 
Embryos were then incubated with hybridisation solution (50% Formamide, 5x 
SSC pH 4.5, 0.1% Tween-20, 50μg/mL heparin, 50μg/mL yeast tRNA, 
100μg/mL salmon sperm DNA and 1μg/mL of denatured probe in DEPC-treated 
water) at 70oC overnight in a hybridisation oven with gentle rocking. 
 
The following day embryos were washed twice in pre-warmed (70oC) solution I 
(50% formamide, 4x SSC, 1% Sodium dodecyl sulphate (SDS, w/v) in DEPC-
treated water) for 30 minutes at 70oC, followed by a 10 minute wash in pre-
warmed (70oC) solution I/solution II mix (1:1 v/v; solution II: 0.5M sodium 
chloride, 0.01M Tris pH 7.5, 0.1% Tween-20) in the hybridisation oven with 
gentle agitation. 
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Embryos were further washed three times for 5 minutes at room temperature in 
solution II, and then treated with 100μg/mL RNAse A (in solution II) for 30 
minutes at 37oC, twice. Embryos were then washed for 5 minutes with solution 
II at room temperature, followed by a 5 minutes wash in solution III (50% 
formamide, 4x SSC, 0.2% SDS in DEPC-treated water) at room temperature; 
embryos were then incubated in solution III for 30 minutes at 65oC, twice.  
 
Embryos were then transferred into glass vials, and washed three times with 
TBST (0.05M Tris pH7.5, 0.15M NaCl, 0.05% Tween-20) for 5 minutes at room 
temperature. 
 
Prior to antibody incubation, embryos were blocked with 10% fetal bovine 
serum (FBS; in TBST) for 2.5 hours at room temperature with gentle agitation; 
embryos were then incubated with 0.5μl/mL anti-Digoxigenin-alkaline 
phosphatase Fab fragments (Roche) in 1% FBS (in TBST) overnight at 4oC with 
gentle rocking. 
The following day, the antibody was removed and embryos were washed five 
times for 1 hour each in TBST at room temperature with gentle rocking, followed 
by a final overnight wash in TBST at 4oC. 
 
Embryos were then washed twice for 10 minutes at room temperature, in NTMT 
(100M NaCl, 0.1M Tris pH 9.5, 0.1% Tween-20) and then incubated with 
20μl/mL of NBT/BCIP (nitro blue tetrazolium chloride/ 5-Bromo-4-chloro-3-
indolyl phosphate; Roche) developing solution (in NTMT) in the dark. 
Developing of staining was monitored every 10 minutes and the reaction 
stopped at the same time for all embryos. 
 
To stop the developing reaction, embryos were washed for 10 minutes at room 
temperature twice with NTMT followed by a 10 minute wash with PBT pH 5.5 at 
room temperature. 
 
Embryos were then fixed in 0.1% glutaraldehyde/4% PFA for 1 hour at room 
temperature and then rinsed with PBS. Embryos were photographed from both 
sides using a stereomicroscope (Leica, Stemi 2000). 
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2.7. Tissue Culture 
 
2.7.1 JEG3 Cells Culture 
 
Human placental choriocarcionoma cells (JEG3; ATCC) were used for all in 
vitro experiments since they have shown to be efficient for Tbx1 expression and 
activation of the 2xTtkGL2 reporter (Zweier et al, 2007).  
 
JEG3 cells were cultured in high glucose Dulbecco’s modified eagle medium 
(Life Technologies) supplemented with 10% (v/v) fetal bovine serum (FBS, Life 
Technologies) and 100units/mL of Penicillin and 100μg/mL of Streptomycin (Life 
Technologies); cells were kept at 37oC in a humidified incubator with 5% CO2. 
 
Cells were passaged every two days before reaching confluency by dissociation 
with 0.05% Trypsin in EDTA (Life Technologies); culture media was removed 
and cells were washed once with 1x PBS followed by incubation with trypsin for 
5 minutes at 37oC. Two volumes of complete culture media were then added to 
stop trypsin activity; cell suspensions were transferred to sterile 50mL centrifuge 
tubes and centrifuged for 5 minutes at 1000g. The supernatant was removed 
and cell pellets were homogeneously resuspended in 10 mL of complete culture 
media; cells were counted using a hemocytometer and resuspended in the 
appropriate volume of media to achieve the final cell density required. Cells 
were plated at the desired density in T75 flask, 100mm dishes or multiwell 
plates according to each experiment. 
 
2.7.2. Mouse Embryonic Fibroblasts 
 
Mouse embryonic fibroblasts were obtained from wild-type E14.5 embryos; 
pregnant females were euthanized by cervical dislocation and the uterus was 
collected in PBS. Embryos were dissected in PBS removing all membranes and 
the head; carcasses were washed twice with PBS and then minced in 2mL of 
trypsin/EDTA, the liver was removed and an extra 3mL of trypsin/EDTA added. 
Minced tissue was transferred into a 15mL centrifuge tube and incubated at 
37oC for 30 minutes, mixing the tube vigorously every 10 minutes to dissociate 
clumps.  
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One volume (5mL) of FBS was added to the minced tissue and incubated for 5 
minutes to allow larger clumps to settle; supernatant was then transferred into a 
fresh centrifuge tube and centrifuged at 1000g for 5 minutes. 
 
The supernatant was discarded and cells were resuspended in complete 
medium (1x DMEM, 10% FBS, 100units/mL of Penicillin and 100μg/mL of 
Streptomycin); cells were resuspended, pipetting up and down vigorously to 
further dissociate into single cells.  
 
Cells were counted using a hemocytometer, resuspended in the appropriate 
volume of media and seeded in T75 flasks. MEFs were passaged before 
reaching confluency using trypsin/EDTA as described above for JEG3 cells. 
 
2.8. Molecular Cloning 
 
2.8.1. Cloning 
 
Human and mouse Tbx1 and Pax9 cDNAs sub-cloned into pcDNA3.1 had been 
previously generated in the lab. 
 
For the luciferase constructs, DNA fragments containing the conserved TBEs, 
the Pax9 promoter and introns, and the conserved Gbx2 enhancer region were 
obtained by PCR from mouse genomic DNA using the primers described in 
Table 2.4, resolved in a 1.5% agarose gel to confirm the size and specific 
amplification, and purified using a gel extraction purification kit (Qiagen). 
 
PCR fragments were subcloned into the respective pGL3 plasmid (Table 2.4) by 
enzymatic digestion with the corresponding restriction enzyme (Table 2.5), 
followed by ligation with T4 DNA ligase (Promega). 
 
Ligated constructs were subsequently transformed into DH5α competent cells 
(as described in section 2.8.2); plasmid DNA was purified by mini-prep (section 
2.8.3) and the cloned fragments were verified by sequencing. The verified 
constructs were further transformed and midi-prepped (section 2.8.3). 
 
 
48 
 
  
The Pax9 intron 3 was produced from two fragments (intron 3.1 and 3.2), which 
were initially generated by PCR as mentioned above, and then ligated together 
into one fragment by digestion with Bgl II (Table 2.4) and T4 DNA ligase before 
ligation into the pGL3 vector. 
 
Table 2.4. List of primers and restriction enzymes used for cloning  
Target Oligo Sequence Enzyme 
pGL3 
vector 
Pax9 locus 
TBE-1 
F ggggcTAGCCTGGCTAGGAAGACTTG Nhe I 
Promoter 
R AGATCTcGAGGGCTGGGGAAAG Xho I 
 TBE-2 
F ggggctAGCCAGGAGTATTGCTCCTTG Nhe I 
Promoter 
R cccctCGAGTCTATAAGCAAATCTTCCC Xho I 
TBE-3 
F ggggctAGCCAGGAGTATTGCTCCTTG Nhe I 
Basic 
R cccctCGAGCGCTTAGCCCGGCTC Xho I 
 TBE-4 
F ggggctAGCCTGGGTCGTTGGAGGCAG Nhe I 
Promoter 
R cccctcGAGGTCATGGGGGAATCAGGAG Xho I 
 TBE-5 
F cccgagCTCCAAGGGTCAGTGGCGG Sac I 
Promoter 
R cccagaTCTCAAAACAAGCTGCGGCCAG Bgl II 
TBE-6+7 
F CGCGCTGCCCTACAACCACA Sac I 
Promoter 
R TCAAGTCGCCCGGGAAAGCC Bgl II 
TBE-
8+9+10 
F cccgaGCTCTGTCCTGGACGTCTGTTGTG Sac I 
Promoter 
R cccagaTCTGGTTGCAGGATTCCCCAGAGG Bgl II 
Intron 2 
F ccccggatccGTGAGTGGCTGATGGGGGAC Bam HI 
Promoter 
R ccccgtcgacCTGCAAAAGGAGCACAGAGC Sal I 
Intron 3.1 
F cccggatcCTCAGAGGCAGTGTGCAGAG Bam HI 
Promoter 
R CCGAGATCTTTCTGAACAATCACAACAGACGTC Bgl II 
Intron 3.2 
F GTCCTGGACGTCTGTTGTGA Bgl II 
R GTCGCTCACTCCTGAGAAGG Sal I 
5kb 
promoter 
F ggggctAGCGAGGTCTCCTCTGGACAAT Nhe I 
Basic 
R cccgctagCGCACTCCCAGAAAGAAACT Nhe I 
     Gbx2 conserved region 
Gbx2 
enhancer 
F TCCTGGAACCCCAGAGC Kpn I Promoter 
(upstream) R TTCTGATCATAATTATTTGATCTGC Bgl II 
F TCCTGGAACCCCAGAGC Bam HI Promoter 
(enhancer) R TTCTGATCATAATTATTTGATCTGC Sal I 
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2.8.2. Transformations 
 
For plasmid subcloning, DH5α chemically competent E. coli cells (Invitrogen) 
were transformed according to manufacturer’s instructions; DH5α cells were 
aliquoted and stored at -80oC. 
 
For transformation, 1-5ng of plasmid DNA was added to an aliquot of competent 
cells with gently mixing followed by a 30 minutes incubation on ice. Competent 
cells were then heat-shocked for 20 seconds in a 42oC water bath and then 
returned to ice for 2 minutes; pre-warmed sterile LB broth (170mM NaCl, 1% 
tryptone, 0.5% yeast extract) was then added to the cells to a final volume of 
1mL and incubated at 37oC for 60 minutes with gentle agitation (250rpm) to 
allow cells to recover. Cells were then centrifuged for 5 minutes at 3000g, the 
supernatant discarded and cells resuspended in 100μl of LB broth; cell 
suspension was then spread onto pre-warmed agar plates (170mM NaCl, 1% 
tryptone, 0.5% yeast extract, 1.5% agar, 50μg/mL ampicillin), and incubated 
overnight (12-18 hours) at 37oC. 
 
2.8.3. DNA Plasmid Preps 
 
For plasmid miniprep, 5mL of LB broth with ampicillin (50μg/mL) were 
inoculated with an individual colony picked from the agar plate. Inoculated LB 
broth was the incubated overnight (12-18 hours) at 37oC with agitation 
(250rpm). Miniprep was performed using the Qiaprep spin miniprep kit 
(Qiagen), according to the manufacturer’s protocol. Plasmid DNA from 
minipreps was eluted in 30μl of ddH2O and quantified with a Nanodrop 
spectrophotometer. 
 
For plasmid midiprep, a starter culture was set up by inoculating 5mL of LB 
broth with ampicillin (50μg/mL) with a single colony picked from an agar plate 
and incubated for 8 hours at 37oC with constant agitation (250rpm). After 8 
hours, 50mL of LB broth with ampicillin (50μg/mL) were inoculated with 100μl of 
the starter culture and incubated overnight (12-18 hours) at 37oC with agitation 
(250rpm). 
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Midiprep was performed using the plasmid midi kit (Qiagen), according to the 
manufacturer’s protocol. Plasmid DNA from midipreps was eluted in 100μl of 
ddH2O and quantified with a Nanodrop spectrophotometer. 
 
2.8.4. Site-directed mutagenesis 
 
Mutation of the TBE-9 site was performed using the QuickChange II XL site-
directed mutagenesis kit (Agilent).  
 
Primers introducing the multiple nucleotide changes into TBE-9 (Table 2.5) 
were designed using the QuickChange Primer Design tool 
(www.genomics.agilent.com). Three nucleotides were changed (lowercase 
underlined, Table 2.5) to modify the core sequence of TBE-9. 
 
The mutated sequence was generated by PCR using proof-reading high-fidelity 
DNA polymerase (Agilent) with the designed primers (Table 2.5) and TBE-
8+9+10 construct as template. The parental DNA was digested with Dpn I 
restriction enzyme, and the mutated DNA was transformed into XL10-gold 
ultracompetent cells (Agilent) according to manufacturer’s protocol. Plasmid 
DNA from transformed colonies was purified by mini prep and verified by 
sequencing. 
 
To delete the VP motif from Pax9, primers flanking the VP motif were designed 
(Table 2.5) with the forward primer binding the 3’ end of the motif and the 
reverse primer binding to the 5’ region of the motif, in order to amplify the rest of 
the Pax9 cDNA except for the flanked region (VP motif).  
 
The mutated DNA was generated by PCR using proof-reading phusion DNA 
polymerase (Thermo Scientific) using the designed primers and the pcDNA3.1-
Pax9 cDNA as a template. The PCR product was resolved in a 1% gel to verify 
fragment size (Pax9 cDNA minus the VP motif). Resolved DNA was purified 
using a gel extraction purification kit (Qiagen) and ligated using T4 DNA ligase 
(Promega), followed by transformation into NEB 5α ultracompetent cells (NEB) 
according to manufacturer’s protocol. 
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Transformed colonies were initially screened by colony PCR using the primers 
designed for the deletion (Table 2.5). Plasmid DNA from colonies showing the 
desired size was extracted by mini-prep and further confirmed by sequencing.  
 
Table 2.5. Primers used for mutagenesis 
Target Oligo Sequence 
TBE-
8Δ9+10 
F GAAGCCCCTGTTCATGGGAAAaaaTGATATCAGCAGAAATGGGGGCTC 
R CTTCGGGGACAAGTACCCTTTtttACTATAGTCGTCTTTACCCCCGAG 
VP 
deletion 
F CGCGCTGCCCTACAACCACA 
R CGGTGATGGAGCGGATGCCC 
 
2.9. Luciferase Assays 
 
Luciferase assays were performed using the Dual-Luciferase Reporter Assay 
System (Promega) according to the manufacturer’s protocol. Optimal seeding 
density and concentrations of plasmids for luciferase experiments were 
optimised and shown in appendix A.  
 
JEG3 cells were plated at a density of 100,000 cells/well in 12-well plates in 
complete medium one day prior to transfections. The following day, cells were 
transfected with the DNA mixture containing the specific concentration of each 
plasmid as specified for each experiment, 20ng/well of a Renilla luciferase 
expression plasmid (pGL4.70; Promega) as a control reporter for normalisation 
of transfection efficiency, and XtremeGene9 transfection reagent (Roche) in a 
3:1 ratio (µl transfection reagent: µg DNA) in 1x PBS (Life Technologies). 50μl 
of the transfection mixture was added drop-wise to each well and incubated for 
48 hours. Each group was done in triplicate (i.e. 3 wells per group).  
 
After 48 hours, culture medium was removed and cells were washed twice with 
cold 1x PBS; cells were lysed with 250μl of 1x passive lysis buffer (dual-
luciferase reporter assay kit, Promega) and incubated at room temperature for 
15 minutes with gentle rocking. Samples were then transferred to individual 
1.5mL centrifuge tubes and centrifuged for 3 minutes at 3000g to pellet cell 
debris.  
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Firefly and Renilla luciferase were measured using a luminometer (Fluroskan, 
ThermoFisher); 25μl of each sample were dispensed into an opaque 96 well 
plate, followed by addition of 100μl of luciferase assay substrate (Promega) and 
Firefly luciferase was measured immediately. 100μl of Stop and Glo reagent 
(Promega) were then added to each well and Renilla luciferase was measured. 
A well containing just passive lysis buffer was measured every time as a blank 
and the value subtracted from the Firefly and Renilla measurements. Firefly 
luciferase measurements were then normalised against Renilla measurements 
for analysis. 
 
A synthetic T-site reporter construct (2xTtkGL2, Zweier et al, 2007) was used in 
all experiments as a positive control for Tbx1 activity, whereas the same vector 
without the synthetic T-site (tkGL2) was used as a negative control. Likewise, 
two groups containing just the empty vectors (pGL3 or pcDNA3.1) were 
included in all experiments as negative controls.  
 
The concentration of each plasmid was specific for each experiment, but the 
total DNA concentration (2μg) was matched in all groups with the empty 
pcDNA3.1 vector. 
 
From the optimisation experiments, the optimal concentrations of reporter and 
plasmids were: 20ng of Renilla plasmid (pGL4.7), 1μg of 2xTtkGL2 reporter and 
25ng (0.25μg) of Tbx1 to give the optimal activation of the 2xTtkGL2 reporter 
(appendix A). 
 
2.10. Immunocytochemistry 
 
To verify expression of the Tbx1 and Pax9 expression plasmids, 
immunofluorescence on JEG3 cells was performed as described below. 
 
JEG3 cells were cultured on 300mm dishes and transfected with 5μg of Tbx1, 
Pax9 or both (total of 10μg) using XtremeGene9 transfection reagent (Roche) in 
a 3:1 ratio (µl transfection reagent: µg DNA). 48 hours later, culture media was 
removed and cells were washed once in PBS, and then fixed for 30 minutes at 
room temperature with ice-cold 4% PFA (in PBS).  
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Cells were then washed three times for 20 minutes with PBS at room 
temperature, and then blocked with 2% fetal bovine serum (v/v in PBS) for 30 
minutes at room temperature. 
 
Table 2.6. List of primary and secondary antibodies 
Primary antibodies 
Antibody Information Dilution 
Rat anti-Pax9 
Abcam, 
ab28538 
IP: 5μg/mL 
WB: 1μg/mL 
ICC: 10μg/mL 
Rabbit anti-Tbx1 
Abcam, 
ab18530 
IP: 5μg/mL 
WB: 1μg/mL 
ICC: 1:100 
Rabbit anti-Histone H3 
Abcam, 
ab1791 
IP: 5μg/mL 
Rabbit IgG 
Abcam, 
ab46540 
IP: 5μg/mL 
Secondary antibodies 
Anti-rat IgG-HRP 
Jackson,1 
12-036-003 
WB: 1:20000 
Anti-rabbit IgG-HRP 
DAKO, 
P0448 
WB: 1:2000 
Anti-rat IgG  
Alexa Fluor 488 
Life Technologies, 
A21208 
ICC: 1:200 
Anti-rabbit IgG  
Alexa Fluor 594 
Life Technologies, 
A21207 
ICC: 1:200 
 
 
Blocking solution was removed and cells were incubated with primary antibody 
at the appropriate dilution (Table 2.6) in 0.1% Triton X-100 in PBS overnight at 
4oC. 
  
Cells were then washed four times for 20 minutes in PBS at room temperature, 
and then incubated with the respective secondary antibody (Table 2.6) diluted 
1:200 in PBS for 2 hours in the dark at room temperature. 
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Cells were then washed four times for 20 minutes with PBS at room 
temperature in the dark, and finally mounted with 5 drops of Vectashield plus 
DAPI and a round coverslip. 
 
Dishes were let dry overnight and the edges were sealed with nail polish and 
the rims removed. Images were taken using a Fluorescence microscope (Zeiss 
Axioimager). 
 
2.11. Chromatin Immunoprecipitation (ChIP) 
 
2.11.1 ChIP From Embryos 
 
For chromatin immunoprecipitation of the potential TBEs within the Pax9 locus 
(section 5.2), nine E9.5 wild-type embryos were collected and pooled for each 
IP; while nine (E8.5), eight (E9.5) and twelve (E10.5) embryos were pooled for 
each IP of the Gbx2 locus (section 5.4). 
 
Wild-type embryos were collected and homogenised in ice-cold PBS containing 
protease inhibitors (Sigma); homogenised tissue samples were fixed in 1% 
formaldehyde and then neutralized in 125mM glycine. Tissue samples were 
then centrifuged for 1 minute at 3000g and washed twice in PBS; samples were 
then lysed in RIPA buffer (radioimmunoprecipitation assay buffer; 50mM Tris, 
150mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 1% Triton X) containing 
protease inhibitors, and chromatin was sonicated into 200–600bp long 
fragments. Sonication into the right size was assessed by electrophoresis in a 
1% agarose gel. 
 
The sonicated chromatin was divided equally into the number of samples 
required for each immunoprecipitation and controls (i.e Input, p-HH3, Tbx1, IgG, 
no antibody); the Input aliquot was stored at -20oC until used, while the 
remaining samples were diluted 1:10 in RIPA buffer. 
Diluted samples were pre-cleared with 20μl of pre-absorbed protein A/G 
sepharose beads (Sigma) for 1 hour rotating at room temperature. 
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Pre-cleared samples were then incubated with the respective primary antibody 
(Table 2.6), except for the ‘no antibody/beads-only’ sample; 20μl of pre-
absorbed protein A/G sepharose beads was added to all samples and these 
were incubated overnight with rotation at 4oC.  
 
Samples were extensively washed as follows: samples were centrifuged for 1 
minute at 3000g, the supernatant removed and samples were resuspended in 
wash buffer (20mM Tris-HCl pH 8.0, 150mM NaCl, 2mM EDTA, 1% Triton-
X100, 0.1% SDS); the procedure was repeated six times, leaving samples in 
the final wash overnight at 4oC with rotation. 
 
Samples were washed one last time with LiCl buffer (0.25M LiCl, 10mM Tris-
HCl pH 8.0, 1mM EDTA, 1% NP-40, 1% sodium deoxycholate). The 
immunocomplexes were then eluted in 120μl of elution buffer (100mM NaHCO3, 
1% SDS) and incubated for 15 minutes at 30oC with rotation.  
 
Cross-linking of the Input and immunoprecipitated DNA samples was reversed 
at 65°C for 4 hours with shaking, followed by treatment with 20mg/mL of 
proteinase K and 10mg/mL of RNAse A at 45°C for 1 hour.  
 
The DNA was subsequently purified using the QIAquick PCR purification kit 
(Qiagen), and equal volumes of all samples were analysed by qPCR using 
SYBR Green JumpStart Taq ReadyMix (Sigma) and specific primers targeting 
the regions of interest (Table 2.7). 
 
A sample incubated with an anti-IgG antibody was used as an isotype negative 
control for the immunoprecipitation, and a sample incubated only with the 
protein A/G beads and no primary antibody was also used as a negative 
control. 
 
For qPCR, each sample was run in triplicate, and a Ct average value was 
obtained from the replicates; samples were then normalised with the Input 
sample and represented as a percentage of input (which was set as a 100% of 
total chromatin). 
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A sample containing genomic DNA (gDNA) was used as a positive control for 
the qPCR, whereas a sample with no DNA and only water was used as a 
negative control. 
 
Table 2.7. List of primers used for ChIP 
Target 
Gene 
Primer Name Sequence 
Pax9 
TBE-1-F TGTCAGCTCGCCAGAACATCAGA 
TBE-1-R GCAGGGTTGAGACAACAGCCCC 
TBE-2-F ACGCAATCATACCATAGGAGGCTCA 
TBE-2-R CCCGGGAAATTGCCGTGACC 
TBE-3-F CGCCTTCAAAGCGGGAGGGG 
TBE-3-R CCGATCAGCCGGGGTTGGTT 
TBE-4-F CTGCCCGGTGCCAAGTGTGT 
TBE-4-R TGGGGCGACCCCTTCTCTGG 
TBE-5-F AAGAGGGCCGTGGCATTGGC 
TBE-5-R CCCCTCCCTTCTGCGGGGTT 
TBE-6-F CGGAGTGGGTTCCTGCACGC 
TBE-6-R AGGCTGGAGACTGTGTGTGGCA 
TBE-7-F GCAGCTACGAGTCCCCGCAC 
TBE-7-R AGACCGAGACCTCCGTTTCCGA 
TBE-8+9+10-F ACCTTAGTTGGAGACGTTGCCCT 
TBE-8+9+10-R ACAAAAGGCAGTCGGTGGGC 
MusChr12C1-F TGGGAAAGACAAGAGGATGC 
MusChr12C1-F CTTGGAAAACTCCACCCTCA 
Gbx2 
Gbx2_T5b-F GAGCTAGCCTCGGGCACTAT 
Gbx2_T5b-R GTCTCCAAGGCCAAGAACTG 
Gbx2_T5c-F TGGTGTGTCTGATGGGGAAT 
Gbx2_T5c-R TCTTGCTCCTGGCCATAGTT 
Gbx2_T5d-F TGGGTATCCCACAGACACCT 
Gbx2_T5d-R TGTTGCATCCCTTCACTTCA 
Gbx2_T5e-F GATGGAGCAGATAAAAGACTCG 
Gbx2_T5e-R GACATTCTTAATCATCGCACCT 
Gbx2_P9-F CCAAGGCCCTGGAGACAG 
Gbx2_P9-R TTCTCTCTGCCTGTGATGTGA 
Gbx2_T5f-F GCTGATTAATGAGACCCACGA 
Gbx2_T5f-R TTTGAAGCTCAGACAAGTTGC 
Gbx2_P5-F CTCTGGCCTGAGATGCTGTT 
Gbx2_P5-R CCGGTCTGTGCACTTCTGAT 
Synthetic 
T-site 
2xTt-F1 TGTAACTGAGCTAACATAACCCGGGAA 
2xTt-R2 TGACGCGTGTGGCCTCGAAC 
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For ChIP-western blot (section 5.4), a 20μl aliquot was taken from the samples 
incubated with Tbx1 and Pax9 antibodies after immunoprecipitation and prior 
reversing the cross-linking. Samples were then incubated with 20μl of 2x SDS-
PAGE buffer (2% SDS, 5% β-mercaptoethanol, 10% glycerol, 0.05% 
bromophenol blue, 62.5mM Tris pH 6.8) at 95oC for 30 minutes, followed by 
centrifugation at 14,000g for 5 minutes. Supernatants were then used for 
western blot as described below (section 2.13). 
 
2.11.2 ChIP From MEFs 
 
For chromatin immunoprecipitation from MEFs, two confluent T75 flasks were 
used; formaldehyde was added drop-wise to each flask to a final concentration 
of 1%, and incubated at room temperature for 10 minutes. Glycine was then 
added to a final concentration of 125mM and incubated for further 5 minutes at 
room temperature; cells were then rinsed twice with cold PBS, scraped 
thoroughly with a cell scraper and transferred into a 50mL centrifuge tube. Cells 
were centrifuged at 1000g for 5 minutes; supernatant was discarded and cells 
were resuspended in 750μl of RIPA buffer and incubated for 10 minutes on ice. 
Chromatin was then sonicated and samples treated as previously described for 
IP. 
 
2.11.3 2xTtkGL2 ChIP From JEG3 Cells 
 
To determine binding of Tbx1 to the 2xTtkGL2 reporter (section 5.3), JEG3 cells 
were cultured on 6-well plates; when 80% confluency was reached, cells were 
transfected with 1μg of 2xTtkGL2 construct, 0.25μg of Tbx1-expressing vector 
and increasing concentrations (0, 0.01, 0.05, 0.1, 0.25 and 0.5μg) of Pax9-
expressing plasmid using XtremeGene9 transfection reagent (Roche) in a 3:1 
ratio (µl transfection reagent: µg DNA). Each group was done in triplicate (i.e. 3 
wells per group); after 24 hours post transfection, formaldehyde was added 
drop-wise to each flask to a final concentration of 1%, and incubated at room 
temperature for 10 minutes. Glycine was then added to a final concentration of 
125mM and incubated for a further 5 minutes at room temperature; cells were 
then rinsed twice with cold PBS.  
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Cells were scraped thoroughly from the wells with a cell scraper and triplicates 
were pooled into 50mL centrifuge tubes. Cells were centrifuged at 1000g for 5 
minutes; supernatant was discarded and cells were resuspended in 500μl of 
RIPA buffer and incubated for 10 minutes on ice. DNA was then briefly 
sonicated and samples treated as previously described for IP using an anti-
Tbx1 antibody, an IgG and a ‘no antibody’ sample. No anti-Histone H3 antibody 
was used as the target DNA was from a plasmid and not from the chromatin. A 
PCR from the pure plasmid was used as a positive control for PCR, while a 
PCR from genomic DNA was used as a negative control. 
 
ChIP for the 2xTtkGL2 reporter was assessed by end-point PCR, using specific 
primers (Table 2.7) targeting the 2xT site. 
 
2.12. Co-Immunoprecipitation 
 
Co-immunoprecipitation was used to detect a physical interaction between Pax9 
and Tbx1 in vivo; for this purpose, E9.5 wild-type embryos were collected and 
pooled in ice-cold PBS with protease inhibitors. 
Pooled embryos were homogenised in 250μl of cold RIPA buffer with protease 
inhibitors and incubated with constant agitation for 2 hours at 4oC. 
 
The lysed sample was then centrifuged for 20 minutes at 14,000g at 4oC to 
remove cell debris; supernatant was transferred into a fresh tube and kept on 
ice, the pellet was discarded. 
 
The lysate was pre-cleared with 5% normal serum for 1 hour on ice, followed by 
addition of 100μl of protein A/G beads and incubation for 30 minutes at 4oC with 
gentle agitation. 
 
Lysate was then centrifuged at 14,000g for 10 minutes at 4oC; the pellet was 
discarded and supernatant used for immunoprecipitation. The lysate was 
divided equally in two aliquots for IP with anti-Tbx1 and anti-Pax9 antibodies. 
 
Each sample was then incubated with 50μl of protein A/G and 5μg of the 
respective antibody (Table 2.6) overnight at 4oC on a rotating wheel. 
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Samples were then centrifuged at 10,000g for 5 minutes at 4oC; supernatants 
were discarded and samples were washed five times with cold RIPA buffer. 
After the final wash, supernatant was discarded and 50μl of 2x SDS-PAGE 
buffer was added to each sample. 
 
Diluted samples were denatured at 95oC for 5 minutes, followed by 
centrifugation at 14,000g for 5 minutes; supernatants were used for Western 
blotting as described below. 
 
For co-immunoprecipitation from JEG3 cells, cells were cultured in a 6-well 
plate; when 80% confluency was reached, cells were transfected with 5μg of 
Tbx1-expressing vector and 5μg of Pax9-expressing plasmid using 
XtremeGene9 transfection reagent (Roche) in a 3:1 ratio (µl transfection 
reagent: µg DNA) and incubated for 24 hours.  
 
Cells were then washed twice with cold PBS, and 100μl of RIPA buffer with 
protease inhibitors was added to each well; all wells were pooled and RIPA 
buffer was added to a total of 1mL. Lysed cells were incubated for 30 minutes at 
4oC in a rotating wheel. 
 
The sample was then centrifuged at 10,000g for 5 minutes at 4oC; supernatant 
was transferred into a fresh tube and kept on ice. 
 
Lysate was then pre-cleared and immunoprecipitated as described above using 
antibodies for Tbx1 and Pax9 (Table 2.6). Immunoprecipitated samples were 
then used for Western blot as next described. 
 
2.13. Western Blot 
 
Samples from IP or ChIP were diluted in 2x SDS-PAGE buffer and denatured at 
95oC for 5 minutes as previously mentioned prior to polyacrylamide 
electrophoresis. 10 μl of each sample were loaded into 10% Tris/glycine pre-
cast gels (Bio-rad) along with a pre-stained protein ladder (Thermo Scientific).  
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Gels were run in 1x running buffer (25mM Tris pH8.0, 190mM glycine, 0.1% 
SDS) for 45 minutes at 180V. Resolved samples were then transferred into 
polyvinyl difluoride (PVDF) membranes for immunoblotting. 
 
PVDF membranes were activated prior to transfer; to activate them, 
membranes were immersed in 100% methanol for 30 seconds, rinsed in dH2O 
for 5 minutes and equilibrated in ice-cold transfer buffer (48mM Tris, 39mM 
glycine, 0.04% SDS, 20% methanol) for 20 minutes. 
 
The resolved gels and activated membranes were stacked together in-between 
two sheets of blotting paper and sponge on either side. The samples were wet-
transferred for 1 hour at 100V in cold transfer buffer; transfer was performed in 
a cold room, maintaining gentle agitation of the transfer buffer inside the tank 
using a magnetic stirrer.    
 
After transfer, membranes were blocked in 5% (w/v) skimmed-milk in TBST 
(50mM Tris pH7.0, 150mM NaCl, 0.05% Tween-20) for 1 hour with gentle 
agitation. Blocking solution was then replaced with the corresponding primary 
antibody at the appropriate dilution (Table 2.6); primary antibody was diluted in 
5% milk/TBST and incubated overnight at 4oC with constant agitation. 
 
The primary antibody was then removed and membranes were washed four 
times in 5% milk/TBST for 10 minutes. Membranes where then incubated with 
the corresponding horseradish peroxidase (HRP) linked-secondary antibody 
(Table 2.6) diluted (1:20,000) in 5% milk/TBST for 1 hour at room temperature 
with gentle agitation. Membranes were then washed four times in 5% milk/TBST 
for 10 minutes, followed by four washes in TBST for 10 minutes prior to 
development. 
 
Immunocomplexes were detected by chemiluminescence using the Supersignal 
West Dura substrate (Thermo Scientific); solutions A and B were mixed (1:1), 
and added to the membrane and incubated for 5 minutes. Excess substrate was 
drained, and the membrane wrapped in a plastic sheet; membranes were 
exposed to an X-ray film sheet (Amersham Hyperfilm, GE Healthcare), and 
exposed film was developed in an automated Film developer (Konica Minolta). 
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2.14. Quantitative PCR 
 
Expression of Pax9 and Tbx1 mRNA in double heterozygous was analysed by 
quantitative PCR. Complementary DNA (cDNA) samples from wild-type, Pax9+/-
, Tbx1+/- and double heterozygous embryos was previously generated in the lab 
from the dissected pharyngeal region of E9.5 embryos; six samples of each 
genotype were used for qPCR, and each sample was done in triplicate. 
 
qPCR was performed using SYBR Green Taq ready mix (Sigma) in a mix 
containing 1x SYBR green mix, 1x internal reference dye (Rox), 1mM of each 
primer and 2μl of diluted cDNA (1:10). Samples were loaded into a 384-well 
plate sealed with optical adhesive film; the plate was run on a 7900HT Real-
time PCR system (Applied Biosystems) under a standard thermo-cycling 
program: an initial denaturation step of 95oC for 15 minutes, followed by 39 
cycles of a denaturation step of 95oC for 30 seconds, an annealing stage at 
60oC for 30 seconds, an elongation step of 72oC for 30 seconds, and a data 
collection point of 79.5oC for 10 seconds at the end of each cycle; followed by a 
final data collection ramp from 68oC to 99oC. 
 
Specific primers targeting Pax9 and Tbx1 mRNA (Table 2.8) were used for 
qPCR, along with primers targeting GAPDH as a housekeeping gene for 
relative quantification analysis. 
 
Relative gene expression was analysed by the comparative Ct method (ΔCt; 
Schmittgen and Livak, 2008). In qPCR, a product is detected by accumulation 
of a fluorescent signal; the Ct (cycle threshold) value is the number of cycles 
required for the fluorescent signal to pass the threshold of background signal, 
Ct values are therefore inversely proportional to the amount of target RNA.    
 
For relative quantification, the average Ct value of triplicates is calculated for all 
samples; the average Ct of the target gene is then normalised to the 
housekeeping (GAPDH) average Ct value (Ct target gene – Ct GAPDH). 
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Based on the assumption of a 100% efficiency of the PCR reaction to produce 2 
copies of each gene at each cycle, the ΔCt of each sample is calculated by 2 
raised to the power of the negative normalised Ct value. 
 
                                            
 
The average ΔCt of the six samples of each genotype was calculated; the 
average ΔCt of Tbx1+/-, Pax9+/- and double heterozygous samples was then 
normalised to the wild-type ΔCt of each gene (ΔCt mutant/ΔCt wild-type) and 
this change was plotted as the fold change over the wild-type relative 
expression. 
 
Table 2.8. List of primers used in qPCR 
Target Gene Primer name Sequence 
GAPDH 
Gapdh-f TGTGCAGTGCCAGCCTCGTC 
Gapdh-r TGACCAGGCGCCCAATACGG 
Pax9 
Pax9-F GGGCCGGGTTGGTGTACTGC 
Pax9-R GGTCGGATGCCCAGTTGGGC 
Tbx1 
Tbx1-F AGGCGGAAGGAAGTGGTATT 
Tbx1-R CTCGGTCGTCTACACTGCAA 
 
 
2.15. Statistics 
 
Statistical differences between the incidences of cardiovascular defects among 
different genotypes were calculated using the one tailed Fisher’s exact test. 
Statistical significance in luciferase assays and qPCR was calculated using a 
two-paired T-test. 
 
Statistical significance was considered when p-value<0.05. 
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Chapter 3. Tbx1- And Pax9-null Phenotypes 
 
3.1. Introduction 
 
Tbx1 mutant mice have been thoroughly studied and are considered a model of 
22q11 deletion syndrome. Tbx1 knockout mice have severe cardiovascular 
defects, mostly persistent truncus arteriosus, and pups die soon after birth due 
to cardiovascular and respiratory insufficiency (Lindsay et al, 2001; Jerome and 
Papaioannou, 2001). However, Tbx1 heterozygous mice present with 4th PAA-
derived defects although their incidence varies greatly as seen in different 
previously published studies, as summarized in Table 3.1. 
 
Table 3.1. Summary of reported incidences of cardiovascular defects in Tbx1 
heterozygotes at late embryogenesis. 
Age n Abnormal (%) IAA-B ARSA C-AoA Reference 
E18.5 41 
11 3 6 2 
Vitelli et al, 2002 
(26.8%) (7.3%) (14.6%) (4.8%) 
E17.5 5 
0 0 0 0 
Aggarwal et al, 2006 
(0%) (0%) (0%) (0%) 
E16.5 18 
6 0 4 1 
Guris et al, 2006 
(33.3%) (0%) (22.2%) (5.5%) 
E18.5 29 
11 1 8 NR 
Zhang et al, 2008 
(37.9%) (3.4%) (27.5%) 
 
E15.5 19 
5 2 2 NR 
Calmont et al, 2009 
(26.3%) (10.5%) (10.5%) 
 
E14.5 25 
6 1 4 1 
Randall et al, 2009 
(24%) (4%) (16%) (4%) 
E14.5 - E18.5 36 
9 1 4 4 
Ryckebush et al, 2010 
(25%) (2.7%) (11.1%) (11.1%) 
E15.5 17 
5 2 3 0 Papangeli and Scambler, 
2013 (29%) (11.7%) (17.5%) (0%) 
NR, Not reported 
 
Tbx1 haploinsufficiency mainly affects the 4th PAAs either unilaterally or 
bilaterally. The proportion of affected Tbx1+/- embryos at mid embryogenesis 
(Table 3.2) is higher than the incidence of 4th PAA-derived defects seen at late 
embryogenesis (Table 3.1). The lower incidence seen at later stages is 
considered to be due to some form of recovery occurring during the remodeling 
process (between E11.5 and E13.5), where hypoplastic vessels may be able to 
recover and develop normally (Lindsay and Baldini, 2001; Calmont et al, 2009; 
Papangeli and Scambler, 2012). 
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Table 3.2. Summary of reported 4
th
 PAAs abnormalities in Tbx1 heterozygotes at mid 
embryogenesis 
Age n 
Abnormal 
(%) 
Unilateral 
defects 
Bilateral 
defects 
Reference 
E10.5 48 
48 
(100%) 
NR NR 
Lindsay and Baldini, 
2001 
E10.5 11 
5 
(46%) 
3 2 Calmont et al, 2009 
E10.5 14 
9 
(64%) 
6 3 Randall et al, 2009 
E10.5 17 
14 
(82%) 
6 8 
Ryckebush et al, 
2010 
E10.5 29 
21 
(71%) 
15 6 
Papangeli and 
Scambler, 2013 
E11.5 23 
22 
(95%) 
NR NR 
Caprio and Baldini, 
2014 
NR, not reported 
 
In order to establish a baseline of the penetrance of Tbx1 heterozygous defects 
for further analysis in the context of Pax9 heterozygosity, as well as to compare 
the penetrance of our study with previous reports, Tbx1 heterozygous embryos 
were analysed by MRI and hematoxylin and eosin (H&E) staining at E15.5, and 
by intracardiac ink injections at E10.5. 
 
3.2. Tbx1 Mouse Phenotype 
 
3.2.1. Cardiovascular Phenotype Of Tbx1 Mutant Embryos 
 
Tbx1 mice were bred by intercrossing Tbx1+/- mice; no Tbx1-null mice were 
found alive after weaning, concordant with perinatal lethality previously reported 
(Lindsay et al, 2001; Jerome and Papaioannou, 2001).  
 
Tbx1 heterozygous embryos from double heterozygous (Pax9+/- with Tbx1+/-) 
crosses were collected at E15.5 and analysed by MRI and histology to 
determine the penetrance of Tbx1 haploinsufficiency defects to set the basis for 
future analysis of double heterozygotes. As seen in Table 3.3 and Figure 3.1, 
Tbx1 heterozygosity leads to various cardiovascular defects including VSD, 
ARSA, IAA-B, coRSA, coAA (Figure 3.1b).  
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The penetrance of each of these defects is summarised in Table 3.3. Only 1 
(5%) Tbx1+/- embryo had an interrupted aortic arch type B (IAA-B) and 
ventricular septal defect (VSD), 2 (10%) Tbx1+/- embryos had a cervical aortic 
arch (coAA), 5 (26%) Tbx1+/- embryos had a cervical right subclavian artery 
(coRSA), and 7 out of 19 (36%) presented with a retro-esophageal right 
subclavian artery (ARSA, Figure 3.1b). 
 
 
Figure 3.1. Cardiovascular phenotype of E15.5 Tbx1 heterozygous embryos. 
(a) Wild-Type embryos present with normal branching of the great arteries, whereas (b, c) Tbx1 
heterozygous embryos (Tbx1
+/-
) present with some cardiovascular defects including anomalous 
retro-esophageal right subclavian artery (ARSA), cervical right subclavian artery (CoRSA). Ao, 
aorta; dAo, dorsal aorta; RV, right ventricle; LV, left ventricle; RSA, right subclavian artery; RCC, 
right common carotid artery; LSA, left subclavian artery; LCC, left common carotid artery; ARSA, 
anomalous retro-esophageal right subclavian artery. Scale 500μm. 
 
Table 3.3. Incidence of cardiovascular defects in E15.5 Tbx1 heterozygous embryos. 
Genotype n VSD 
Cervical 
Ao 
IAA 
Cervical 
RSA 
ARSA 
Wild-Type 16 0 0 0 0 0 
Tbx1+/- 19 
1 2 1 5* 7* 
(5.3%) (10.5%) (5.3%) (26.3%) (36.8%) 
Fisher’s exact test, *p<0.05  
 
It is well known that Tbx1 haploinsufficiency mostly affects the development of 
the pharyngeal arch arteries causing the PAA-derived defects previously 
discussed. 
 
Therefore, the development of the PAAs in Tbx1+/- embryos was analysed by 
intracardiac ink injection to visualise the patterning of the PAAs at E10.5. 
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3.2.2 Development Of The Pharyngeal Arch Arteries In Tbx1 Mutant 
Embryos 
 
Tbx1+/- embryos present defects mostly derived from abnormal development of 
the PAAs as described before (Figure 3.1). To analyse the patterning of the 
PAAs in Tbx1+/- embryos India ink was injected directly into the beating left 
ventricle to be pumped into the PAAs to visualise their patency. 
 
As seen in Figure 3.2, all Tbx1+/- embryos present abnormal patterning of the 4th 
PAAs, which can be a hypoplastic or a completely absent vessel either 
unilateral or bilaterally (Figure 3.2b, Table 3.4). Four out of eight (50%) Tbx1+/- 
embryos have bilaterally abnormal 4th PAAs (Table 3.4), mainly showing a 
hypoplastic artery (Figure 3.2b). 
 
As can be seen in Table 3.4, the incidence of abnormal Tbx1+/- embryos (100%) 
is much higher compared to the incidence of defects seen at E15.5 (Table 3.3), 
which can be explained by the proposed recovery during the remodelling 
process (Calmont et al, 2009; Papangeli and Scambler, 2012). 
 
Interestingly, we also found that 9 out of 19 (50%) of Tbx1 heterozygous adult 
mice have an ARSA (Figure 3.3), which did not appear to affect their viability, 
and correlates with the incidence of non-patent 4th right PAA at mid 
embryogenesis (Table 3.4). 
 
The incidence of 4th PAA-derived defects in Tbx1 heterozygous mice varies 
among different studies as discussed before; similarly, the incidence and 
severity of cardiovascular defects in human patients with 22q11DS varies 
among individuals, suggesting such cardiovascular defects are not monogenic 
due to only Tbx1 loss but a result in the disruption of other genes or pathways 
that modify the phenotype. 
 
In this context, several reports have studied potential genetic interactions 
between Tbx1 and other genes involved in cardiovascular development as 
discussed in section 1.5 (reviewed in Scambler, 2010).  
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Figure 3.2. Pharyngeal arch artery defects in Tbx1 mutant embryos. 
Patterning of the pharyngeal arch arteries at E10.5 was visualised by intracardiac injection of 
India ink. (a) Wild-type embryos present normal patterning of the 3
rd
, 4
th
 and 6
th
 PAAs on both 
sides, whereas Tbx1
+/-
 embryos (b) present abnormal 4
th
 PAAs on both sides, mainly displaying 
hypoplastic vessels. Tbx1
-/-
 embryos (c) present a more severe phenotype with no caudal 
pharyngeal arches being formed (red asterisk), showing only formation of the 1
st
 and 2
nd
 PA; 
consequently, the PAAs are not formed and a single vessel connects the aortic sac with the 
paired dorsal aortas on both sides. Scale 500μm.   
 
 
Table 3.4. Incidence of 4
th
 PAA abnormalities in E10.5 Tbx1 heterozygous embryos. 
Genotype n 
Abnormal 
(%) 
Bilateral 
defects 
Bilateral defects 
Hypo/Hypo Hypo/NP NP/NP 
Wild-type 6 0 0 - - - 
Tbx1+/– 8 
8* 
(100%) 
4* 
(50%) 
3 1 - 
Fisher’s exact test, *p<0.001  
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Figure 3.3. Great artery defects in neonate and adult Tbx1 heterozygous mice. 
Neonate (a) and adult (b) Tbx1 heterozygous mice were dissected to visualise the heart and 
great arteries, revealing 4
th
 PAA-derived defects, with some mice presenting a right subclavian 
with cervical origin (coRSA), and many presenting a retro-esophageal right subclavian artery 
(ARSA). Ao, aorta; RCC, right common carotid; LCC, left common carotid; LSA, left subclavian 
artery; da, ductus arteriosus; coRSA, cervical origin of the right subclavian; ARSA, anomalous 
retro-esophageal right subclavian artery. 
 
Epistasis between Tbx1 and other genes such as Vegf (Stalmans et al, 2003), 
Crkl (Guris et al, 2006), Cdh7 (Randall et al, 2009), Aldh1a2 (Ryckebusch et al, 
2010), or direct downregulation of Tbx1 target genes including Fgf8 (Vitelli et al, 
2002), Gbx2 (Calmont et al, 2009; Caprio and Baldini, 2014) and Wnt5a (Chen 
et al, 2012) have been shown to modify the Tbx1+/- phenotype (reviewed in 
Aggarwal and Morrow, 2008).  
 
However, more than 200 genes have been found affected by homozygous 
deletion of Tbx1 (Ivins et al, 2005; Liao et al, 2008), that could potentially be 
involved in cardiovascular development and modify the Tbx1 phenotype. 
Among those affected genes, Pax9 is found significantly downregulated in 
Tbx1-null embryos at E8.5, E8.75 and E9.5 (Ivins et al, 2005; Liao et al, 2008). 
 
3.2.3 Pax9 Is Downregulated In Tbx1 Knockout Embryos 
 
Microarray analysis of Tbx1-null embryos revealed Pax9 to be significantly 
down-regulated, and it was further confirmed by in situ hybridisation and qPCR, 
showing about a 50% reduction of Pax9 expression in Tbx1-null embryos (Ivins 
et al, 2005; Liao et al, 2008). To confirm this Pax9 reduction in our model, Tbx1-
null, heterozygous and wild-type embryos were collected at E9.5 and in situ 
hybridisation was performed using a probe against Pax9 mRNA. 
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Figure 3.4. Pax9 mRNA expression is reduced in Tbx1-null embryos 
Whole-mount in situ hybridisation using a Pax9 riboprobe shows an obvious decrease of Pax9 
expression within the pharyngeal region of Tbx1-null embryos (c) compared to wild-type (a) and 
Tbx1
+/-
 embryos (b) at E9.5. Scale bar 500μm. 
 
As seen in Figure 3.4, Pax9 expression does not seem to be qualitatively 
affected by Tbx1 haploinsufficiency (Figure 3.4b) as compared to wild-type 
embryos (Figure 3.4a), whereas Tbx1-null embryos show a significant reduction 
in Pax9 expression (Figure 3.4c), concordant with what has been previously 
reported by Ivins et al (2005). 
 
3.3 Pax9 mouse 
 
Expression of Pax9 is significantly down-regulated in Tbx1-null embryos as 
previously mentioned, suggesting Pax9 could be a down-stream target of Tbx1. 
Additionally, both Pax9 and Tbx1 are co-expressed at E9.5 and E10.5 within the 
pharyngeal endoderm (Figure 3.5). 
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Figure 3.5. Pax9 and Tbx1 are co-localised within the pharyngeal endoderm. 
Fluorescence double immunohistochemistry staining for Tbx1 (green) and Pax9 (red) on 
coronal sections from wild-type E9.5 embryos shows both proteins co-localise within cells in the 
pharyngeal endoderm (pe). Representative picture showing co-localization within the 
pharyngeal endoderm in the 3
rd
 pouch. Image provided by Kathleen Allison. 
 
Both Pax9 and Tbx1 knockout embryos present with abnormal development of 
the thymus, parathyroids and with craniofacial defects (Peters et al, 1998; 
Lindsay et al, 2001; Jerome and Papaioannou, 2001), showing some overlap 
between both knockout phenotypes. This overlapping of phenotypes, as a 
phenocopy, is suggestive of a genetic interaction or a common genetic pathway 
(Aggarwal and Morrow, 2008) between Tbx1 and Pax9.   
 
Although the craniofacial and skeletal defects, along with abnormal 
development of pharyngeal arch-derived glands in Pax9 knockout embryos has 
been reported (Peters et al 1998; Kist et al, 2005), cardiovascular development 
has not been investigated in Pax9-null embryos.  
 
Preliminary results from our group indicate that Pax9 knockout embryos have 
some cardiovascular defects (Figure 3.6, Simon Bamforth unpublished data). In 
this context, E14.5 Pax9-null embryos were analysed by hematoxylin and eosin 
(H&E) staining. As seen in Figure 3.6, Pax9-/- embryos present DORV, IAA-B 
and ARSA (Figure 3.5e-h). 
 
Therefore, the second aim of this chapter was to analyse the development of 
the heart and great arteries in Pax9-null embryos in detail, by MRI and H&E 
staining at E15.5.   
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Figure 3.6. Pax9-null embryos present many cardiovascular defects at E14.5. 
Histological analysis of E14.5 embryos revealed defects within the heart of Pax9-null embryos 
(e-h), including double outlet right ventricle (DORV) with the aorta ascending from the right 
ventricle (e); Pax9-null embryos also present with interruption of the aortic arch (IAA) (g), retro-
esophageal right subclavian artery (ARSA) (g), and abnormal origin of the carotid arteries (h). 
Additionally, the thymus is not apparent in Pax9-null embryos compared to wild-type embryos 
where the thymus (Th) is clearly visible (d). Ao, aorta; DA, ductus arteriosus; AoA, aortic arch; 
LSA, left subclavian artery; RCC, right common carotid; LCC, left common carotid; Th, thymus; 
DORV, double outlet right ventricle; IAA, interruption of the aortic arch; A-RSA, anomalous 
retro-esophageal right subclavian artery. Scale bar, 100μm. (Simon Bamforth, unpublished 
data). 
 
 
3.3.1. Cardiovascular phenotype of E15.5 Pax9-mutant embryos 
 
Pax9-null embryos were generated by intercrossing Pax9+/- mice; embryos were 
collected at E15.5 and imaged by MRI (Section 2.3) and 3D models of the heart 
and great arteries were reconstructed from the data sets using Amira software 
(Visage Imaging). Wild-type (n=2), Pax9+/- (n=2) and Pax9-/- (n=4) embryos 
were analysed by MRI and subsequently embedded in wax, sectioned and 
stained with haematoxylin and eosin for detailed histological analysis.  
 
Externally Pax9-null embryos are indistinguishable from Wild-type and 
heterozygous embryos (Figure 3.7), except for an extra limb digit seen in Pax9 
knockout embryos (not shown), as previously described (Peters et al, 1998). 
Additionally, all Pax9 knockout embryos have cleft palate and ectopically placed 
hypoplastic thymus (Peters et al, 1998). 
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Figure 3.7. External phenotype of Pax9 mutant embryos. 
Pax9-null embryos (c) are indistinguishable from wild-type (a) and Pax9
+/-
 (b) embryos 
externally. Scale bar, 1mm.  
 
MRI (Figure 3.8) and histological analysis (Figure 3.9) shows Wild-type and 
Pax9 heterozygous (Pax9+/-) embryos display normal morphology of the heart 
and great arteries (Figure 3.8a, b), where the ascending aorta (Ao) arises from 
the left ventricle (LV) forming the aortic arch to join the descending aorta (dAo). 
Normal branching of the great arteries can be seen with the brachiocephalic 
artery arising as the first branch of the aortic arch and the left common carotid 
(LCC) and left subclavian (LSC) arising from the aortic arch as the second and 
third branch, respectively. Branching of the brachiocephalic artery into the right 
subclavian artery (RSA) and right common carotid (RCC) is normal in both wild-
type and Pax9+/- embryos. Further normal branching of the common carotids 
into the internal and external carotids is observed in both wild-type (Figure 3.8a) 
and Pax9+/- (Figure 3.8b) embryos. Moreover, Wild-type and Pax9+/- hearts don't 
present any abnormalities within the ventricles or atrial chambers, showing 
normal size of the chambers and proper septation (Figure 3.9a). 
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Figure 3.8. Cardiovascular phenotype of E15.5 Pax9-null embryos. 
(a) Wild-Type and Pax9
+/-
 (b) embryos present with normal branching of the great arteries; (c) 
All Pax9-null (Pax9
-/-
) embryos present with some form of cardiovascular defect affecting the 
branching of the great arteries displaying interruption of the aortic arch type B (IAA), anomalous 
retro-esophageal right subclavian artery (ARSA), and unilateral or bilateral absence of the 
common carotids, consequently causing the internal and external carotids to arise directly from 
the aortas; additionally all Pax9-null embryos present VSD and DORV. LV, left ventricle; RSA, 
right subclavian artery; RCC, right common carotid artery; LSA, left subclavian artery; LCC, left 
common carotid artery; iRC, internal right carotid artery; eRC, external right carotid artery; iLC, 
internal left carotid artery; eLC, external left carotid artery; ARSA, anomalous retro-esophageal 
right subclavian artery; IAA, interruption of the aortic arch; VSD, ventricular septal defects. 
Scale 500μm. 
 
 
Figure 3.9. Histological analysis of E15.5 Pax9-null embryos. 
Histological analysis shows in more detail the cardiovascular defects in Pax9-null embryos 
(Pax9
-/-
) including VSD (e), DORV (f), IAA (h, i), and ARSA (j-l). The internal (iRC) and external 
right carotid (eRC) arteries can be seen arising directly from the aorta (Ao) as a consenquence 
of absent right common carotid (j-l). LV, left ventricle; RSA, right subclavian artery; RCC, right 
common carotid artery; LSA, left subclavian artery; LCC, left common carotid artery; iRC, 
internal right carotid artery; eRC, external right carotid artery; iLC, internal left carotid artery; 
eLC, external left carotid artery; ARSA, anomalous retro-esophageal right subclavian artery; IAA, 
interruption of the aortic arch; VSD, ventricular septal defects; DORV, double outlet right 
ventricle; Thy, thymus. Scale bar, 100μm. 
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Pax9-null (Pax9-/-) embryos however, display several abnormalities within the 
heart and great arteries. All Pax9-/- embryos show an absence of the common 
carotid arteries, either unilaterally or bilaterally (Figure 3.8c). Three out of four 
Pax9-null embryos analysed lack both (right and left) common carotids (Figure 
3.8c), and one Pax9-null embryo had the left common carotid (LCC) but lacked 
the right common carotid. Such absence of the common carotids consequently 
causes the internal (iRCA, iLCA) and external (eRCA, eLCA) carotids to arise 
directly from the ascending and descending aorta (Figure 3.8c, Figure 3.9j-l).   
 
Furthermore, the four Pax9-null embryos presented interruption of the aortic 
arch type B (IAA-B, Figure 3.8c, Figure 3.9h), ARSA (Figure 3.8c, Figure 3.9j-i), 
VSD (Figure 3.8c, Figure h, i), DORV (Figure 3.9f), bicuspid aortic valves (BAV) 
and a hypoplastic aorta. 
 
The penetrance of these cardiovascular defects at E15.5 was further confirmed 
with data already available in the lab from the analysis of 15 more embryos, for 
a total of 19 Pax9-/- embryos (Table 3.5). 
 
Table 3.5. Incidence of cardiovascular defects in E15.5 Pax9-null embryos. 
n VSD IAA ARSA CoRSA 
Absent 
CC 
Abnormal 
thymus 
Cleft 
palate 
19 
19 17 14  2 15 19 19 
(100%) (15.8%) (73.7%) (10.5%) (79%) (100%) (100%) 
 
Since all Pax9-/- embryos display abnormal patterning of the great arteries, the 
development of the pharyngeal arch arteries was analysed at E10.5 by India ink 
injection. 
 
3.3.2. Pharyngeal Arch Artery Phenotype Of E10.5 Pax9-null Embryos 
 
To analyze the development of the pharyngeal arch arteries (PAAs), Pax9-null 
embryos were collected at E10.5 and India ink was injected into the left 
ventricle, and allowed to be circulated to visualize the patterning of the 
pharyngeal arch arteries.  
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As observed in Figure 3.10, wildtype (a) and Pax9+/- (b) embryos display normal 
patterning of the 3rd, 4th and 6th pharyngeal arch arteries on both sides, 
connecting the aortic sac (as) with the paired dorsal aortas (dAo) at E10.5. By 
this stage the 1st and 2nd PAAs have already remodeled and are no longer 
visible. In contrast, all Pax9-null embryos present with abnormal patterning of 
the pharyngeal arch arteries at E10.5 (Table 3.6), showing delayed remodeling 
of the 1st and 2nd pharyngeal arch arteries bilaterally (Figure 3.10c), with 50% of 
Pax9-/- embryos exhibiting patent 1st PAAs and 20% embryos showing patent 
2nd PAAs. Moreover, 50% of Pax9-/- embryos show hypoplastic 3rd arteries, and 
100% of Pax9-/- embryos show non-patent 4th PAAs on both sides (Figure 
3.10c; Table 3.6). 
 
 
Figure 3.10. Pharyngeal arch artery defects in Pax9 mutant embryos. 
Patterning of the pharyngeal arch arteries at E10.5 was visualised by intracardiac injection of 
India ink. (a) Wild-type and Pax9
+/-
 (b) embryos present normal patterning of the 3
rd
, 4
th
 and 6
th
 
PAAs on both sides, whereas Pax9
-/-
 embryos (c) show abnormal patency of the 1
st
 PAAs on 
both sides at E10.5, suggesting a delay in their remodelling; Pax9-null embryos also display 
abnormal hypoplastic 3
rd
 PAAs and the 4
th
 PAAs (red asterisk) are non-patent to ink on both 
sides (c). Scale 500μm.   
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Table 3.6. Pharyngeal arch artery defects in E10.5 Pax9-null embryos. 
n PAA Abnormal (%) 
Defects 
Patent Hypoplastic Non-patent 
10 
1st 5 (50%) 5 - - 
2nd 2 (20% 2 - - 
3rd 6 (60%) - 3 1 
4th 10 (100%) - 2 8 
 
Delayed regression of the 1st and 2nd PAA together with the hypoplastic 3rd PAA 
could explain the abnormal patterning of the carotids seen at E15.5, where the 
common carotids are absent as these are formed from the 3rd PAAs. Therefore, 
abnormal regression of the 3rd PAAs causes the internal and external carotids 
to arise directly from the ascending and dorsal aorta. Furthermore, the absence 
of the 4th pharyngeal arch arteries in Pax9-/- embryos explains the IAA-B and 
ARSA seen at E15.5 (Figure 3.8), as the aortic arch is formed by the left 
4thPAA, while the right 4th PAA forms the distal portion of the right subclavian 
artery (RSA).  
 
3.4. Discussion 
 
The results shown in the first section of this chapter further confirm the crucial 
role of Tbx1 for pharyngeal arch artery development and their derived structures 
(i.e. the great arteries). Although the incidence of Tbx1 heterozygous defects 
varies among different studies at late embryogenesis, our results along with 
previous studies show the 4th PAAs as the main affected vessels at mid 
embryogenesis (Figure 3.3). 
 
The recovery that takes place during the remodelling of the PAAs highly 
increases this variability, however, given the high phenotypic variability seen in 
22q11DS patients, it is likely that genetic modifiers in epistasis with TBX1 
modify the presentation of the phenotype.  In this context, various genes have 
been shown to be in direct epistasis with Tbx1 modifying the penetrance of 
Tbx1-heterozigosity defects (reviewed in Aggarwal and Morrow, 2008), 
including Vegf (Stalmans et al, 2003), Crkl (Guris et al, 2006), Pitx2 
(Nowotschin et al, 2006), Gbx2 (Calmont et al, 2009), and Aldh1a2 
(Ryckebusch et al, 2010). 
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Moreover, expression of many other genes is affected by loss of Tbx1 (Ivins et 
al, 2005; Liao et al, 2008), however their role in cardiovascular development or 
as potential modifiers of the Tbx1 phenotype has not been studied for many of 
those genes. Among them, the transcription factor Pax9 is found significantly 
downregulated in Tbx1-null embryos (Ivins et al, 2005; Figure 3.4). 
 
Pax9 transcription factor is required for development of some pharyngeal arch-
derived tissues including the thymus, parathyroids and ultimobranchial bodies 
(Peters et al, 1998), which are also affected in 22q11DS patients. 
 
The results in this chapter show the a novel role for Pax9 during cardiovascular 
development; particularly, Pax9 is required for correct development of the 
pharyngeal arch arteries at mid embryogenesis, since homozygous deletion of 
Pax9 causes a delay in the remodelling of the cranial 1st and 2nd PAAs, 
abnormal regression of the 3rd PAAs and completely disrupts the formation of 
the 4th PAAs (Figure 3.10).  
 
The lack of formation of the 4th PAA on the left side prevents the formation of 
the aortic arch, whereas the absent right 4th PAA results in the right subclavian 
artery to abnormally originate on the left side and migrate behind the 
esophagous towards the right side forming a retro-esophageal right subclavian 
artery (ARSA). 
 
Although the presence of ARSA can be asymptomatic and patients may not 
present with further complications, IAA is perinatally lethal, and patients need 
pharmacological and surgical attention immediately as previously mentioned.   
 
Additionally, Pax9-null embryos display the internal and external carotids arising 
directly from the aortic arch due to absence of the common carotids as a 
consequence of the abnormal regression of the 3rd PAAs at E10.5. Such 
absence of the common carotids as a consequence of abnormal regression of 
the 3rd PAAs and persistence of the carotid duct has been previously reported in 
a female patient, who presented bilateral absence of the common carotids with 
the internal and external carotids arising directly from the aortic arch (Roberts 
and Gerald, 1978). 
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Although there is no direct evidence to date associating PAX9 with 
cardiovascular development in humans, a few published papers have found 
patients with PAX9 deletions presenting cardiovascular anomalies. 
 
In 1999, Schuffenhauer et al reported a male patient with 14q chromosomal 
deletion that included PAX9 presenting persistent ductus arteriosus and 
pulmonary stenosis. In 2001, Kamnasaran and colleagues reported another 
patient with persistent ductus arteriosus also with 14q deletion that included 
PAX9. Furthermore, Santen et al (2012) recently reported a case of a patient 
carrying a 14q13 deletion that included PAX9, presenting severe cardiovascular 
malformations including interrupted aortic arch type B, bicuspid aortic valve, 
ventricular septal defect and hypoplastic aorta; interestingly, these 
cardiovascular anomalies greatly overlap with the phenotype seen in Pax9-null 
embryos presented in this chapter. 
 
Although TBX1 deletion was excluded in the last report of a patient with PAX9 
deletion (Santen et al, 2012), the possibility of mutations or deletions of PAX9 in 
patients with 22q11DS has not been analysed to date, leaving open the 
possibility of PAX9 being a modifier gene of the 22q11DS phenotype. 
Therefore, a potential genetic interaction between Tbx1 and Pax9 during 
cardiovascular development was studied in the next chapter.  
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Chapter 4. Pax9 And Tbx1 Genetically Interact During 
Cardiovascular Development 
 
4.1 Introduction 
 
As described in section 3.3, Pax9 is required for normal cardiovascular 
development as homozygous deletion of Pax9 leads to severe cardiovascular 
anomalies including IAA-B, ARSA, VSD, DORV and absence of the common 
carotids (Figure 3.8). Furthermore, Pax9 homozygous deletion affects the 
development of the pharyngeal arch arteries, as Pax9-null embryos show 
abnormal remodelling of the 1st, 2nd and 3rd PAAs, and complete lack of 
formation of the 4th PAAs (Figure 3.10). 
 
The similarity between both Pax9 knockout and Tbx1 heterozygous phenotypes 
showing ARSA and IAA, which are caused by abnormal development of the 4th 
PAAs suggests both Pax9 and Tbx1 are required for normal 4th PAAs 
development. Moreover, Tbx1 and Pax9 are co-expressed within the 
pharyngeal endoderm at E9.5 and E10.5 (Figure 3.5), and Pax9 expression is 
significantly downregulated in Tbx1-null embryos (Ivins et al, 2005; Figure 3.4), 
suggesting Pax9 as a potential down-stream target of Tbx1. 
 
Therefore, to investigate whether Pax9 and Tbx1 interact during cardiovascular 
development either as part of the same pathway or working in parallel 
pathways, Pax9+/- mice were crossed with Tbx1+/- mice and their progeny were 
analyzed for cardiovascular defects at different embryonic and postnatal stages. 
 
4.2 Perinatal survival of double heterozygous mice 
 
Pax9+/- mice were crossed with Tbx1+/- mice to generate compound 
heterozygotes for analysis. From this cross it is expected that 25% will be wild-
type (i.e. Pax9+/+;Tbx1+/+), 25% will be Pax9+/-, 25% Tbx1+/-, and the final 25% 
being doubly heterozygous (i.e. Pax9+/-;Tbx1+/-). Interestingly, only 2 double 
heterozygous mice (out of 168 pups weaned) were found alive after weaning at 
3 weeks old.  
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Table 4.1. Survival of double heterozygous mice after weaning 
Genotype Wildtype Pax9+/- Tbx1+/- Pax9+/-;Tbx1+/- Total 
Observed 
(3 weeks old) 
55 68 43 2* 168 
Expected 42 42 42 42 168 
*Fisher’s exact test, p<0.0001 
 
This is a significant deviation from the expected Mendelian ratio, where 42 pups 
of each genotype were expected (p<0.0001). Whereas all other genotypes were 
found within Mendelian ratios (Table 4.1). 
 
Although all Pax9+/- and the majority (95%) of Tbx1+/- mice are viable, all 
homozygous null mice die soon after birth as previously mentioned. To 
determine whether double heterozygotes were dying during the foetal period or 
after birth, neonates were collected within 48 hours of birth.  
 
All pups from Pax9+/- and Tbx1+/- mice crosses were born alive, however all 
double heterozygous pups (n=7, Table 4.2) died within 48 hours, with the rest of 
the pups surviving. When dissected, 5 out of 7 double heterozygotes had an 
interrupted aortic arch (Figure 4.1c, Table 4.2) and no visible brachiocephalic or 
right subclavian artery, suggesting they had a retro-esophageal right subclavian 
artery (ARSA, arrow in Figure 4.1c). No wild-type or Pax9+/- mice had 
cardiovascular defects, whereas 3 out of 5 Tbx1+/- pups had ARSA and one 
presented with IAA-B (Table 4.2). 
 
The analysis of neonatal survival indicates that double heterozygous mice die 
after birth, the majority likely dying from the consequence of having an 
interrupted aortic arch, with the time of death being variable depending on the 
time of closure of the ductus arteriosus (Figure 4.1). 
 
To analyse in more detail the cardiovascular defects in double heterozygotes, 
E15.5 embryos were collected and analysed by MRI and histology. 
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Table 4.2 Perinatal lethality of double heterozygous mice. 
Genotype Wild type Pax9+/- Tbx1+/- Pax9+/-;Tbx1+/- Total 
Observed 5 10 5 7 27 
Expected 6.75 6.75 6.75 6.75 27 
Abnormal 0 0 1a 6*b  
*Fisher’s exact test, p<0.005 (compared to abnormal Tbx1+/- mice) 
a, one embryo presented IAA 
b, six embryos presented IAA 
 
 
Figure 4.1. Cardiovascular defects in neonate double heterozygous mice. 
Dissection of neonate mice (P0) revealed double heterozygotes (Tbx1
+/-
;Pax9
+/-
) present with 
interruption of the aortic arch (IAA) and retro-esophageal right subclavian artery (ARSA) (d); 
some Tbx1
+/-
 pups (c) displayed ARSA, whereas Pax9
+/-
 (b) do not have any cardiovascular 
defects. Ao, aorta; da, ductus arteriosus; AoA, aortic arch; RSA, right subclavian artery; LSA, 
left subclavian artery; RCC, right common carotid; LCC, left common carotid; IAA, interruption of 
the aortic arch; ARSA, anomalous retro-esophageal right subclavian artery. 
 
4.3 Cardiovascular phenotype of double heterozygotes 
 
Embryos from Pax9+/- and Tbx1+/- mice crosses were collected at E15.5, 
imaged by MRI and analysed by histology afterwards.  Wild-type (n=16), Pax9+/- 
(n=15), Tbx1+/- (n=19) and Pax9+/-;Tbx1+/- (n=20) embryos were imaged and 3D 
models of the heart and great arteries were built from the MRI data sets (Figure 
4.2).  
 
As can be seen in Table 4.3, Wild-type and Pax9 heterozygous embryos do not 
present any cardiovascular defects (Table 4.3, Figure 4.2a, b), whereas a 
proportion of Tbx1 heterozygotes (Table 4.3) have some form of cardiovascular 
defect mainly affecting the great arteries (Figure 4.2c).  
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As described before in section 3.1, ARSA is most commonly found in Tbx1 
heterozygous embryos with 7 out of 19 (36%) presenting ARSA (Figure 4.2c). 
Five (26%) Tbx1+/- embryos also presented with cervical right subclavian artery 
(coRSA), and 2 (10%) Tbx1+/- embryos had a cervical aortic arch (coAoA). Only 
1 (5%) Tbx1+/- embryo had IAA-B with VSD (Table 4.3). 
 
However, all double heterozygous (Pax9+/-;Tbx1+/-) embryos had some form of 
cardiovascular defect affecting the great arteries (Table 4.3). Of particular 
interest is that double heterozygous embryos showed a statistically significant 
increase (p<0.001) in the incidence of IAA-B (Table 4.3, Figure 4.2 d-f, Figure 
4.3f,g), with 14 out of 20 (70%) Pax9+/-;Tbx1+/- embryos being affected, 
compared to only one (5%) Tbx1 heterozygote with an IAA-B. Three (15%) 
double heterozygotes had a cervical aortic arch, 11 (55%) double heterozygotes 
had a coRSA (Figure 4.2d, f), and 9/20 (45%) had ARSA (Figure 4.2e, Figure 
4.3f-h).  
 
Moreover, double heterozygotes had a statistically significant increase (p-value 
<0.005) in the incidence of VSD, with 6 (30%) double heterozygous embryos 
affected (Table 4.3, Figure 4.2d, Figure 4.3e) compared to only one Tbx1 
heterozygous embryo (Table 4.3). 
 
All Tbx1+/- and double heterozygous embryos were externally indistinguishable 
from wild-type and Pax9 heterozygotes (Figure 4.4). However, 4 (21%) Tbx1 
heterozygous embryos had an abnormal thymus, whereas 17 (85%) double 
heterozygotes displayed an abnormally developed thymus, where the thymus 
appears hypoplastic and asymmetric with unfused lobes. 
 
The great arteries appear to be mainly affected by Pax9 and Tbx1 double 
haploinsufficiency, and it is well known Tbx1 heterozygosity affects the 
development of the pharyngeal arch arteries as discussed in sections 1.4 and 
3.1. Therefore, the development of the PAAs in double heterozygous embryos 
was analysed by intracardiac ink injection at E10.5. 
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Table 4.3. Incidence of cardiovascular defects in E15.5 double heterozygous embryos. 
Genotype n VSD 
Cervical 
Ao 
IAA 
Cervical 
RSA 
ARSA 
WildType 16 0 0 0 0 0 
Pax9+/- 15 0 0 0 0 0 
Tbx1+/- 19 1 2 1 5 7 
(5.3%) (10.5%) (5.3%) (26.3%) (36.8%) 
Pax9+/-;Tbx1+/- 20 6* 3 13** 11 9 
(30.0%) (15.0%) (65.0%) (55.0%) (45.0%) 
Fisher’s exact test, *p<0.05 ** p<0.001 
 
 
Figure 4.2. Cardiovascular phenotype of E15.5 double heterozygous embryos. 
(a) Wild-Type and Pax9
+/-
 (b) embryos present with normal branching of the great arteries 
where the aorta (Ao) arises from the left ventricle (LV) forming the aortic arch to connect with 
the descending aorta (dAo), the brachiocephalic artery arising from the right side of aortic arch 
and branching into the righ subclavian artery (RSA) and the right common carotid artery (RCC), 
while the left common carotid (LCC) and the left subclavian artery (LSA) arise from the left side 
of the aortic arch; (c) Tbx1
+/-
 embryos present with some cardiovascular defects, including 
anomalous retro-esphageal right subclavian artery (ARSA), whereas (d-f) double heterozygous 
embryos (Tbx1
+/-
;Pax9
+/-
) present with a higher incidence of cardiovascular defects, including 
ventricular septal defects (VSD), cervical origin of the right subclavian artery (coRSA, d, f), 
anomalous right subclavian artery (e), and interruption of the aortic arch type B (IAA, d, e). LV, 
left ventricle; RSA, right subclavian artery; RCC, right common carotid artery; LSA, left 
subclavian artery; LCC, left common carotid artery; ARSA, anomalous retro-esophageal right 
subclavian artery; coRSA, cervical origin of the right subclavian artery; IAA, interruption of the 
aortic arch; VSD, ventricular septal defects. Scale 500μm. 
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Figure 4.3. Histological analysis of E15.5 double heterozygous embryos. 
Histological analysis shows in more detail the cardiovascular defects in double heterozygous 
embryos (Tbx1
+/-
;Pax9
+/-
) including VSD (e), IAA (f,g) and ARSA (f-h). Additionally, the thymus 
is not apparent in double heterozygous embryos compared to wild-type embryos where the 
thymus is clearly visible (c,d). Ao, aorta; AoA, aortic arch; dAo, descending aorta; LV, left 
ventricle; RSA, right subclavian artery; RCC, right common carotid artery; LSA, left subclavian 
artery; LCC, left common carotid artery; ARSA, anomalous retro-esophageal right subclavian 
artery; IAA, interruption of the aortic arch; VSD, ventricular septal defect; Thy, thymus. Scale 
bar, 100μm. 
 
 
Figure 4.4. Double heterozygous embryos do not present external abnormalities. 
Tbx1
+/-
;Pax9
+/-
 embryos (d) are indistinguishable externally from wild-type (a), Pax9
+/-
 (b) and 
Tbx1
+/-
 (c) embryos and do not present any external abnormalities. Scale bar, 1mm.  
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4.4 Pharyngeal Arch Artery Remodelling In Double Heterozygotes 
 
To analyse the development of the pharyngeal arch arteries, E10.5 embryos 
were collected and India ink was injected directly into the left ventricle to be 
pumped by the heart through the pharyngeal arch arteries. 
 
Wild-type and Pax9+/- embryos (Figure 4.5a, b) present normal patency of the 
3rd, 4th and 6th pharyngeal arch arteries on both sides, as expected at this stage, 
whereas all Tbx1+/- embryos (Figure 4.5c) present abnormal 4th PAAs, with 50% 
of them showing bilateral defects (Table 4.4). Tbx1+/- embryos mainly display 
hypoplastic 4th PAAs as seen in Figure 4.5c and Table 4.4. Interestingly, the 
incidence of bilaterally absent 4th PAAs was significantly increased (p<0.005) in 
double heterozygous embryos, with 7 out of 9 embryos showing absent 4th 
PAAs on both sides (Table 4.4, Figure 4.5d). 
 
Table 4.4. Incidence of 4
th
 PAA abnormalities in E10.5 double heterozygous embryos. 
Genotype n 
Abnormal 
(%) 
Bilateral 
defects 
Bilateral defects 
Hypo/Hypo Hypo/NP NP/NP 
Wild-type 6 0 0 - - - 
Pax9+/– 4 0 0 - - - 
Tbx1+/– 8 
8 
(100%) 
4 
(50%) 
3 1 - 
Pax9+/–;Tbx1+/– 9 
9 
(100%) 
8* 
(88%) 
- 1 7** 
Fisher’s exact test, *p<0.05, compared to Tbx1
+/-
 bilateral defects; **p<0.001 compared to 
NP/NP bilateral defects in Tbx1
+/-
 
 
The penetrance of 4th PAA defects seen at E10.5 by ink injection in double 
heterozygous embryos (Table 4.4) corresponds to the penetrance of 4th PAA-
derived defects seen at E15.5 by MRI and histology (Table 4.3). Particularly, the 
incidence of non-patent left 4th PAA (77%, Table 4.4) corresponds to about 70% 
of IAA seen in double heterozygotes at E15.5 (Table 4.3). Although nearly all 
double heterozygotes died after birth as previously discussed, two male double 
heterozygous mice survived until adulthood. We crossed these double 
heterozygous mice with Pax9+/- females to generate embryos that would include 
the Pax9-/-;Tbx1+/- genotype, and analysed their PAA phenotype by ink 
injections at E10.5.  
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Figure 4.5. Pharyngeal arch artery defects in double heterozygous embryos. 
Patterning of the pharyngeal arch arteries at E10.5 was visualised by intracardiac injection of 
India ink. (a) Wild-type and Pax9
+/-
 (b) embryos present normal patterning of the 3
rd
, 4
th
 and 6
th
 
PAAs on both sides, whereas Tbx1
+/-
 embryos (c) display abnormal hypoplastic 4
th
 PAAs 
unilateral or bilaterally. Tbx1
+/-
;Pax9
+/-
 (d) present abnormal 4
th
 PAAs which are non-patent to 
ink on both sides (d). Scale 500μm.   
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As seen in Figure 4.6, all double heterozygous embryos present abnormal 4th 
PAAs that are non-patent to ink as described before (Figure 4.6a), whereas 
Pax9-/-;Tbx1+/- embryos display the Pax9-null phenotype (Figure 4.6b), with 
delayed regression of the 1st and 2nd PAAs, and completely absent 4th PAAs on 
both sides (Figure 4.6b). Pax9+/-;Tbx1-/- embryos were not generated (by 
crossing the double heterozygous males with Tbx1+/- females) since Tbx1 
homozygous deletion disrupts the formation of the caudal pharyngeal arches 
and consequently the PAAs below the 2nd PAA are not formed. As this is 
already a severe phenotype with most of the PAA not formed, it was therefore 
decided not to try and look at the effect of Pax9 heterozygosity in combination 
with complete Tbx1 loss on the development of the PAAs.  
 
 
Figure 4.6. Pharyngeal arch artery defects in Tbx1
+/-
;Pax9
-/-
 embryos. 
Patterning of the pharyngeal arch arteries at E10.5 was visualised by intracardiac injection of 
India ink. Tbx1
+/-
;Pax9
+/-
 embryos (a) present with abnormal 4
th
 PAAs which are non-patent to 
ink on both sides as previously described; however, Tbx1
+/-
;Pax9
-/-
 embryos (b) display the 
Pax9-null phenotype with patent 1
st
 and 2
nd
 PAAs at E10.5, abnormal 3
rd
 PAAs unilateral or 
bilaterally, and bilateral non-patent 4
th
 PAAs (red asterisk). Scale 500μm.   
 
 
 
 
 
88 
 
  
4.5 Pax9 Down-regulation In Double Heterozygous Embryos 
 
The results from the analysis of double heterozygous embryos at E15.5 clearly 
shows a significant increase in the penetrance of IAA (70%) compared to 
Tbx1+/- embryos (5%), as well as a significant increase in the incidence of 
absent 4th PAAs and bilateral defects at E10.5. Given that the incidence of IAA 
in Tbx1+/- embryos is very low (5%) and Pax9+/- embryos do not have any 
defects, such significant increase suggests some form of synergy between 
Pax9 and Tbx1 heterozygosity. 
 
Moreover, Pax9 expression is significantly downregulated in Tbx1-null embryos 
by quantitative real-time PCR (qPCR) by approximately 50% compared to wild-
type embryos (Ivins et al, 2005). This downregulation of Pax9 mRNA in Tbx1-
null embryos is also confirmed in this thesis by whole-mount in situ hybridisation 
(section 3.2.3, Figure 3.4). 
 
To determine whether Pax9 and Tbx1 mRNA levels are affected by double 
haploinsufficiency, total RNA was extracted from the pharyngeal region of E9.5 
double heterozygous embryos (six embryos of each genotype), cDNA was 
synthesized and mRNA levels were analysed by qPCR.  
 
As seen in Figure 4.7a, Tbx1 mRNA expression (white bars) is reduced to 58% 
in Tbx1+/- embryos compared to wild-type embryos and it is not affected by 
Pax9 haploinsufficiency nor double heterozygosity. Pax9 mRNA (black bars) 
expression is reduced to 52% in Pax9+/- embryos compared to wild-type 
embryos and it is not significantly affected by Tbx1 heterozygosity. However, 
double heterozygous embryos show a statistically significant (p<0.005) further 
21% reduction compared to Pax9+/- embryos. This further downregulation in 
double heterozygous embryos compared to Pax9+/- embryos suggests that 
some form of synergy between Pax9 and Tbx1 may exist. To further confirm 
this down-regulation, in situ hybridisation using a probe against Pax9 mRNA 
was performed in double heterozygotes (three embryos per genotype). As seen 
in Figure 4.7b, double heterozygous embryos (Pax9+/-;Tbx1+/-) display an 
obvious reduction in Pax9 expression compared to Pax9+/- embryos (Figure 
4.7b).    
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Figure 4.7. Pax9 mRNA levels are further reduced in double heterozygous embryos. 
(a) Pax9 and Tbx1 mRNA levels were analysed by qPCR from the dissected pharyngeal region 
of E9.5 embryos (six embryos per genotype). Relative expression was normalised against wild-
type embryos and plotted as the fold change over the wild-type samples. Tbx1 levels (white 
bars) are significantly reduced to 58% in Tbx1
+/-
 embryos (p<0.05) compared to wild-type levels, 
and are not affected in Pax9
+/-
 embryos nor double heterozygous embryos. Pax9 levels (black 
bars) are not significantly affected in Tbx1
+/-
 embryos, but significantly reduced to 52% in Pax9
+/-
 
samples (p<0.001) compared to wild-type samples. Interestingly, Pax9 levels are significantly 
reduced to 31% in double heterozygous embryos (p<0.05) compared to wild-type and Pax9
+/-
 
embryos, representing a significant further 21% reduction (p<0.05) compared to Pax9
+/-
 
embryos. Error bars represent standard error of the mean (SEM) from triplicates of each 
sample. Statistical significance was calculated using a two-paired T-test. 
(b) Whole-mount in situ hybridisation using a Pax9 riboprobe was performed to further confirm 
Pax9 down-regulation in double heterozygous embryos. Pax9 levels appear visibly reduced in 
double heterozygous embryos (Tbx1
+/-
;Pax9
+/-
) compared to wild-type, Pax9
+/-
 and Tbx1
+/-
 
embryos (n=3 per genotype); the pharyngeal region is enlarged in the bottom panels for better 
appreciation. Scale bar, 500μm. 
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4.6 Discussion 
 
The results presented in this chapter show a strong genetic interaction between 
Tbx1 and Pax9 for the formation of the 4th PAAs, with double heterozygous 
embryos showing a significant increase in the frequency of bilateral 4th PAA 
defects at mid embryogenesis and a significant increase in the incidence of IAA-
B at later fetal stages. 
 
This interaction is very strong with a 100% penetrance in double heterozygous 
embryos, and also very specific only affecting the formation of the 4th PAAs and 
their derived structures, the aortic arch and right subclavian artery. 
 
The specificity of Tbx1 and Pax9 double haploinsufficiency affecting only the 4th 
PAA implies that 4th PAA precursors are molecularly distinct from the other 
PAAs as they respond differently to changes in Pax9 and Tbx1 mRNA levels. 
 
Although other genes have been shown to interact with Tbx1, particularly in the 
development of the 4th PAAs, such interactions are not typically as strong as 
that observed here in Pax9 and Tbx1 double heterozygotes. For instance, only 
10% of Tbx1 and Smad7 double heterozygous present with IAA (Randall et al, 
2009), while only 9% of Moz and Tbx1 double heterozygous embryos have IAA 
(Voss et al, 2012), compared to 65% of Tbx1+/-;Pax9+/- embryos that present 
IAA-B. 
 
In other cases where a higher penetrance of IAA is seen, the interaction 
requires homozygous deletions to observe an increased incidence, such as 
complete deletion of Bmp4 expression in Tbx1 expressing cells with a 40% 
penetrance of IAA (Nie et al, 2011).  
 
The model presented here suggests some form of synergy between Pax9 and 
Tbx1 exists, since 65% of double heterozygous embryos display IAA-B, but 
Pax9+/- embryos do not present cardiovascular defects and only 5% of Tbx1+/- 
embryos have IAA-B, ruling out the possibility of an additive effect. 
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Although interruption of the aortic arch is a rare congenital cardiovascular 
defect, it is commonly associated with 22q11DS, with 50% of patients with IAA 
presenting 22q11 deletion. 
 
Moreover, IAA is one of the most severe CCVM, requiring immediate attention 
on the newborn to keep the ductus arteriosus open to preserve the flow of blood, 
followed by open heart surgery to graft a connection between the ascending 
and thoracic aortas; if untreated, IAA can lead to mortality within 4 days. 
 
The analysis of perinatal survival shows double heterozygous mice die after 
birth, likely as a consequence of having an interrupted aortic arch; however, the 
time of death was variable (between 24 and 48 hours) depending on the time of 
closure of the ductus arteriosus. 
 
Given that in double heterozygous embryos only the 4th PAAs are affected and 
not the 1st, 2nd and 3rd PAAs as occurs in Pax9-null embryos, Pax9 
heterozygosity seems to exacerbate the Tbx1+/- phenotype, suggesting PAX9 
could be a modifier of the 22q11DS phenotype, increasing the prevalence of 4th 
PAA defects and consequently increasing the incidence of IAA. 
 
In this context, mutations leading to PAX9 heterozygosity in patients with 22q11 
deletion would imply a more severe presentation of the 22q11 syndrome 
including IAA-B. 
 
Additionally, the possibility of PAX9 mutations in humans leading to 
cardiovascular defects including IAA may be supported by the report of a 
patient with PAX9 deletion presenting IAA-B, BAV, DORV and hypoplastic aorta 
(Santen et al, 2012), which resembles the phenotype seen in the Pax9-null 
mouse model presented in chapter 3. 
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Chapter 5. Tbx1-Pax9 Mechanism of Interaction 
 
5.1 Introduction 
 
The phenotype seen in double heterozygous embryos (Tbx1+/-;Pax9+/-) clearly 
show a genetic interaction between Pax9 and Tbx1 as the incidence of 
bilaterally abnormal 4th PAAs at mid embryogenesis and the incidence of IAA at 
later stages are significantly increased compared to the Tbx1 heterozygous 
embryos. This genetic interaction results in a 100% penetrance specifically in 
4th PAA defects in the double heterozygotes. 
 
Therefore, the aim of this chapter was to identify the mechanism by which Pax9 
and Tbx1 interact at a molecular level. 
 
Microarray analysis of Tbx1-null embryos previously revealed Pax9 expression 
to be significantly downregulated (Ivins et al, 2005; Liao et al, 2008), suggesting 
Pax9 as a potential downstream target of Tbx1. Additionally, both Tbx1 and 
Pax9 are co-localized within the pharyngeal endoderm (Figure 3.5), and Pax9 
expression (about E8.5) starts after Tbx1 expression (about 7.5) during 
embryogenesis. Therefore, we first hypothesized that Tbx1 directly regulates 
Pax9 expression through binding to T-box binding elements (TBE) within the 
Pax9 locus. 
 
5.2 Binding of Tbx1 within the Pax9 locus 
 
TBX1 is a T-box binding transcription factor that binds to T-box binding 
elements (TBE, also known as T-half sites) within the DNA. Therefore the PAX9 
locus was analysed using Mulan MultiTF tool (http://mulan.dcode.org) to identify 
potential T-box binding elements (TBE) within the PAX9 gene.  
 
The human PAX9 sequence was aligned with other species including mouse 
(Mus musculus), rat (Rattus novergicus), monkey (Macaca mulatta), chicken 
(Gallus gallus domesticus), frog (Xenopus laevis) and zebrafish (Danio rerio) 
and analysed for conserved elements among these species. 
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The results from the MultiTF analysis revealed 10 highly conserved potential 
TBEs within the PAX9 locus (Figure 5.1). Three TBEs (TBE-1, -2 and -3) are 
found within the PAX9 promoter upstream of the first exon, one TBE (TBE-4) 
within the first intron, a fifth TBE (TBE-5) within the second intron, and 5 more 
TBEs (TBE-6 to -10) within the third intron. 
 
 
Figure 5.1. Alignment and identification of conserved potential TBEs within the PAX9 
locus. 
Human PAX9 locus was aligned with Macaque, Rat, Mouse, Chicken, Frog and Zebrafish Pax9 
using the Mulan online tool (http://mulan.dcode.org); the alignment was then used in MultiTF 
analysis tool to look for conserved potential T-box binding sites. Ten conserved potential T-box 
binding sites (TBEs) were identified within the PAX9 locus. Three TBEs were found within the 
promoter upstream of the first exon (1), one TBE was found within the first intron, and another 
was found within the second intron. Five more TBEs were found within the third intron proximal 
to the 3
rd
 exon (3). 
 
To determine whether TBX1 binds to any of these potential TBEs, 500bp 
fragments containing each of the identified TBEs were generated by PCR and 
cloned into the Firefly luciferase expressing constructs pGL3-Basic or pGL3-
promoter vectors (Figure 5.2a) as described in section 2.8.1. TBEs 6 and 7, and 
8, 9 and 10 are found too close to each other, therefore, TBEs 6 and 7 were 
cloned together as one fragment, and 8, 9 and 10 were also cloned together as 
another fragment (Figure 5.2a). 
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The luciferase-expressing constructs containing each of the potential TBEs 
(Figure 5.2a) were then co-transfected into JEG3 cells as described in section 
2.4.2, along with a TBX1 cDNA expressing plasmid (cloned into pcDNA3.1) and 
a Renilla luciferase vector (pGL4.7) as a transfection control. A plasmid 
containing two synthetic T-box binding sites (2xTtkGL2; Zweier et al, 2007) was 
used as a positive control, whereas the same vector without the T-box sites 
(tkGL2) was used as a negative control. Cells were co-transfected with the 
corresponding plasmids and after 48 hours Renilla and Firefly luciferase were 
measured using the dual-luciferase assay (Promega) as described in section 
2.9. Each group was performed in triplicate and each experiment was repeated 
at least three times. 
 
As can be seen in Figure 5.2b, TBX1 (black bars) is able to bind to the 
2xTtkGL2 construct that contains the two synthetic T-box binding sites, and 
activate luciferase in a robust way as expected, showing a significant 9-fold 
increase compared to the group co-transfected with an empty plasmid 
(pcDNA3.1, white bars). The vector lacking the T-box sites (tkGL2) does not 
show any activation of luciferase in the presence of TBX1 (black bars). 
 
However, TBX1 does not seem to be able to activate luciferase expression in 
any of the TBE-containing constructs, with the exception of the construct 
containing TBEs 8, 9 and 10 (TBE-8+9+10), where TBX1 (Figure 5.2b, black 
bars) causes a significant 2-fold increase (p<0.01) compared to the group co-
transfected with an empty plasmid (Figure 5.2b, white bars). The graph shown 
in Figure 5.2b is representative of 3 independent experiments showing the 
same trend of a significant increase in the TBE-8+9+10 construct. 
 
To confirm this activation was due to actual binding of TBX1 and rule out an 
artefact of the experiment, one of the potential TBEs within the construct (TBE-
8+9+10) was mutated using site-directed mutagenesis as described in section 
2.8.4. TBE-9 was chosen because of its correspondence with the putative T-box 
binding sequence (AGGTGTGAAATT). The core sequence of TBE-9 
(AAAGTGTGAG) was changed to AAAAAATGAG (Figure 5.2c), to completely 
abolish any potential TBX1 binding. As shown in Figure 5.2c, mutation of TBE-9 
(TBE-8Δ9+10) abolishes binding of TBX1 and prevents activation of luciferase.    
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Figure 5.2. Luciferase assays on conserved TBEs within the PAX9 locus. 
(a) The potential TBEs found within the PAX9 locus were cloned into luciferase expressing 
vectors, and luciferase assays were performed to assess for TBX1 binding to any of the 
identified TBEs (b). A construct containing 2 synthetic T-box binding sites (2xTtkGL2) was used 
as a positive control, whereas the same vector lacking the T-box elements was used as a 
negative control. (b) TBX1 (black bars) is able to robustly activate luciferase expression in the 
2xTtkGL2 reporter causing a significant 9-fold increase (p<0.001) compared to the group 
transfected with the reporter in the absence of TBX1 (white bars). However, TBX1 does not 
seem to bind any of the identified TBEs as there is no luciferase activation in any of them, 
except for the last construct containing three TBEs (TBE-8+9+10), on which TBX1 presence 
caused a significant 2-fold increase in luciferase activity (p<0.01). To further validate binding to 
these TBEs, the middle element (TBE-9) was mutated using site directed mutagenesis to 
completely change its core sequence (c), and the mutated construct (TBE-8Δ9+10) was then 
assayed for luciferase activation in the presence of TBX1. (c) Mutation of the core sequence of 
TBE-9 prevents luciferase activation by TBX1. Error bars represent SEM from triplicates of each 
group, and graphs are representative of three independent experiments. Statistical significance 
was calculated using a two-paired T-test. 
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The luciferase results (Figure 5.2) suggested that TBX1 binds to a conserved 
region within the 3rd intron of the PAX9 gene. To confirm this in vivo, chromatin 
immunoprecipitation (ChIP) was performed. 
 
Wild-type E9.5 embryos were collected and processed as described in section 
2.11. Briefly, embryos were homogenized and fixed in 1% formaldehyde to 
preserve the DNA-protein interactions. Tissue was then lysed and the chromatin 
was sonicated into 200-500bp fragments. The sonicated chromatin was then 
incubated with protein A beads and antibodies raised against TBX1 and 
phospo-histone H3 (as a positive control) were used to immunoprecipitate the 
DNA-protein complexes. A rabbit immunoglobulin (IgG), and a sample without 
antibody and just the protein A beads, were used as negative controls. After 
immunoprecipitation, the cross-linking was reversed and the precipitated DNA 
was purified. A sample containing total chromatin (collected prior to 
immunoprecipitation) was used as the “input”. 
 
Immunoprecipitation of the target DNA sequences was assessed by end-point 
and qPCR (described in section 2.11) using primers (Table 2.7) targeting the 
previously identified TBEs. A set of primers targeting a random region within the 
same chromosome as Pax9 (chromosome 12) but more than 1000 bp away 
from the Pax9 gene was used as a negative control for the ChIP to show 
specificity of the precipitation and efficacy of the sonication. 
 
The end-point PCR (Figure 5.3a) shows a PCR product in the positive controls 
(gDNA, INPUT and pHH3) as expected. However, amplification in the samples 
precipitated with a TBX1 antibody (Figure 5.3a, 4th lane) is not evident for most 
TBEs. Although TBE-1 and TBE-5 show amplification in the sample precipitated 
with TBX1, this is considered as unspecific amplification, as the IgG and no 
antibody (no AB) lanes also show amplification. Furthermore, contamination in 
these samples was ruled out since the water sample (H2O) does not show any 
product, which suggests the amplification in the negative controls (IgG and no 
AB) is due to high background signal of the protein A beads themselves. 
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To accurately quantify the amount of specific immunoprecipitation and to 
potentially outstrip the background signal qPCR was performed. ChIP samples 
were amplified using SYBR green; the target samples were normalised with the 
INPUT sample and plotted as a percentage of the INPUT (total chromatin) as 
described in section 2.6. The qPCR results show that Tbx1 does not bind any of 
the potential TBEs as there is no specific amplification with any of them. 
Although TBE-5 and TBE-8+9+10 show a noticeable increase compared to the 
other TBEs, this amplification is not specific as it is similar to that seen in the 
IgG sample. 
 
The ChIP experiment was repeated a second time with a different batch of 
embryos showing the same result, with no specific amplification of any of the 
TBEs and a high background signal of TBE-5 (Appendix B). 
 
Chromatin immunoprecipitation requires large amounts of tissue to be able to 
obtain significant and detecTable amounts of chromatin after the precipitation, 
and typical ChIP protocols are designed to be performed from cells in culture.  
 
To determine whether the high background signal seen in the previous ChIP 
experiments was due to insufficient starting tissue, a third ChIP experiment was 
performed from mouse embryonic fibroblast (MEFs) obtained from E13.5 
embryos as described in section 2.7.2, using 5μg of chromatin (5 times more 
compared to embryonic tissue). 
 
Chromatin immunoprecipitation from MEFs showed the same result as the 
previous experiments with no specific amplification of any of the TBEs and a 
high background signal of TBE-5 (Appendix B). 
 
Three independent ChIP experiments show Tbx1 does not bind to any of the 
previously identified potential TBEs in vivo. Although the results from the 
luciferase assays and the ChIP are reproducible and consistent, both were 
targeted to specific regions of the PAX9 locus based on the predicted TBEs. 
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Figure 5.3. Chromatin immunoprecipitation of conserved TBEs within the Pax9 locus. 
Chromatin immunoprecipitation from E9.5 embryos was performed using an anti-TBX1 antibody 
and specific primers targeting the identified TBEs. 
End-point PCR (a) and qPCR (b) were performed on immunoprecipitated samples. No binding 
was detected in any of the conserved TBEs; although TBE-5 appears to be amplified by end-
point and qPCR, the IgG sample was also amplified, suggesting such amplification is not 
specific to Tbx1 immunoprecipitation. A sample immunoprecipitated with an anti-histone H3 
antibody was used as a positive control for the immunoprecipitation procedure, whereas a 
sample incubated with an IgG and protein A/G beads only (no AB) were used as negative 
controls. Genomic DNA (gDNA) was used as positive control for the PCR, whereas a sample 
with no DNA and only water (H2O) was used a negative control of the PCR. Primers targeting a 
random region within chromosome 12 distal to Pax9 gene were used as control for specificity of 
immunoprecipitation. For qPCR analysis, samples were run in triplicate and the average of each 
sample was calculated. TBX1 and IgG samples were then normalised with the INPUT and 
plotted as a percentage of INPUT. 
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To determine whether Tbx1 could potentially bind any other region of the Pax9 
locus, a 5kb fragment of the Pax9 promoter, and the 2nd and 3rd introns of the 
Pax9 gene were cloned into luciferase plasmids (Figure 5.4a). The promoter 
itself and the promoter plus the 2nd or 3rd intron were cloned into pGL3-basic, 
while the introns alone were cloned into pGL3-promoter downstream of 
luciferase (Figure 5.4a). 
 
These constructs were co-transfected into JEG3 cells along with a Tbx1 
expressing construct and a Renilla plasmid, and binding of Tbx1 to any of these 
constructs was assessed. 
 
The luciferase assays on the constructs containing 5kb of the Pax9 promoter 
and the 2nd and 3rd introns of the Pax9 gene (Figure 5.4) show no activation of 
luciferase in any of the constructs suggesting that TBX1 does not bind 
anywhere within these regions of the promoter and the 2nd and 3rd introns 
(Figure 5.4). 
 
The results from luciferase experiments with the promoter and intronic regions 
or the isolated predicted TBEs, together with the chromatin immunoprecipitation 
results indicate Tbx1 does not regulate Pax9 expression by directly binding to 
elements within the Pax9 locus.  
 
Although Pax9 expression is affected by loss of Tbx1 (Ivins et al, 2005; Liao et 
al, 2008) the results show this regulation is not through direct binding of Tbx1 to 
the Pax9 locus, suggesting Tbx1 may indirectly regulate Pax9 expression 
through directly regulating expression of other genes upstream of Pax9. 
 
However, the results presented in chapter 4 show a clear specific interaction 
between Pax9 and Tbx1 for the formation of the 4th PAAs and their derivatives. 
 
Given that there is no direct interaction between Tbx1 and the Pax9 gene as 
shown in this section, it was next hypothesised that Pax9 and Tbx1 interaction 
may occur at the protein level. 
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Figure 5.4. Luciferase assays on Pax9 promoter and introns. 
(a) A 5Kb region of the promoter and the 2
nd
 and 3
rd
 introns containing the conserved TBEs 
were cloned into luciferase expressing vectors. The promoter itself, or along with the 2
nd
 or 3
rd
 
introns downstream of luciferase were generated to test for TBX1 binding to any of these 
constructs. Additionally, the introns without the promoter were also cloned downstream of 
luciferase as enhancers. 
(b) Luciferase assays using these constructs was performed with (black bars) or without (white 
bars) TBX1. TBX1 is able to robustly activate luciferase expression in the 2xTtkGL2 reporter 
causing a significant 14-fold increase (p<0.001) compared to the group transfected without 
TBX1 (white bars). Luciferase activity was not detected in any of the constructs containing the 
promoter and introns. Error bars represent SEM from triplicates of each group, and the graph is 
representative of three independent experiments. Statistical significance was calculated using a 
two-paired T-test. 
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5.3 Investigating A Physical Interaction Between Tbx1 And Pax9 Proteins  
 
As a second hypothesis for the interaction between Tbx1 and Pax9, a physical 
interaction between Tbx1 and Pax9 proteins was proposed.  
 
As a first approach to assess whether Pax9 affects Tbx1 transcriptional activity, 
Tbx1 was co-transfected with Pax9 in a luciferase assay, using the 2xTtkGL2 
construct as a reporter for Tbx1 activity. 
 
JEG3 cells were co-transfected with different concentrations (0, 0.01, 0.05, 0.1, 
0.25, 0.5, and 1 µg) of a Pax9-expressing construct and 0.25 µg of a Tbx1-
expressing plasmid. Each group was performed in triplicate and the experiment 
was repeated at least 3 times. Samples were normalised with the Renilla 
luciferase measurements as a transfection control, and plotted relative to the 
group transfected with Tbx1 alone, which was set as 100% of 2xTtkGL2 
activation. 
 
As seen in Figure 5.5a, Pax9 prevents Tbx1 luciferase activation in a dose-
dependent manner, with the lowest dose of Pax9 (0.01μg) repressing about 
40% of luciferase activation by Tbx1, while 0.1ug of Pax9 represses almost 
completely luciferase activation as it is not significantly different from the groups 
transfected with an empty plasmid (i.e. no Tbx1 or Pax9, only pcDNA3.1). To 
show specificity of Pax9 repression over Tbx1, one group was co-transfected 
with Tbx1 and AP2α; co-transfection with AP2α does not affect Tbx1 
transcriptional activity (Figure 5.5a, grey bar). 
 
To confirm that the observed repression of Tbx1 activity was an actual effect 
and not an artefact of the co-transfection, co-expression of both Pax9 and Tbx1 
in the same cells was detected by immunocytochemistry (described in section 
2.10) using antibodies against Pax9 and Tbx1. As shown in Figure 5.5b both 
Pax9 (green) and Tbx1 (red) are co-expressed within the same cells (Figure 
5.5b).  
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Figure 5.5. Co-transfection of PAX9 and TBX1 and Luciferase assays. 
(a) To determine whether PAX9 affects TBX1 transcriptional activity, TBX1 was co-transfected 
with different concentrations (0.01, 0.05, 0.1, 0.25, 0.5 and 1µg) of PAX9 in a luciferase assay, 
using the 2xTtkGL2 construct as a reporter for TBX1 activity. DNA concentration in all samples 
was topped up to 2µg with the empty vector. Samples were normalised to the group transfected 
with TBX1 alone and plotted as the fold change over TBX1 activity. PAX9 prevents TBX1 
luciferase activation in a dose-dependent manner, with the lowest dose of PAX9 (0.01μg) 
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significantly repressing about 40% of luciferase activation (p<0.001) compared to the group 
transfected with TBX1 only. 
(b) co-expression of TBX1 and PAX9 within the same cells was detected by double 
immunocytochemistry of co-transfected cells with an anti-Tbx1 (red) and anti-Pax9 (green); 
merged image shows co-localization (yellow) of Tbx1 and Pax9 proteins within the same cells. 
(c) a luciferase assay from cells transfected only with human PAX9 (hPAX9) or mouse Pax9 
(mPax9) shows Pax9 itself does not activate luciferase in the 2xTtkGL2 reporter construct. Error 
bars represent SEM from triplicates of each group, and the graphs are representative of three 
independent experiments. Statistical significance was calculated using a two-paired T-test. 
 
 
Furthermore, Pax9 itself does not activate luciferase in the 2xTtkGL2 reporter 
construct (Figure 5.5c), indicating the transcriptional repression is due to an 
effect over Tbx1 activity and not due to competition over the 2xTtkGL2 binding 
sites. Additionally, Tbx1 and Pax9 are highly conserved between mouse and 
human, therefore both mouse and human plasmids have the same effects, with 
both human and mouse Tbx1 being able to robustly activate the 2xTtkGL2 
reporter, and both human and mouse Pax9 having similar repressive activity 
over Tbx1 transcriptional function (Figure 5.5c). 
 
These results suggest Pax9 interferes in some way with Tbx1 transcriptional 
activity. To determine whether Pax9 prevents Tbx1 binding to the DNA, 
chromatin immunoprecipitation was performed from JEG3 cells co-transfected 
with Tbx1 and increasing doses of Pax9 as assayed before in the luciferase 
assay. 
 
Cells were co-transfected, fixed in 1% formaldehyde and lysed. Chromatin was 
then sonicated as described before and samples were incubated with an anti-
TBX1 antibody, an IgG isotype control or protein A beads only. DNA was then 
purified and immunoprecipitation was assessed by end-point PCR using 
specific primers (Table 2.7) targeting the two T-box binding sites within the 
2xTtkGL2 construct.   
 
The result from the ChIP on the 2xTtkGL2 plasmid co-transfected with Tbx1 and 
increasing doses of the Pax9-expressing vector show that Pax9 does not affect 
Tbx1 binding to the 2xTtkGL2 construct (Figure 5.6) but instead just averts 
luciferase transcription. 
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Figure 5.6. Chromatin immunoprecipitation of the 2xTtkGL2 construct from co-
transfected cells. 
To determine whether Pax9 prevents Tbx1 binding to the DNA, ChIP targeting the 2 synthetic T-
box sites within the 2xTtkGL2 reported was performed from co-transfected cells with TBX1 and 
different concentrations (0.01, 0.05, 0.1, 0.25, 0.5µg) of PAX9. Immunoprecipitation of the DNA 
of interest was assessed by end-point PCR. PCR results show PAX9 does not interefere with 
DNA binding to the 2xTtkGL2 construct since an amplification product is detecTable in the 
samples immunoprecipitated with an anti-TBX1 antibody, whereas the IgG samples used as 
negative controls for the IP do not show any amplification product. 
 
Pax9 has been previously reported to act as a repressor (Nornes et al, 1996; 
Tan et al, 2003). In this context, a conserved sequence within the Pax9 protein 
named the VP motif was found to directly interact with PLU-1 protein; this 
interaction has a repressive effect in vitro, whereas mutation or deletion of the 
VP motif completely disrupts this interaction and the repressive capacity 
(Nornes et al, 1996; Tan et al, 2003). 
 
Therefore, to try to understand the repressive mechanism of Pax9 over Tbx1, a 
second approach was to prevent the repressive activity of Pax9. 
 
The human PAX9 protein sequence was aligned with the mouse, rat, monkey, 
chicken, frog and zebrafish sequence to identify conserved residues within the 
VP motif. The PAX9 VP motif is highly conserved (Figure 5.7a) between human, 
mouse, rat and monkey, however, chicken pax9 presents one amino acid 
change, whereas frog and zebrafish have only 60% homology with human 
PAX9 (Figure 5.7a).  
 
The amino acid changes in zebrafish pax9 modifiy the secondary structure 
according to the predicted structure (Figure 5.7b) using Geneious software 
(Biomatters). 
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Figure 5.7. Alignment of the PAX9 protein sequence and conservation of the VP motif. 
(a) Human PAX9 protein sequence was aligned with the mouse, rat, monkey, chicken, frog and 
zebrafish sequence to identify conservation of the VP motif. The PAX9 VP motif is highly 
conserved  between human, mouse, rat and monkey. Chicken pax9 presents one amino acid 
change, whereas frog and zebrafish have only 60% homology with human PAX9.  
(b) The secondary structure of human, mouse and zebrafish pax9 was predicted using 
Geneious software (Biomatters); the different residues in zebrafish pax9 present a different 
secondary structure compared to human and mouse (red boxes). 
 
 
Given that precise protein folding and secondary structure are critical for 
protein-protein interactions, zebrafish pax9 was co-transfected with TBX1 in a 
luciferase assay to determine whether zebrafish pax9 can also repress TBX1 
activity.  
 
Zebrafish pax9 is also capable of repressing TBX1 activity (Figure 5.8a), 
suggesting the different residues and possible change in the secondary 
structure of the Pax9 protein do not affect Pax9 repressive activity. 
 
 
To finally determine whether the VP motif is required for the repressive activity 
of Pax9 over Tbx1, the VP motif was completely deleted by mutagenesis using 
PCR as described in section 2.8.4. The repressive capacity of Pax9 without the 
VP motif was tested by luciferase assays. As seen in Figure 5.8b, the VP motif 
is not necessary for Pax9 repression over Tbx1, as Pax9 without the VP motif 
shows the same repression as wild-type Pax9 (Figure 5.8b). Additionally, to 
show specificity of this repression among other Pax family members, TBX1 was 
co-transfected with Pax1. As seen in Figure 5.8b, Pax1 does not significantly 
affect TBX1 activity, suggesting the repression is highly specific for PAX9. 
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Figure 5.8. Luciferase assays of co-transfected cells with TBX1 and zebrafish pax9, and 
VP motif deletion. 
(a) To determine whether the amino acid changes in zebrafish pax9 and possible change in the 
secondary structure, TBX1 was co-transfected with 0.05 and 0.25μg of zebrafish pax9 (Zf 
pax9a) in a luciferase assay. Zebrafish pax9 is able to repress TBX1 activity as luciferase 
activity was significantly reduced to 50% (p<0.001) in the presence of Zfpax9. 
(b) The VP motif was deleted and Pax9 lacking the VP motif (PAX9-VPdel) was co-transfected 
with TBX1 in a luciferase assay. Deletion of the VP motif does not affect PAX9 repression over 
TBX1 as luciferase activity was significantly reduced to 30% (p<0.001) in the presence of PAX9-
VPdel, similarly to wild-type PAX9. One group co-transfected with TBX1 and Pax1 was included 
showing Pax1 does not affect luciferase activation by TBX1. Error bars represent SEM from 
triplicates of each group, and the graphs are representative of three independent experiments. 
Statistical significance was calculated using a two-paired T-test. 
 
 
 
Given that complete deletion of the VP motif does not affect Pax9 repressive 
capacity over Tbx1 transcriptional activity, a second approach to try to prevent 
this repression was to mutate Tbx1. This approach has a direct implication with 
human pathology as patients with cardiovascular malformations presenting 
mutations in TBX1 have been previously reported (Zweier et al, 2007). 
 
 
 
107 
 
  
 
Four mutations in TBX1 have been reported to cause 22q11DS-like 
phenotypes; three mutations (F148Y, H194Q, G310S) are located within the T-
box domain and are known to cause a gain-of-function of TBX1, whereas the 
fourth, a cysteine deletion (1223delC) causes a complete loss of function of 
TBX1 due to deletion of a C-terminal nuclear localization signal (Zweier et al, 
2007). 
 
Furthermore, crystallography analysis of TBX1 structure revealed phenylalanine 
148 (F148) to be exposed at the surface of the TBX1 protein and not at the 
DNA binding interface (El Omari et al, 2012). Additionally, given that 
hydrophobic residues are typically involved in protein-protein interactions it has 
been proposed F148 is required for interactions with other proteins. This 
therefore suggests that the F148Y mutation affects TBX1 interaction with other 
proteins (El Omari et al, 2012). 
 
The TBX1 mutated constructs (F148Y, H194Q, G310S, 1223delC) were used in 
a luciferase assay in the presence of PAX9 to determine whether any of these 
mutations prevents PAX9 repression of TBX1. 
 
The F148Y, H194Q and G310S mutated versions of TBX1 can robustly promote 
luciferase expression, while F148Y and G310S constructs displayed a further 
significant increase in luciferase activity compared to wild-type TBX1, showing a 
gain-of-function due to mutation, whereas truncation mutation 1223delC 
showed complete loss of function (Figure 5.9, white bars) as previously reported 
by Zweier and colleagues (2007).  
 
However, none of these mutations prevented the repression by PAX9 as they 
all showed a significant decrease in luciferase expression in the presence of 
PAX9 (black and grey bars, Figure 5.9). 
 
These results suggest none of these residues are involved in any potential 
interaction with PAX9, as their mutations do not affect PAX9 repressive activity. 
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Figure 5.9. Luciferase assays on mutated TBX1. 
Luciferase assays from cells co-transfected with 0.05 (grey bars) and 0.25μg (black bars) of 
PAX9 and human mutations of TBX1 shows F148Y, H194Q and G310S constructs can 
significantly promote luciferase expression (white bars), while F148Y and G310S constructs 
displayed a further significant increase compared to wild-type TBX1; whereas truncation 
mutation 1223delC showed complete loss of function with a 78% reduction in luciferase 
expression compared to wild-type TBX1. However, PAX9 can significantly repress this activity. 
Error bars represent SEM from triplicates of each group, and the graphs are representative of 
three independent experiments. Statistical significance was calculated using a two-paired T-
test. 
 
 
To this point, the interaction between Pax9 and Tbx1 at the functional level 
appears to be very robust with Pax9 showing a high capacity to repress Tbx1 
activity in vitro in various luciferase assays. Therefore, to confirm this interaction 
between Tbx1 and Pax9, co-immunoprecipitation was performed (as described 
in section 2.12) in vitro and in vivo. 
 
JEG3 cells co-transfected with Pax9 and Tbx1, and E9.5 mouse embryos, were 
immunoprecipitated using protein A/G beads and antibodies raised against 
TBX1 and PAX9. Following immunoprecipitation, Western blotting for both Tbx1 
and Pax9 was performed for all samples.  
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Co-immunoprecipitation revealed that Tbx1 and Pax9 do not bind to each other 
as seen in Figure 5.10, where Pax9 is only detectable by western blot in the 
samples precipitated with a Pax9 antibody (Figure 5.7 lanes 3 and4) but not in 
samples precipitated with the Tbx1 antibody (Figure 5.7 lanes 1 and 2) in both 
JEG3 cells and E9.5 embryos. Similarly, Tbx1 is only detectable by western blot 
in the samples precipitated with the Tbx1 antibody but not in those precipitated 
with the Pax9 antibody. 
 
 
 
Figure 5.10. Co-immunoprecipitation of Tbx1 and Pax9. 
To determine whether Tbx1 and Pax9 physically interact, co-IP was performed from wild-type 
E9.5 embryos (E9.5) and co-transfected JEG3 cells. Samples were immunoprecipitated with 
antibodies anti-TBX1 (lanes 1 and 2) or anti-PAX9 (lanes 3 and 4) and immunoblotted against 
both TBX1 (top panel) and PAX9 (bottom panel). Tbx1 can be detected by western blot in 
samples immunoprecipitated with an anti-TBX1 antibody, but not in those immunoprecipitated 
with anti-PAX9 antibody; whereas Pax9 is not detected in samples IP with anti-TBX1 antibody 
but is clearly detected after IP with an anti-PAX9 antibody. Tbx1 expected band was 43kDa, 
and Pax9 expected band was 38kDa. 
 
 
Chromatin immunoprecipitation showed Tbx1 does not bind to the Pax9 locus 
as a direct target (Figure 5.11a), while co-immunoprecipitation shows Tbx1 and 
Pax9 do not physically interact with each other (Figure 5.11b). However, Tbx1 
transcriptional repression by Pax9 seen in luciferase assays is very robust, 
indicating some form of functional interaction, in addition to the genetic 
interaction discussed in chapter 4. Therefore, as a third hypothesis to explain 
the interaction between Tbx1 and Pax9, the possibility of both acting on a 
common downstream target (Figure 5.11c) was analysed. 
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Figure 5.11. Proposed mechanism of interaction. 
(a) Direct regulation of Pax9 expression through direct binding of Tbx1 to potential T-box 
binding elements within the Pax9 locus was initially proposed but excluded based on the 
chromatin immunoprecipitation results in section 5.2. 
(b) A physical interaction at the protein level between Pax9 and Tbx1 was proposed as a 
second hypothesis for the interaction, but has been excluded based on the co-
immunoprecipitation experiments in section 5.3. 
(c) The possibility of both Tbx1 and Pax9 acting on a common downstream target is proposed 
as a third hypothesis to explain the interaction 
 
 
5.4 Exploring Gbx2 As A Common Downstream Target Of Tbx1 And Pax9  
 
Given that a direct interaction between Tbx1 and the Pax9 gene was ruled out 
by chromatin immunoprecipitation (section 5.2), and a physical interaction 
between Pax9 and Tbx1 proteins was also excluded (section 5.3), the potential 
of Tbx1 and Pax9 acting on a common downstream target was analysed. 
 
Preliminary results in our group from a candidate gene analysis of 40 genes 
involved in cardiovascular development and/or expressed within the pharyngeal 
endoderm, revealed that Gbx2, Ripply3 and Gata5 were significantly 
downregulated in Pax9-null embryo pharyngeal arches. However, only Gbx2 
was also found to be downregulated in double heterozygous embryos (Tbx1+/-
;Pax9+/-). 
 
Gbx2 is downregulated about 30% in Pax9-null embryos and about 50% in 
double heterozygous embryos (Tbx1+/-;Pax9+/-) at E9.5 as analysed by qPCR 
(Figure 5.12; Simon Bamforth, unpublished data). 
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Figure 5.12. Gbx2 mRNA levels are reduced in Pax9-null and double heterozygous 
embryos. 
(a) qPCR from the dissected pharyngeal region of E9.5 Pax9-null embryos (black bars) 
revealed a significant 30% down-regulation of Gbx2 (p<0.005) and Ripply3 (p<0.001) compared 
to wild-type embryos (white bars). 
(b) qPCR from the dissected pharyngeal region of E9.5 double heterozygous embryos (Pax9
+/-
;Tbx1
+/-
) (black bars) shows a significant 55% down-regulation of Gbx2 (p<0.05) compared to 
wild-type embryos (white bars); while Gbx2 mRNA levels were not different in Pax9
+/-
 or Tbx1
+/-
 
embryos. Error bars represent SEM from triplicates of each group. Statistical significance was 
calculated using a two-paired T-test. (Simon Bamforth, unpublished data). 
 
Gastrulation brain homeobox 2 gene (Gbx2) encodes a homeobox transcription 
factor known to be required for the specification of the mid/hindbrain regions 
(Wassarman et al, 1997; Martinez, 2001). Gbx2 is expressed in the region 
caudal to the midbrain (Wassarman et al, 1997; Martinez, 2001) as well as 
within the pharyngeal arches between E8.5 and E10.5 (Wassarman et al, 1997; 
Waters et al, 2003). 
 
Gbx2-null mice die soon after birth with forebrain and cerebellar defects 
(Wassarman et al, 1997) and these defects are mainly due to a significant 
reduction in proliferation and survival of anterior hindbrain precursors 
(Wassarman et al, 1997). Furthermore, homozygous loss of Gbx2 also affects 
neural crest cell (NCC) migration leading to a reduced number of NCC within 
the caudal pharyngeal arches, consequently affecting the development of the 
PA-derived structures including cranial nerves, the middle ear bones and the 4th 
PAAs (Byrd and Meyers, 2005).  
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Figure 5.13. Gbx2-null and Gbx2
+/-
;Tbx1
+/-
 phenotypes. 
Gbx2-null and double heterozygous embryos (Gbx2
+/-
;Tbx1
+/-
) present with 4
th
 PAA defects, 
such as hypoplastic or non-patent vessels unilateral or bilaterally. Additionally, Gbx2 mRNA 
levels are visibly decreased in Tbx1
-/-
 embryos. 
(Adapted from Byrd and Meyers, 2005 and Calmont et al, 2009)    
 
Gbx2-null embryos present with similar cardiovascular defects as those seen in 
Tbx1+/-;Pax9+/- embryos including IAA and ARSA derived from abnormal 
formation of the 4th PAAs (Figure 5.13a, Byrd and Meyers, 2005). Furthermore, 
Gbx2 was also found to genetically interact with Tbx1 as double heterozygous 
embryos (Tbx1+/-;Gbx2+/-) show a significant increase in penetrance of 4th PAAs 
defects (Figure 5.13b, Calmont et al, 2009).  
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The 4th PAAs defects seen in Gbx2-null and Tbx1+/-;Gbx2+/- embryos are due to 
defective migration of NCC towards the PAs as previously mentioned. This 
abnormal migration is due to loss of Slit/Robo signalling in NCC, which is critical 
for their migration (Calmont et al, 2009), although neither Tbx1 nor Gbx2 are 
expressed in NCC. 
 
The similarity between Gbx2-null, Tbx1+/-;Gbx2+/- and Tbx1+/-;Pax9+/- embryos 
specifically affecting the development of the 4th PAA suggest Gbx2 could 
potentially be within the same genetic network as Tbx1 and Pax9. 
 
Byrd and Meyers (2005) previously suggested that Gbx2 expression was 
regulated indirectly by Tbx1 through Fgf8, however, Caprio and Baldini (2014) 
have recently shown that Gbx2 is a direct target of Tbx1, where Tbx1 directly 
binds to a T-box binding element found downstream of the 2nd exon of the Gbx2 
gene (Caprio and Baldini, 2014). 
 
Therefore, as a third hypothesis to explain the genetic interaction between Tbx1 
and Pax9, Gbx2 was proposed as a common downstream target of both Tbx1 
and Pax9. 
 
To test this hypothesis, the downregulation of Gbx2 in double heterozygous 
embryos (Tbx1+/-;Pax9+/-) was confirmed by in situ hybridisation in E9.5 
embryos (3 embryos per genotype). As seen in Figure 5.14d, Gbx2 expression 
is notably reduced in double heterozygous embryos (Tbx1+/-;Pax9+/-) and not 
significantly affected in Pax9 nor Tbx1 heterozygotes (Figure 5.14b, c), 
corroborating the downregulation of Gbx2 identified previously by qPCR (Figure 
5.12). 
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Figure 5.14. Gbx2 mRNA levels are visibly reduced in E9.5 double heterozygous embryos. 
Whole-mount in situ hybridisation using a Gbx2 riboprobe was performed to further confirm 
Gbx2 down-regulation in double heterozygous embryos. Gbx2 mRNA levels appear visibly 
reduced within the pharyngeal region of double heterozygous embryos (d) compared to wild-
type (a), Pax9
+/-
 (b) and Tbx1
+/-
 (c) embryos at E9.5 (n=3 per genotype). Scale bar, 500μm. 
 
 
Knowing that Gbx2 is significantly downregulated in double heterozygotes, to 
determine whether both Tbx1 and Pax9 directly regulate Gbx2 expression, the 
Gbx2 locus was analysed using MultiTF software as previously described to 
search for potential T-box binding elements (TBE) and Pax-binding sites. 
 
MultiTF analysis revealed two putative Pax-binding sites (Pax) within a 490bp 
region found 2.5kb downstream of the 2nd exon of Gbx2 (Figure 5.15a); 
interestingly this region is highly conserved between human and mouse with 
99% homology. Within this region, one T-box binding site (TBE) was also found 
(Figure 5.15a), corresponding to the one previously identified by Caprio and 
Baldini (2014).  
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Figure 5.15. Alignment and identification of conserved potential TBEs and Pax-binding 
sites within the GBX2 locus. 
(a) Human GBX2 locus was aligned with Macaque, Rat, Mouse, Chicken, Frog and Zebrafish 
Gbx2 using the Mulan online tool (http://mulan.dcode.org); the alignment was then used in 
MultiTF analysis tool to look for conserved potential T-box binding sites and Pax-binding sites. 
Two putative Pax-binding sites (green lines) were identified within a 490bp highly conserved 
region found 2.5kb downstream of exon 2 of Gbx2 gene; within this region, one T-box binding 
site (red line) was also found. 
(b) The 490bp conserved region containing the two Pax-binding sites and one TBE was cloned 
into luciferase expressing vectors with a minimal promoter (pGL3-promoter) upstream as a 
promoter, and down-stream of luciferase as an enhancer. 
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Therefore, to test whether Tbx1 and/or Pax9 bind within this region of the Gbx2 
gene, the 490bp region was cloned into a luciferase-expressing vector (pGL3-
promoter) both upstream of the promoter and downstream of luciferase as an 
enhancer (Figure 5.1b). These constructs were co-transfected along with 
different doses of TBX1, PAX9, or both, and the Renilla construct, into JEG3 
cells, and luciferase expression was measured as previously described. 
 
Interestingly, TBX1 seems to significantly down-regulate luciferase expression 
to 50% (p<0.005) of the Gbx2 enhancer (Figure 5.16a) at a concentration of 
0.5μg, compared to the group transfected with an empty plasmid (pcDNA). 
However, PAX9 is able to significantly promote luciferase expression in the 3 
tested doses (Figure 5.16a). Moreover, co-transfection of both TBX1 and PAX9 
shows no significant change in luciferase expression, suggesting luciferase 
activation by PAX9 is prevented by the presence of TBX1 (Figure 5.16b). 
 
Taken together these results suggest that PAX9 is able to promote luciferase 
expression in vitro of this region of GBX2. Furthermore, TBX1 presence is able 
to repress PAX9-driven luciferase expression and even to down-regulate the 
activity of the minimal promoter within the pGL3-promoter construct. 
 
Although in an opposite way, this latter result resembles the repression by Pax9 
over Tbx1 discussed previously in section 5.3; altogether supporting a strong 
interaction between Tbx1 and Pax9 at the functional level. However, this 
interaction over the Gbx2 gene needs to be further validated in vivo using 
chromatin precipitation. 
 
In this context, chromatin immunoprecipitation was performed from E8.5, E9.5 
and E10.5 embryos. Samples were immunoprecipitated using an anti-TBX1 or 
anti-PAX9 antibody and chromatin precipitation was assessed by end-point 
PCR (Figure 5.17) using primers (Table 2.7) targeting the TBEs and Pax-
binding sites found within the identified conserved region downstream of exon 
3, and TBEs previously predicted within the Gbx2 promoter (Ivins et al, 2005; 
Caprio and Baldini, 2014). 
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Figure 5.16. Luciferase assays on the GBX2 conserved region. 
Luciferase assays from cells co-transfected with the cloned GBX2 conserved region and TBX1 
and PAX9 alone or together were performed to determine potential binding to this region. (a) 
Cells were co-transfected with the cloned GBX2 region as an enhancer and with different doses 
(0.1, 0.25, 0.5μg) of TBX1 or PAX9 in a luciferase assay. A significant 0.5-fold reduction in 
luciferase activity was observed with 0.5μg of TBX1 (p<0.005) compared to the GBX2 construct 
co-transfected with an empty vector (pcDNA). PAX9 can promote luciferase expression of the 
Gbx2 construct, showing a significant 1.5-fold increase in luciferase expression (p<0.001).  
(b) The GBX2 construct was co-transfected with both TBX1 and PAX9 in a luciferase assay; co-
transfection with both PAX9 and TBX1 does not show any significant changes in luciferase 
expression compared to the empty vector. (c) Both constructs of the GBX2 conserved region 
cloned upstream as a promoter (white bars), and down-stream of luciferase as an enhancer 
(black bars) were co-transfected with TBX1 or PAX9 in a luciferase experiment. TBX1 causes a 
significant 0.5-fold reduction in luciferase expression (p<0.005) compared to the groups co-
transfected with an empty vector (pcDNA) in both constructs. PAX9 is able to significantly 
promote a 0.4-fold increase in luciferase expression (p<0.001) compared to the empty vector in 
both constructs. Error bars represent SEM from triplicates of each group, and graphs are 
representative from three independent experiments. Statistical significance was calculated 
using a two-paired T-test. 
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However, this ChIP experiment was not successful as the negative controls 
(IgG and no antibody) showed noticeable amplification in all samples (Figure 
5.17), indicating a high level of background caused just by the protein A/G 
beads, since the ‘no antibody’ (no AB) samples present high amplification 
(Figure 5.17). Possible contamination of the samples was excluded, as PCR 
samples with only water (H2O) do not show amplification. 
 
Additionally, from the previous ChIP experiment, aliquots of all samples after 
immunoprecipitation and before reversing the cross-linking were collected, and 
ChIP-western blot was performed (described in section 2.11 and 2.13; Caprio 
and Baldini, 2014). 
 
Briefly, samples from the 3 stages (E8.5, E9.5, E10.5) were collected after 
immunoprecipitation with TBX1 and PAX9 and were then subjected to typical 
western blot against TBX1 and PAX9. This approach allows for the detection of 
protein co-occupancy within a region of DNA, but it is not possible to know 
specifically which genomic region is being targeted. 
 
However, from this approach Tbx1 and Pax9 co-occupancy was not identified 
(Figure 5.18), as Tbx1 was only detected in samples immunoprecipitated with 
an anti-TBX1 antibody (Figure 5.18), whilst similarly Pax9 was only detected in 
samples precipitated with an anti-PAX9 antibody (Figure 5.18). 
 
Although the results from ChIP and ChIP-Western blot did not show an 
interaction in vivo, the luciferase assays show a robust and reproducible effect 
of both Tbx1 and Pax9 over the Gbx2 enhancer region, suggesting both could 
work together on regulating Gbx2 expression through acting on a down-stream 
conserved regulatory region. 
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Figure 5.17. Chromatin immunoprecipitation of TBEs and Pax-binding sites within the 
GBX2 locus. 
Chromatin immunoprecipitation from E8.5 (a), E9.5 (b) and E10.5 (c) embryos was performed 
using an anti-TBX1 antibody and anti-PAX9 antibody, and specific primers targeting the 
identified TBEs and Pax-binding sites; end-point PCR was performed on immunoprecipitated 
samples.  
(a) ChIP from E8.5 embryos resulted unreliable since the negative controls (IgG and no AB) 
show unspecific amplification of all identified TBEs and Pax-binding sites.  
(b) No binding was detected in any of the TBEs or Pax-binding sites from ChIP of E9.5 
embryos, with only the positive controls (INPUT and pHH3) showing positive amplification.  
(c) No specific binding was detected at E10.5 in any of the TBEs or Pax-binding sites, although 
amplification is detected in some of the target sites, such amplification does not seem to be 
specific since the negative controls (IgG and noAB) also show amplification. 
 
 
 
 
Figure 5.18. ChIP-western blot 
To detect co-ocupancy of Tbx1 and Pax9 proteins within a region in the DNA, aliquots of 
samples from the 3 stages (E8.5, E9.5, E10.5) were collected after immunoprecipitation with 
TBX1 or PAX9 and before reversing the cross-linking; samples were then subjected to western 
blot with an anti-TBX1 and anti-PAX9 antibodies. Tbx1 and Pax9 co-occupancy was not 
identified as Tbx1 is only detected in samples immunoprecipitated with an anti-TBX1 antibody, 
whilst similarly Pax9 is only detected in samples precipitated with an anti-PAX9 antibody in all 
three stages. 
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5.5 Discussion  
 
The first aim of this chapter was to determine whether Tbx1 directly binds to the 
Pax9 locus to regulate its expression, however, the ChIP results show Tbx1 
does not bind to the Pax9 locus. Although the qPCR results show some 
enrichment in the TBE-5 region, this amplification seems to be unspecific given 
that the IgG control group also showed similar enrichment.   
 
The IgG used as a negative control has no antigen immunoreactivity and 
therefore should not bind to any protein, thus the high background signal seen 
in the IgG and no antibody samples suggest potential DNA secondary 
structures within this region, or other proteins bound to the DNA could be 
interacting with the protein A beads and/or the IgG, consequently causing 
unspecific precipitation. 
 
However, no significant enrichment was seen in any of the analysed TBEs, 
indicating Tbx1 does not bind directly to the Pax9 locus in vivo, and suggesting 
Pax9 expression may be regulated indirectly by Tbx1. To address this, the Pax9 
gene can be analysed using MultiTF software to search for other transcription 
factor binding sites, particularly focusing on transcription factors known to be 
affected by loss of Tbx1. 
 
In this context, Pax9 expression is induced by ectodermal Fgf8 (Neubüser et al, 
1995), which is a known direct target of Tbx1 (Vitelli et al, 2002; Hu et al, 2004), 
suggesting this could be one pathway through which Tbx1 regulates Pax9 
expression. Moreover, Bmp4 signalling represses Pax9 expression (Neubüser 
et al, 1995), whilst Tbx1 is able to inhibit Bmp4 signalling by directly interacting 
with Smad1 (Fulcoli et al., 2009), suggesting another way for Tbx1 to regulate 
Pax9 expression. 
 
Moreover, a functional interaction between Pax9 and Tbx1 was found in vitro 
using luciferase assays where Pax9 is able to repress Tbx1 transcriptional 
activity in a dose-dependent manner and prevent luciferase expression of a T-
box reporter construct (2xTtkGL2). However, Pax9 does not affect Tbx1 binding 
to DNA, but only its transcriptional activity.   
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Although this repression does not seem to be through direct interaction between 
Pax9 and Tbx1 proteins, it is possible other co-factors commonly interact with 
Pax9 and Tbx1, thus the repression seen in the luciferase assays is an off-
target effect over a co-factor required for Tbx1 transcriptional activity.  
 
Additionally, Pax9 was able to drive luciferase expression of a cloned 
conserved region down-stream of the Gbx2 gene, whilst co-transfection with 
Tbx1 prevented this Pax9-mediated luciferase expression, further 
demonstrating a functional interaction between Tbx1 and Pax9 in vitro.  
 
As mentioned before, a physical interaction between Pax9 and Tbx1 was not 
detected by co-immunoprecipitation, nor a co-occupancy of both proteins within 
the Gbx2 cloned region. Therefore, the precise nature of this functional 
interaction in vivo remains to be clarified. 
 
Many technical difficulties for the analysis of this interaction in vivo have been 
identified and are being addressed in order to further investigate and 
corroborate these results. 
 
For instance, the lack of detection of co-occupancy in the latter experiment 
could be due to insufficient tissue to be able to detect the interaction; if Pax9 
and Tbx1 interact either physically with each other in a protein-protein fashion, 
or by co-occupying a region of DNA within the Gbx2 gene to regulate its 
expression, this interaction only occurs within the pharyngeal endoderm, where 
Pax9 is exclusively expressed; additionally, not all cells within the pharyngeal 
endoderm co-express Pax9 and Tbx1 at the same time, consequently making 
the interaction difficult to detect either by chromatin immunoprecipitation and co-
immunoprecipitation.  
 
To address this issue, many more embryos need to be collected for each 
experiment in order to have sufficient starting tissue to be able to detect the 
interaction after the subsequent steps of each technique. 
 
 
 
123 
 
  
Nonetheless, the robustness and reproducibility of the in vitro results are proof 
of concept of a functional interaction between Pax9 and Tbx1. In this context, 
the effect of Pax9 and Tbx1 over the Gbx2 enhancer region suggest both Pax9 
and Tbx1 could work together to regulate Gbx2 expression; although it is not 
possible to conclude from this experiment whether they act as promoters or 
repressors of Gbx2 and their precise role in vivo on Gbx2 remains to be 
elucidated. 
 
Gbx2 is a good common downstream target candidate of Pax9 and Tbx1 given 
that both Gbx2-null and Pax9+/-;Tbx1+/- present defects specifically affecting the 
development of the 4th PAAs. Additionally, it was recently shown Tbx1 and p53 
bind to the same Gbx2 enhancer region identified in this chapter (Caprio and 
Baldini, 2014). In this context, p53 binds to this 490bp down-stream region and 
negatively regulates Gbx2 expression through recruiting the polycomb 
repressive complex to methylate and silence Gbx2 expression (Caprio and 
Baldini, 2014). 
 
Interestingly, it was also recently reported that Pax9 plays a key role for 
maintenance of heterochromatin, where Pax9 knockdown leads to a decrease 
in H3K9me3 regions within heterochromatin, suggesting Pax9 may be involved 
in DNA methylation (Bulut-Karslioglu et al, 2012).  
 
Moreover, other Pax proteins are known to interact with methylation complexes, 
such as Pax2, which interacts with PAXIP1 (Lechner et al, 2000), an essential 
cofactor for H3K4me3 (Patel et al, 2007; Cho et al, 2007) and such interaction 
is associated with active chromatin states (Stein et al, 2011). Moreover, PAXIP1 
also binds p53-binding protein 1 (p53BP1) to control gene expression (Jowsey 
et al, 2004), whereas Pax2 and Pax5 can inhibit p53 expression and p53-
mediated gene expression (Stuart et al, 1995). 
 
Considering these reports, it is possible that Pax9 is also part of the Tbx1-p53 
system that regulates Gbx2 expression, either as a repressor promoting 
methylation and silencing Gbx2 expression, or as a promoter acting over the 
Gbx2 enhancer. 
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Figure 5.19. Proposed pathway. 
Based on the results from this dissertation and previous reports, it is proposed that TBX1 
indirectly regulates PAX9 expression, perhaps through FGF8 signalling, while TBX1 and PAX9 
act on GBX2 to regulate its expression and promote second heart field cells proliferation and 
proper neural crest cell migration to control formation of the 4
th
 PAAs.   
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Chapter 6. Final Discussion 
 
6.1. Pax9 in cardiovascular development as a genetic modifier of 22q11DS 
phenotype 
 
A novel role for Pax9 in cardiovascular development was identified in this 
project, specifically showing Pax9 requirement for correct development of the 
pharyngeal arch arteries. Furthermore, a strong genetic interaction between 
Pax9 and Tbx1 was found, where Pax9 and Tbx1 double haploinsufficiency 
leads to a significant increase in the prevalence of 4th PAA defects, and a 
significant increase in the incidence of IAA-B. 
 
The fact that double haploinsufficiency affects specifically the 4th PAAs (typical 
of Tbx1 heterozygosity), but not the 1st, 2nd and 3rd PAAs as occurs in Pax9-null 
embryos, suggest Pax9 haploinsufficiency exacerbates the Tbx1 heterozygous 
phenotype increasing the incidence of bilateral 4th PAA defects in a synergistic 
interaction. 
 
To this date, TBX1 and PAX9 mutations have not been associated in human 
patients with CCVM, however, the results shown in this dissertation position 
PAX9 as a potential modifier of 22q11 deletion syndrome. Although mutations 
on PAX9 directly affecting its function may define the 22q11DS phenotype, 
mutations affecting other components of the proposed TBX1-PAX9-GBX2 
pathway could determine the presentation of the phenotype but be more difficult 
to detect. 
 
In this context, mutations on GBX2, as the proposed downstream common 
target of TBX1 and PAX9 could result in a double heterozygous-like phenotype. 
Similarly, mutations affecting intermediate elements downstream of TBX1 and 
required for correct PAX9 expression could disrupt the pathway by altering 
PAX9 expression levels to a heterozygous-like level, which in the context of 
22q11 deletion may result in a double heterozygous-like phenotype. 
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6.2. Gbx2 as a common downstream target of Tbx1 and Pax9 
 
The third aim of this project was to determine the molecular mechanism by 
which Tbx1 and Pax9 interact. As part of this objective, Gbx2 mRNA levels 
were found significantly reduced in double heterozygous embryos, which led to 
the hypothesis of Gbx2 as a down-stream target of Tbx1 and Pax9. 
 
In vitro assays revealed both Tbx1 and Pax9 interact with a conserved region of 
the Gbx2 gene suggesting Tbx1 and Pax9 act on Gbx2 as a common 
downstream target to control in part cardiovascular development. 
 
Moreover, Gbx2-null mice present with similar 4th PAA defects as those seen in 
double heterozygous embryos, as a phenocopy of Tbx1;Pax9 double 
haploinsufficiency phenotype, further supporting the idea of Gbx2 being within 
the same genetic pathway and downstream of Tbx1 and Pax9. 
 
In this context, it has been shown Tbx1 directly binds to the conserved 
regulatory region of Gbx2 to promote its expression, whereas p53 negatively 
regulates Gbx2 expression by mediating methylation of the Gbx2 locus. 
Interestingly, it was recently suggested that Pax9 is necessary for epigenetic 
control of heterochromatin by modulating DNA methylation. 
 
Altogether, these evidences suggest Pax9 could be part of the Tbx1-p53 
complex that regulates Gbx2 expression, binding to this conserved regulatory 
region downstream of the Gbx2 gene.  
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6.3. Future work 
 
Although the effect of Pax9 homozygous deletion and Pax9;Tbx1 double 
haploinsufficiency clearly affects the development of the pharyngeal arch 
arteries, the cellular mechanism causing abnormal remodelling of the cranial 
PAAs and lack of formation of the 4th PAAs still remains to be elucidated. 
 
In this context, it remains to be determined whether abnormal development of 
the pharyngeal arch arteries is a consequence of increased apoptosis, 
insufficient endothelial differentiation, or deficient neural crest cell migration into 
the pharyngeal arches. 
 
This can be determined by immunostaining of sectioned pharyngeal arches of 
Pax9-null and double heterozygous embryos using specific markers for 
apoptosis (caspase 3), proliferation (phospho-histone H3, Ki-67), endothelial 
differentiation (CD-31), smooth muscle differentiation (α-SMA), neural crest 
cells (Wnt1, Sox10). 
 
Moreover, the precise role of Tbx1 and Pax9 regulating Gbx2 expression in vivo 
needs to be further analysed to precisely determine how Pax9 and Tbx1 control 
Gbx2 expression. To achieve this, the pharyngeal arch region of wildtype 
embryos will be collected and chromatin immunoprecipitation will be performed, 
targeting the conserved region containing the identified putative Pax-binding 
sites and TBEs.  
 
As mentioned before, many technical difficulties have been identified and will be 
addressed, including the amount of starting tissue, and extra considerations to 
prevent unspecific binding of the IgG and protein A/G beads such as additional 
blocking and washing steps. 
 
Furthermore, it would be interesting to generate Pax9;Gbx2 double 
heterozygous and Tbx1;Pax9;Gbx2 triple heterozygotes, to analyse the 
incidence of 4th PAA defects and determine whether triple heterozygosity 
increases the penetrance of IAA-B up to 100%.  
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Additionally, to further understand the role of Pax9 and Tbx1 in vivo, would be 
interesting to modify the conserved genomic region downstream of Gbx2 where 
Pax9 and Tbx1 presumably bind, using gene-editing tools such as the 
CRISPR/Cas9 system, to prevent Tbx1/Pax9 binding and determine whether 
this mutation recapitulates the Tbx1;Pax9 double heterozygous phenotype; this 
approach would provide with a more clinically relevant insight into the 
mechanism regulating Gbx2 to control cardiovascular development, as 
mutations within this region could occur in 22q11DS patients consequently 
modifying the phenotype.  
 
Similarly, it should be interesting to generate Pax9-/-;p53+/- embryos and 
determine whether p53 heterozygosity can rescue the Pax9-null phenotype as it 
occurs in the Tbx1;p53 double heterozygous embryos (Caprio and Baldini, 
2014). 
 
Moreover, it remains to be investigated which genes and signalling pathways 
are disrupted as a consequence of Pax9 loss. This is being approached by 
using whole transcriptome sequencing (RNA-seq) of Pax9-null embryos, to 
determine which transcripts are dysregulated; targets identified by this approach 
will be further validated by qPCR and in situ hybridisation, and potentially 
analysed in vivo using mouse models. This same approach could be later 
applied to Tbx1;Pax9 double heterozygous embryos. 
 
Finally, in a translational perspective, gene sequencing of PAX9 and GBX2 (or 
other affected genes identified by RNA-seq) in patients with 22q11 deletion 
would help in understanding the genetic aetiology of the phenotype. This would 
need to be approached by whole genome sequencing, as mutations within 
regulatory regions outside exons such as the one proposed downstream of 
GBX2 could be responsible for dysregulation of gene expression.  
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6.4. Conclusions 
 
The data presented in this thesis demonstrates Pax9 is required for 
cardiovascular development, particularly for correct development of the 
pharyngeal arch arteries. 
 
The results also demonstrate that Pax9 genetically interacts with Tbx1 for the 
formation of the 4th pharyngeal arch arteries, and further support the possibility 
of PAX9 being a genetic modifier of 22q11DS phenotype. 
 
The results also demonstrate that Tbx1 does not regulate Pax9 expression 
directly binding to the Pax9 locus, nor Tbx1 and Pax9 physically interact with 
each other. 
 
Finally, the results support the hypothesis that Tbx1 and Pax9 act over Gbx2 as 
a common target to regulate, at least in part, cardiovascular development. 
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Appendix A. Optimization of Luciferase Assays 
 
 
 
Appendix A. Optimization of luciferase assays. 
(a) Increasing number of JEG3 cells (25,000, 50,000 and 100,000) were seeded and 
transfected with different doses (0, 10, 20, 50ng) of a Renilla luciferase expressing vector 
(pGL4.7) to determine the optimal number of cells and concentration of renilla. 
(b) JEG3 cells were co-transfected with different doses of the 2xTtkGL2 reporter (x axis), and 
increasing concentrations of a TBX1 expressing plasmid to determine the optimal concentration 
of TBX1 to activate the 2xTtkGL2 reporter. 
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Appendix B. Chromatin immunoprecipitation of TBEs within the 
Pax9 locus 
 
Appendix B. Chromatin immunoprecipitation of TBEs within the Pax9 locus on MEFs  
(a) ChIP from MEFs (b) ChIP from E9.5 wild-type embryos using an anti-GFP as isotype control 
antibody 
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